var title_f9_9_9360="US of Bakers cyst with needle";
var content_f9_9_9360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of Baker's cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal US scan showing needle moved down to the center of the Baker's cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Juhani Koski, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9360=[""].join("\n");
var outline_f9_9_9360=null;
var title_f9_9_9361="CT scan UPJ obstruction";
var content_f9_9_9361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan: Transverse view of bilateral ureteropelvic junction obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Laurence Baskin, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9361=[""].join("\n");
var outline_f9_9_9361=null;
var title_f9_9_9362="Transperineal fistula repair3";
var content_f9_9_9362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fistula tract is excised.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9362=[""].join("\n");
var outline_f9_9_9362=null;
var title_f9_9_9363="MHC I antigen processing and presentation pathway";
var content_f9_9_9363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    The MHC class I antigen processing and presentation pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proteins from cytoplasmic pathogens and cellular proteins are targeted to the proteasome for proteolysis. Some of the resulting peptide products are selected by the TAP complex for import into the endoplasmic recticulum (ER), where they can be sampled by newly synthesized MHC class I molecules. Class I heavy chains assemble with &beta;2-microglobulin (&beta;2m), and are retained in association with the TAP complex via the chaperone tapasin to facilitate peptide encounter. Assembled MHC I molecules with bound peptide are then exported through the secretory pathway to the cell surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9363=[""].join("\n");
var outline_f9_9_9363=null;
var title_f9_9_9364="Procyclidine: Patient drug information";
var content_f9_9_9364=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Procyclidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/43/19124?source=see_link\">",
"     see \"Procyclidine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PHL-Procyclidine;",
"     </li>",
"     <li>",
"      PMS-Procyclidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by some drugs used to treat schizophrenia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702800",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to procyclidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15560 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9364=[""].join("\n");
var outline_f9_9_9364=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213906\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019752\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019751\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019756\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019757\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019759\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019754\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019755\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019760\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019761\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/43/19124?source=related_link\">",
"      Procyclidine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_9_9365="Varenicline: Patient drug information";
var content_f9_9_9365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Varenicline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     see \"Varenicline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2975238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chantix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4104776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Champix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When used to stop smoking this drug may cause or make diseases of the mind worse. Taking one's own life, ideas of killing yourself or murder, low mood (depression), forceful actions, hallucinations, and psychoses have happened with use. If you think you have any of these problems, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you stop smoking.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703121",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to varenicline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on dialysis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When you stop smoking, other drugs may be affected. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad dreams.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not been able to quit smoking after taking this drug for 12 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Get counseling to help you quit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after eating with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet early in the day to stop sleep problems. Take at least 6 hours before bedtime.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11654 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9365=[""].join("\n");
var outline_f9_9_9365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975238\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104776\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011301\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011303\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011302\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011307\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011308\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011310\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011305\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011306\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011311\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011312\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=related_link\">",
"      Varenicline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_9_9366="Evaluation of the patient with hypokalemia";
var content_f9_9_9366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with hypokalemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9366/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9366/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9366/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9366/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9366/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9366/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9366/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/9/9366/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia is a common clinical problem, the cause of which can usually be determined from the history (as with diuretic use, vomiting, or diarrhea). In some cases, however, the diagnosis is not readily apparent.",
"   </p>",
"   <p>",
"    The diagnostic approach to the patient with hypokalemia will be reviewed here. There are two major components to the diagnostic evaluation: assessment of urinary potassium excretion to distinguish renal potassium losses (eg, diuretic therapy, primary aldosteronism) from other causes of hypokalemia, and assessment of acid-base status, since some causes of hypokalemia are associated with metabolic alkalosis or metabolic acidosis.",
"   </p>",
"   <p>",
"    The causes, clinical manifestations, and treatment of hypokalemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link\">",
"     \"Causes of hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REGULATION OF POTASSIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the filtered potassium is reabsorbed in the proximal tubule and loop of Henle with most of the potassium that is excreted being derived from tubular secretion by the principal cells in the cortical and outer medullary collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Aldosterone plays a central role in this process. An increase in plasma potassium stimulates the secretion of aldosterone, which then appropriately increases potassium secretion to return the plasma potassium to normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urinary response to potassium depletion is twofold:",
"    <strong>",
"     decreased potassium secretion",
"    </strong>",
"    by the principal cells (mediated at least in part by reductions in the cell potassium concentration and in aldosterone release) (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and",
"    <strong>",
"     increased active potassium reabsorption",
"    </strong>",
"    by H-K-ATPase pumps in the luminal membrane of the adjacent type A intercalated cells in the cortical collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. These pumps, which are activated by hypokalemia, reabsorb potassium and secrete hydrogen.",
"   </p>",
"   <p>",
"    Aldosterone secretion is reduced by hypokalemia, which appropriately reduces potassium secretion by the potassium channels in the cortical collecting tubule. In addition, renin release and angiotensin II formation are increased by potassium depletion, and angiotensin II reduces collecting tubule potassium secretion by a different mechanism from aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60964991\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF URINARY POTASSIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-hour urine collection is the most accurate method to measure urinary potassium excretion. A normal individual can, in the presence of potassium depletion that is",
"    <strong>",
"     not",
"    </strong>",
"    due to urinary losses, lower urinary potassium excretion below 25 to 30 meq per day on a 24-hour urine collection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/8\">",
"     8",
"    </a>",
"    ]. Higher values suggest at least a contribution from urinary potassium wasting.",
"   </p>",
"   <p>",
"    Random measurement of the urine potassium concentration can also be used. The minimum urine potassium concentration that can be achieved with hypokalemia is 5 to 15",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/8\">",
"     8",
"    </a>",
"    ]. This minimal degree of potassium wasting with potassium depletion may reflect passive potassium leakage out of the inner medullary collecting cells down a favorable concentration gradient through a nonselective cation channel in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/9\">",
"     9",
"    </a>",
"    ]. Some have suggested that extrarenal losses are present if the urine potassium concentration is less than 15",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/10\">",
"     10",
"    </a>",
"    ], while substantially higher values suggest at least a component of potassium wasting.",
"   </p>",
"   <p>",
"    However, random measurements may be misleading since the urine potassium concentration is determined by both the amount of potassium in the urine and the urine volume. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A urine potassium concentration of less than 15",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      can be seen in patients with renal potassium wasting in two settings: if the cause of potassium wasting has resolved (eg, the effect of the diuretic has worn off), or if the patient is polyuric, which may be due to impaired urinary concentrating ability and possibly increased thirst induced by the hypokalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=see_link&amp;anchor=H3#H3\">",
"       \"Hypokalemia-induced renal dysfunction\", section on 'Impaired urinary concentrating ability'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A urine potassium concentration of 40",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      which seems to favor urinary potassium wasting, can also represent appropriate potassium conservation of 20 meq per day if the urine volume is only 500 mL due to a low rate of water intake.",
"     </li>",
"     <li>",
"      In patients who are volume depleted, sodium and water delivery to the distal potassium secretory site may be substantially reduced. In this setting, the urine potassium concentration may be relatively high due to secondary hyperaldosteronism, but the urine volume and absolute amount of potassium excreted are relatively low [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/3\">",
"       3",
"      </a>",
"      ]. Urinary sodium excretion should be above 30 to 40 meq per day to avoid this problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these limitations, measurement of the urine potassium-to-creatinine ratio is preferred because it is not influenced by the urine volume. (See",
"    <a class=\"local\" href=\"#H60965616\">",
"     'Urine potassium-to-creatinine ratio'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another approach to distinguishing between extrarenal and renal causes of potassium loss is to assess the response to the administration of potassium. Patients with previous extrarenal losses (eg, vomiting or diarrhea) that have ceased will respond to potassium replacement with an increase in serum potassium that will eventually return to normal. A similar response will occur with diuretic-induced hypokalemia if the diuretic has been discontinued. In contrast, potassium replacement in patients with ongoing renal potassium losses will modestly raise the serum potassium, which will be followed by an increase in urinary potassium losses to match intake, and a lesser degree of hypokalemia will persist. In addition, the serum potassium will fall back to the baseline level if potassium therapy is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H23441650#H23441650\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Ongoing losses and the steady state'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60966904\">",
"    <span class=\"h2\">",
"     Severe hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe hypokalemia, measurement of 24-hour potassium excretion is impractical because potassium repletion is urgently needed and, as noted in the previous paragraphs, a random urine potassium may be misleading. The likelihood of a misleading measurement is low if the urine sodium is greater than 30 to 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the urine osmolality is greater than that in the plasma, suggesting that the patient is not polyuric.",
"   </p>",
"   <p>",
"    If these criteria are not met, comparable information can be obtained by calculating the urine potassium-to-creatinine ratio or the transtubular potassium concentration gradient on a single urine specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60965616\">",
"    <span class=\"h3\">",
"     Urine potassium-to-creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since creatinine is excreted at a near constant rate, the urine potassium-to-creatinine ratio corrects for variations in urine volume. The urine potassium-to-creatinine ratio is usually less than 13",
"    <span class=\"nowrap\">",
"     meq/g",
"    </span>",
"    creatinine (1.5",
"    <span class=\"nowrap\">",
"     meq/mmol",
"    </span>",
"    creatinine) when hypokalemia is caused by poor dietary intake, transcellular potassium shifts, gastrointestinal losses, or previous use of diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Higher values are seen with renal potassium wasting.",
"   </p>",
"   <p>",
"    The efficacy of the urine potassium-to-creatinine ratio was evaluated in a study of 43 patients with severe hypokalemia (range, 1.5 to 2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    associated with paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/11\">",
"     11",
"    </a>",
"    ]. The urine potassium-to-creatinine ratio reliably distinguished between the 30 patients with hypokalemic periodic paralysis (whose hypokalemia was caused by an internal shift of potassium from the extracellular fluid into the cells) and the 13 patients with hypokalemia that was due to renal potassium wasting in almost all (10 had renal tubular acidosis or Gitelman syndrome). The urine potassium-to-creatinine ratio was significantly lower in the patients with periodic paralysis (11 versus 36",
"    <span class=\"nowrap\">",
"     meq/g",
"    </span>",
"    creatinine, 1.3 versus 4.1",
"    <span class=\"nowrap\">",
"     meq/mmol",
"    </span>",
"    creatinine). The cutoff value was approximately 22",
"    <span class=\"nowrap\">",
"     meq/g",
"    </span>",
"    creatinine (2.5",
"    <span class=\"nowrap\">",
"     meq/mmol).",
"    </span>",
"    In addition, patients with periodic paralysis had normal acid-base balance, while patients without periodic paralysis often had metabolic alkalosis or metabolic acidosis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assessment of acid-base status'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rebound hyperkalemia (serum potassium greater than 5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    developed in 19 of the 30 patients with periodic paralysis after administration of a mean of 63 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    . This effect is due both to reversal of the shift of extracellular potassium into the cells and to the administered potassium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link\">",
"     \"Hypokalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60965735\">",
"    <span class=\"h3\">",
"     Transtubular potassium concentration gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transtubular potassium concentration gradient (TTKG) has been primarily used in the evaluation of patients with hyperkalemia. However, we do not recommend using the TTKG. Details pertaining to the TTKG and the reasons for our recommendation not to use it in hyperkalemia are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H249933336#H249933336\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Transtubular potassium gradient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF ACID-BASE STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once urinary potassium excretion is measured, the following diagnostic possibilities should be considered in the patient with hypokalemia of uncertain origin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic acidosis with a low rate of urinary potassium excretion is, in an asymptomatic patient, suggestive of lower gastrointestinal losses due to laxative abuse or a villous adenoma [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29589?source=see_link\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=see_link\">",
"       \"Factitious diarrhea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic acidosis with urinary potassium wasting is most often due to diabetic ketoacidosis or to type 1 (distal) or type 2 (proximal) renal tubular acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"       \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic alkalosis with a low rate of urinary potassium excretion may be due to surreptitious vomiting (often in bulimic patients in an attempt to lose weight) or diuretic use if the urine collection is obtained after the diuretic effect has worn off. In addition, some patients with laxative abuse present with metabolic alkalosis, rather than the expected metabolic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9366/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link\">",
"       \"Pathogenesis of metabolic alkalosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic alkalosis with urinary potassium wasting and a normal blood pressure is most often due to diuretic use, vomiting, or Gitelman or Bartter syndrome. In this setting, measurement of the urine chloride concentration is often helpful, being normal (equal to intake) in Gitelman or Bartter syndrome, high or low with diuretics depending upon whether or not the diuretic is still acting, and low in vomiting at a time when urinary sodium and potassium excretion may be relatively high due to the need to maintain electroneutrality as some of the excess bicarbonate is being excreted. The last possibility can be determined at the bedside from the urine pH, which should be above 7 if significant bicarbonaturia is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic alkalosis with urinary potassium wasting and hypertension is suggestive of surreptitious diuretic therapy in a patient with underlying hypertension, renovascular disease, or one of the causes of primary mineralocorticoid excess. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"       \"Approach to the patient with hypertension and hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/54/14177?source=see_link\">",
"       \"Patient information: Hypokalemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33681604\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with hypokalemia, the cause is apparent from the history (eg, vomiting, diarrhea, diuretic therapy). However, the cause is not apparent from the history in some patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two major components to the diagnostic evaluation of the patient with hypokalemia of uncertain origin: assessment of urinary potassium excretion to distinguish renal potassium losses from other causes, and assessment of acid-base status, since some causes of hypokalemia are associated with metabolic alkalosis or metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A 24-hour collection for total urinary potassium is the optimal method to determine the presence of potassium wasting. In hypokalemic patients, total urinary potassium excretion greater than 30 meq per day suggests at least a contribution from urinary potassium wasting. (See",
"      <a class=\"local\" href=\"#H60964991\">",
"       'Assessment of urinary potassium excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A random measurement of the urine potassium concentration may be used in selected individuals, although the values may be misleading. As an example, a random urinary potassium concentration less than 15",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      which suggests the presence of extrarenal rather than renal loss of potassium, may be present with renal potassium wasting in two settings: if the cause of the renal potassium wasting has resolved (eg, the effect of a diuretic has worn off), or if the patient is polyuric, which may result from impaired urinary concentrating ability and possibly increased thirst induced by the hypokalemia.",
"     </li>",
"     <li>",
"      Another approach to distinguishing between extrarenal and renal causes of potassium loss is to assess the response to the administration of potassium. Patients with previous extrarenal losses (eg, vomiting or diarrhea) that have ceased will respond to potassium replacement with an increase in serum potassium that will eventually return to normal. A similar response will occur with diuretic-induced hypokalemia if the diuretic has been discontinued. In contrast, potassium replacement in patients with ongoing renal potassium losses will modestly raise the serum potassium, which will be followed by an increase in urinary potassium losses to match intake and a lesser hypokalemia will persist. In addition, the serum potassium will fall back to the baseline level if potassium therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H60964991\">",
"       'Assessment of urinary potassium excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urine potassium-to-creatinine ratio on a single urine specimen may be more helpful than a random urine potassium concentration since it corrects for variations in urine volume. This test may be used to diagnose renal potassium wasting in patients with severe hypokalemia in whom a timed collection may not be practical. A urine potassium-to-creatinine ratio greater than 13",
"      <span class=\"nowrap\">",
"       meq/g",
"      </span>",
"      creatinine (1.5",
"      <span class=\"nowrap\">",
"       meq/mmol",
"      </span>",
"      creatinine) suggests renal potassium wasting. (See",
"      <a class=\"local\" href=\"#H60965616\">",
"       'Urine potassium-to-creatinine ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acid-base status should be evaluated (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessment of acid-base status'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Metabolic acidosis with a low rate of potassium excretion suggests lower gastrointestinal losses.",
"     </li>",
"     <li>",
"      Metabolic acidosis with renal potassium wasting may be seen with diabetic ketoacidosis and type 1 (distal) or type 2 (proximal) renal tubular acidosis.",
"     </li>",
"     <li>",
"      Metabolic alkalosis with a low rate of renal potassium excretion suggests surreptitious vomiting; diuretic use (when the urine collection is obtained after the diuretic effect has worn off); or, rarely, laxative abuse.",
"     </li>",
"     <li>",
"      Metabolic alkalosis with renal potassium wasting and a normal blood pressure is most often due to diuretic use, vomiting, or Gitelman or Bartter syndrome. Although patients with significant vomiting are typically volume and potassium depleted, urinary sodium and potassium excretion may be relatively high due to the excretion of sodium and potassium together with bicarbonate when substantial excretion of bicarbonate occurs. The urine pH should be above 7 if significant bicarbonaturia is present.",
"     </li>",
"     <li>",
"      Metabolic alkalosis with potassium wasting and hypertension occurs with primary mineralocorticoid excess or a disorder that mimics a mineralocorticoid excess state (Liddell syndrome, licorice ingestion, etc), renovascular disease, or the surreptitious ingestion of diuretics by a patient with underlying hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/2\">",
"      Stanton BA. Renal potassium transport: morphological and functional adaptations. Am J Physiol 1989; 257:R989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/3\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/4\">",
"      Linas SL, Peterson LN, Anderson RJ, et al. Mechanism of renal potassium conservation in the rat. Kidney Int 1979; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/5\">",
"      Wingo CS, Smolka AJ. Function and structure of H-K-ATPase in the kidney. Am J Physiol 1995; 269:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/6\">",
"      Okusa MD, Unwin RJ, Vel&aacute;zquez H, et al. Active potassium absorption by the renal distal tubule. Am J Physiol 1992; 262:F488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/7\">",
"      Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/8\">",
"      SQUIRES RD, HUTH EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest 1959; 38:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/9\">",
"      Light DB, McCann FV, Keller TM, Stanton BA. Amiloride-sensitive cation channel in apical membrane of inner medullary collecting duct. Am J Physiol 1988; 255:F278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/10\">",
"      Groeneveld,J, Sijpkens, Y, Lin, S, et al. An approach to the patient with severe hypokalemia: the potassium quiz. Q J Med 2005; 98:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/11\">",
"      Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med 2004; 164:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/12\">",
"      Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM 2001; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/13\">",
"      SCHWARTZ WB, RELMAN AS. Metabolic and renal studies in chronic potassium depletion resulting from overuse of laxatives. J Clin Invest 1953; 32:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/14\">",
"      Ewe K, Karbach U. Factitious diarrhoea. Clin Gastroenterol 1986; 15:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9366/abstract/15\">",
"      Oster JR, Materson BJ, Rogers AI. Laxative abuse syndrome. Am J Gastroenterol 1980; 74:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2305 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9366=[""].join("\n");
var outline_f9_9_9366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33681604\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REGULATION OF POTASSIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60964991\">",
"      ASSESSMENT OF URINARY POTASSIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60966904\">",
"      Severe hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60965616\">",
"      - Urine potassium-to-creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60965735\">",
"      - Transtubular potassium concentration gradient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSMENT OF ACID-BASE STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33681604\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2305|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 2\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29589?source=related_link\">",
"      Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/54/14177?source=related_link\">",
"      Patient information: Hypokalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_9_9367="Indirect inguinal hernia A";
var content_f9_9_9367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67349%7EPEDS%2F82091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67349%7EPEDS%2F82091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Indirect inguinal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 331px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFLAUkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKK861DwNqWnanLfeGPHGr6feXk7H7LqUn260IJLskcLEFDxwVbgAjvws3jbXPC3lr480ErZZCHWdIZri2XAO6SeMqHgTpz845PPGaAPRKKq6ZqFnqthBfaZdQXdnOu6KeBw6OPUEcGrVABRRRQAV478c/EOt6X4t8E6Zo1/q9tBqSaiZ49JgjmuJWiiRo9qurdGPP+yT06j2Kqtzptjc39nfXNnbTXtnv+zXEkStJBvGH2MRldw4OMZHWgDw66+KHjfQoNH0S/0S0uvEyaQmpXyzHYZiZGXYoTCqdq5ZuVDHGK1dc+Imu32m+OntNOs4NK0K2LPMt7JHdEtbCVQm1SAQWwW3D2Br1LW/D2i675X9uaRp2peScx/bLZJth/2dwOPwp/9haR5N9D/ZVh5V8ALtPs6bbgBdoEgx83ygDnPHFAHjdh8SPEemat43uL/wCyXmkaLpFnfW9lvImzJAz8Nty2SMuWJ24yO9Ty/FvXLSG+tZdP0a81OC502OOW1nf7My3mcBjglWXHvkHOO1et/wDCP6N9uW9/snT/ALYsH2ZZ/syeYIsY8sNjO3H8PSorbwt4ftbIWdroWlQ2gmW5EEdnGqCVTkSbQMbgQMN1oA8mvvi9r2nWc9le6Tp39ux662jebC0jWvEQkD4OGLEHaFyMnnPaqmv/ABp17TtDtJ10rTY9Xispb2/09y7lESZo96uCFVW28A7mycbeMn2e58O6JdW95BdaPps0F5J51zHJaoyzyYA3uCMM2AOTk8VUm8E+FZ7e2t5/DOhyQWyskEb2ERWJW+8FBXCg9wOtAHLfDXXr3W/H3jsXE87WUQ0yS1t3cssAltFdgvpknJ9TWVbfFDUp9N1vW5m8PWGj2Ut7bR291PIbsPAGCs6qD1ZQSgGQpzk16lZaXp9hPPNY2NrbTXAQTSQwqjSBF2oGIHO1QAM9BwKpy+F9Al1G4v5dD0p764jaKa5a0jMkqMMMrNjJBHBB60AeRaV8ZtZ+yaxcavpNksGj3uni9mjLJttLosPNCFmwykKcE9G5xipR8Qtb1d9Evra2FlLqWk6pe2aGdxHsix5LyJjDEjDcjjPvXqtn4S8N2Nnd2ll4f0i3tbxBHcww2UaJOozhXULhgNxwD6n1q7Ho+mRy2ckenWSyWcJt7Z1gUGCIgAohx8q4AGBgcCgDxG3+L+u+HfAHhnWfEtvZaiuq2ExS4tc7mu1iDxRyKAApc7gQo4xxXuWlPdyaXZyalFHDfNCjTxxHKJIQNyg9wDkZrnNV+Hvh7UIdHto7KOwsdM1FdUSzsYo4YZZ1BAMiheRznjGeM5rraACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAqQS3b6hdRzWqRWkYXyZvM3GUkc/Lj5cHjvmqUkTxXba3e3F9DHBaSRPYI4khI3BvM2qu5pMLgYPQkYzV/UVvGtGGnSQR3O5SGmQsmNw3AgEHlcgc9cU9rhRdrblZN7IZN2w7QAQMFumeen1oA89fwHYatqbeJ/DjXPhnWJlWSK9sjhLxCuVFzbsAGXOMqdrcfeHZ2meOdT0PVF0r4lWNtpKyN5VlrcMubK+fBJBz/x7uQBhXPzENg8DPcxrc3MFzHdA2+ZGWJ4X+Yp2bkcH2qj4g0qK+hvFvLaXVbO7iS3l02UxmEruJL4YDnnnn+EYGRQBtKSc5GOeOetKPevLLW7l+FWp2ul6jcy3PgW7kEVne3Epkk0iVuEt5mPP2c4wkh+4flY4w1ep0AFIMgDPU0tHegAoPtRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVS1XVbDSY7d9Tu4bRLiZLaJpWCh5G4VQfU9qu15x8W9T0rUVtvA9yllcXmsRtLOLoAx2VmmTLcsf4GChhGxx+8weimgDtZ9GsJLjTbmdJGl013ktnaZ/lZ0ZCSM4bKuw+bOM8YrSrwDwT8Qf8AhEDp1p4k1C71DwNq5eTRtX1Qk3luisFH2pSoPlO3McmOAy5wDhPcQssmsmRL1xbwwmOS08obS7FWV9+M5ABGAcfNzyBQBBa2uqjWdXkvL+OTSp0iWygji2yW5CsJCX/i3EqR6YqxpNidL0ixsI55rkW0SQ+dcvukkCgDcx7sccmqi2Uy2F1a6vqdxdC7uZPKkiU27xRsxKRK0eCNo435yccmtN5WW4ijEMjK4YmQY2pjHByc854wD0OcUAc/qejadreq6zYarocktpe6fHb3F27jy7iPdJ+6ADbgy5J3YB+YYPArmfhpqs+hatJ4D1m8a8a1h87RNQcD/TrJcLtZgcGWJso3QlQrY6mu/jS5t5bSCBVltArCaWaYmRTxtxwd2ec5Ixx1rzz4m6G2n+GjrvhjTlsdW8ItLfadnaIpo2XdcpsG7IeMyLyA27BBHWgD0+is7w7rNn4h0HT9Y0yTzLK+gSeInGQGGcHHQjoR2IIrRoAKKKKACiiigArJ0bxHpOtahqllpV6l1Ppcogu/LVischGdm/G0sO4BJU8HB4rgNS1bUviT4gutC8LX8+neFtOk8vVNZtWHmXcuObW3b+EDILSDnOAMD73oGh6JYeHNBi0vw5Y21na20eyCBcqucdWPJJJ6sck8k5NAGrRVXSmvW0y1bVY7ePUDGpnS3YtGr45CkgEjPqKtUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYvjPxDb+FPC2pa7eRSzW9jEZXjixvYZxgZIHeua0j4paRPNdQa9a3nh65gsV1PZqBjKyWrHAlR42YEAkAjgjPTrW/4/wDDn/CXeDdW0H7V9k+3wmHz/L8zy+Qc7cjPT1FcNN8IH1W01L/hJPEDX19PpA0W2mt7MW8drACGyE3sWYsASS3qBigDutS8ZeHtM+2/b9XtYPsUUU04dsFFkOIz77iMADk1hJ8WPCcviXR9EgvZZbnVFYwyCIqisHCBHDYZWLcAbe3OOK5tvg7fXd1dX+reKzdasxsJba5TTljWGW0ZijGPeQ6ndypx9fToG8D61P4m8PeILzxLBNqemNOkxXTQkc8EpTMaqJMoQEwGJfr04xQBvw+NPDk1rp9zHrNn9n1CKae1lZ9qyxwjMrAngBRySak8MeLdE8Ui4Og3wuxAEaTEbphXztYbgMg7TgjIOK830b4L3enJpNtL4pW707SbXULSyt5dMQ7Euk2ned+H2nk5GGAxgc56f4WfD6TwKNRD6w97Hd+Xsto43it7faCMojySEE55w2OBgDFAHfUU2aRIYnlmdY4kUszscBQOpJ7CuX/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIqgDqqK5X/hY/gf/ocvDf8A4NIP/iqQ/EfwOP8AmcvDf/g0g/8AiqAOrrhPib8PLPxikN/aOll4kskK2t7tysiHOYJ1/wCWkDZIZDnhm7FgdH/hY/gf/ocvDf8A4NIP/iqqTePvAomnuLbxb4XW+eHy1mbUoMYGSoJ3dATnFAHiumX0+qHW9I8W7tD1iOI/8JVezoEzYB9kNnYKCf3cgKjIxkvkb2YY6/4Y+I73wT4lsfAviiaKPTtTje68OieZmubWAufLs5wRw4XgckAqUBb5QHfFWTwN4w0/T9Ts/GfhO38YaMyXWnXh1GAoZUYOI3BfmNmHf7pOeeQ3nGjeKfC/irw7qS67rEWk6fdhJvEE01xHJqmq6gCpjS3VSxFtE23YVAGFAwBvagD6qv7e4l06aCyvGtbllIjuCgkKH12ng/jUkj3IvIFjija2KsZZC5DKeNoC45zznkYwOtedfCrXtY1zR9R8LeLzPY+LtESKG9mgdT5qSAtFMjcgkqPm/wBrPAzgeg3hlnguYLG5igvAnyu8fmCMnOCVyMjjpkdKAGywQTpe2SCSAzITLJCTG2XBXcHHIbA6jkcUlw1yunx/2R5E8qvGubiVtpQOokO4Akts3Y9WxnjJq9zntWfbXCXVrDfZuLOGIyFo5lEeQMqS4PQcbh+BoA88+E9xD4d8X+LfABkkCWNx/aemRvFsH2ScK7LHgYKpK7Ln1b2wPU68h8WfaNK/aA8DeILaeBtM1rT5tFmbIOQA08eD/tNtwR6Ed69eoAKKKPpQAV5n8RNXvfEPiW2+Hvhu4ltp7mIXOtahAQHsbLptQ54lkOFHBIUlsY5HX+OvE1n4O8Japr2onMFlCXCZwZH6IgODgsxC57ZrmPg7o15o3h2O+18NceJfEUralqNzGN6qzDMce7HyqibVC5IB3beDQB0umaYnh7TtF0nwnp9jFotu5hlTzSvkxBW+ZODvcvjJY5JLEkmtS+uLiCayW3tGuEmn8uVgwXyU2Md5z1GVUY/2qW3t2gjnigSCCIsWh2L0LcsWHHO4k8daZdWct3phtJrqaOR0CvcWx8p9wxkr125x70AXOd3QYx1zS1A93bpexWjzxLdSo0kcJYB3VSoZgOpALLk+4qVO+c5z3oAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHzdqfi7VNb+JGhwahqcaXNl4qlto9CjiEbxQpG4jkZzy2/rk/Lzx0qlZ/Ejxlrvh7xMt7qtjaXH9iX08tmkYjurCaJSwCoPnUbQVy5zkhge1fT1FAHy/L4o8S+BdD8M6PpF9p+nW02ixakl7eRKkV5cyMSY2ZyRwu0EKQ5J3d8V2C+OPGtzpHjvWtPayuE0ORobbTUsmd5GMUb7jJuBITexxtycdRXuFFAHzrpXxL8V3WmRx22uaTeSXOuabp8N6kKStGlzvDrIiFVypQEDIbBwcdara98T/F+kaTcwXGs6cZtP1y/wBOmuhDFBPcxwxxMhjWT91uzKcrncQF25+Y19J0UAZPhK+l1PwtpF9c+d59xaRSyedB5LligJLR5Ow5/hycdMmtaiigAooooAKKKKACqtztti115lvBCuXuZJFxlFU87sgDHqc8Vaqi8aR21ymq3MU9vcSFAsyqqhXwoi9GyTjnk5xQBIj2vF8twrRTIgSTzMoQfule3ORz34ryL40WN34L1ZPiR4Zhs1utiafq7XFuZUW3Z1C3W1WUtJHgJ/ESrdgpr1yWOKP7JarZB7bO0bVXZDtGV47dABgccUl9a2t+tzZ3URkWeBopFZSVaNuCDng9elAHznfpe+HpYPHnhmO9vrfQo2Ora/qkwhfxDFIU3JGu0lkUCPy34XgBd2AT9HWGoW2oIktlIJ7eSGOeOePmKVHyVKuOG4GeOxHqK+ePDWlPZeKp/B19p83iHxV4dkB0F9RuMWltpjKFSZ1XaHMYKqylSxJUIQASvXfAfxBBY3eq+ApNcttYTSNkmk30cgYXNky8KpHDGM/KSpI5A/hNAHqVpeWGLY2DLNDeszxy24MkbEDJJdcgdOpPJ4p9+bprq0gitYZ7GYut20jYKJsOMLj5stgEehNR2E86aVaN/ZT2sjMqvaI8Z8gFsE5B2kDrxUxlks47651CeL7LGTIhCkeXGFGd3qchjn0oA8r/AGjpJdO0HwXe6eFiNj4ls3BTA2LtkXAHpyBivYK8b/aNs7CD4GX19p0ar9hubbUbJxn5JWuF+fn1Er8H+9XrmnTm60+1uCQTLEsmQCByAeh5oAsUU1N2xfMwXx8xUYGadQB458ab2fW/H3gHwJYzwlL69GpanbyDIa2gYSBW4PDFJMDuyDOK9VF3dHXXsjYSCyFsJhe712mQsQYtvXIADZ6c15N4OZfFH7RvjHU76BFk8M2VvpdkFB+7IXdnY/3s7wO21sc4yfWLWK6l0p4tbNs8z+Ysn2YMqFCzbQMknOzGeeucUAXnG5GXJGRjI6imxRmKBIw7OUULvfknA6n3qpd2FpcaULSaJ3tEVCEVmBwhBXkHJ5UfWlku7SK0TUruRbWERgmS5PlbFbHDbsYOcde9AFiQxxJ507Rr5andI2FCjvyeg4/SpSORWc1tdXd1qMGpLZTaRNEiQxBG8w5DCQSEnBB+XGAO+c8Vo0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV5US5cw3FtvjQrIGkUFdwbIIHqCAQfpViqTXCaZZRtqV4pzIsYlkAXczvtRcDjOWVaAHSyXT3dobQWz2ZLi4ZnO8YHy7AAQfm4OSOKi1ISaha3dnp2ovY3ibQZ4o1doskN91wVORxyO9LeaVBcaabGJprKHerg2bmFlIcPwV6Akc+oJHerYCFpRGVEh+8VxkHHBNAHjn7RGm20EvhnXp1umtzd/2NqUNtP8AZvtVlcfejllyu1A6L95lX5myRmuR1PxBJ4f8TeBtTuNY8PPNps7Wdzpmh2bnTbKynfbJMJwMKyhYyVYgDjCgZLey/Ebw9d6/8MNc0Jbj7Tf3Fi6JI6KDLIBlcgcDJA6DjOa8TfV9P1/4fpo1z4h0nRDrWiSXFv4b8MacWUyH5wzOqkh8qVaIbc8jJ5JAPoi0sptOlsbTTVt49IijdXjfe0ueNu1icY65zntVm9dLdZ7q8uI49PigZpRIAFUDlmZj2ArkPh9qdz4+8B2Or6lJ5dlq+m+TNZxDaUky6SOsikEbh0HVcdc10yvGbttEfTrqSzFmGNxKqvA4JKGIksWL4GSCMYPXtQB5x+0a5uPgT4plRreSydLV7Vos8p50Jye3XJGO2K7z4euZPAPhp2yWbTLZjuOTzEvWvPPjtq2ma1+zx4ku9EkWSwUJAm2NowpjukRl2sARhlI6duOK774a4/4Vz4V5z/xKrTk/9cVoA6Q9OOtICSTxx/OlPtWD491KfRvAviPUrIqLqy025uYsjgOkTMP1AoA8o/Zie71HwZ4x1+JI21nVNZuZEmuC2yQhFMYYjnYGZhx717fB9oxH5wi/1Y37Cfv98Z7V55+z1A1t8FPCiQquTAZCDkDDSsxP15NegA3f9oNuFv8AYPKBByfM8zJzkdNuMd85zQBMG37TEyMmSGPXpxx+NRXUFtfQy2t3DFcQkDzIpUDK3cZB4PSks4IbRBBaQLHbkvJ8mAAzMWPHuWJqGTWLGPXYdGecDUprd7uOHa3MSMqs2cYGC6jGc8+xoAW8R76OP7DqDW/lTgyNAEfeFPzRnIOM9DjkVeFZ7Qxy/bLBLWe2hkQs1xCRGGZ87ipU7g/fOB1BzmrVpbra2kNujyusSBA0shd2AGMsx5J9zQBNRQOlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcn8TfGtv4B8OJrV9aTXVoLqGCbyjzEjtgydOcenc4GRmtSwvIx4eivdWv7G5tzidbxAEhdC26JxkkDgpznryKuazpllrWlXem6pbpc2N1GYpoX6Op6j1H1HI6ivG/gXe3fg/wAR6z8LPEEvmHT2a70a4lIX7TaOd21QQNxU7icE4O8dEoA9lW0jbUhqCyzFzD5IQSnyiud27b03f7XXHFNsfsNwJNQ037LK9wAGuIdp8zbkAFh1xyPbmlspb17u+S7tooreOQC1kSXcZU2KSzDA2kMWGOeAD3qrpMNrLZQ/YLa402CC5kPkCHyN5DOGJXHKsSWB78GgC+kCu0E9xHEbuNCu9RnbuxuCk84JA/IV80/C/UrPwn/anh5vGMWhadpPiG+szp8OnpLeXsQK+XK7gFl5437MEKFzwK+lYru1mvJ7eKeJ7q2C+bGrAtGGGVyO2ccfSvn7R7e+0fx38U9EfXtV0nTHvoNXjXTrPzrmQ3By7REKxGSFQ/KenbByAdT+zmI7r4bSaKjXccGgaxPZxSlTbSzBJBMDIgPy5MhVkJOQOepFeptetL5y2UXnSQTrDKrkxgZ2kkEjnCtnjr0rzD4JX7tb/EIWX268u49dmmji1QmC5ctBFsEgIyikrtUlfujpxivTNSa//s6OSze0trgPG8puAXRYwwMoyCOdu4A9M4JFAHmH7ROpm9+D/jq0NjfW4sjbR+fPEFjuN0sL7ojn5lGcE4HII7V3fwz/AOSb+FMf9Am0/wDRKVx/7S0jP8E/FPyr5Hk27JIGzuJuI+MenTn3rtPh2CPh/wCGQwAI0u1yAOB+6XpQB0Fec/tEaudF+DPiedE3tNbfYwPaZhGT+AcmvRq8T/a8V5fhKsEKs80+pW8ccaAlnY7sKAOp9qAPRPAuiXGgaHo9mNRWXTLTS7a0SAwBT5qA7pS+f4gVG3HG3OTmtq7uJbCGWd4p7wNMipHbxAuisVXnnkAksT2GfSozaQ6hZT2OpWKPaxOqBZgrLKFCsHA7Yb9Vq2JZjemLyP8AR/LDCbeOWyfl29emDn3oAYUe2aCOxtoPIaQ+cd2zYCCdwAB3EtgY46k54xUcOoebf39r9jvE+yBD5rx4jm3AnEbZ+YjGD0wSKd5aWUt3dS3E7JM6HY7blj4CgIMcA9T7kmrY3bjkDHY560AZ+l6mdR0Wz1D7DfWpuY0k+y3MQjni3dnXPykdxnitGoENyb2QOsQtAi7CCd5bnOe2OlT0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV4v4F+NNz4g1vSrO+0W2jh1Nb0wmyuzPPD9myW82LYNofHykE5PH0u6x8ctFtvDmv6hp+m39zfaOkUktjMBGSrvtDF13hQD1zyDgY5oA9borgPEHxV0Pw9PYJrVnq9kl2sbCSa12CPexUBlLbsgjnAOKV/ir4fTxAuktDqm7+1P7Ga6+xt9mW74xGZOmTkYx9Tgc0Ad9RXF/DHx2vjqy1KcaRe6abK7ktsXCnbJtZlyCQPm+X5l/hyBk12lABRRRQAV4Z+0lZT+Hrzw18StItt15oN1HFess2xpLRmx5eDkYJdlyBkeZ0I6e51zHxN0BfE/w+8QaObZbmW6s5BBGxwDMF3RHPbDhT+FAGrp91/bNjpOp2M7xWk8a3PlsgzIjx5VT6Y3A8elSWN8mpwrPYuyxRzyRSCSJlLbCyMADj+IZB6EDjrXlv7PWtWNz8G9Cn1nUFS50SWSyuGupfK+zSB2RI2yQPuPGoB9QOtemn+2f+ElBB0//hHvshyMP9q+07xjn7nl7M/7W72oAn1WO8bT7j+yZLaHUGX91JcRmSMN23KpUkfQivG/FE72fxa8WWq3viS0N9pdhcB9AsftMuImnBDHY+wnBA4Gc9ex9MmhJ07W5vBNxpr6zJOVd7qV54FnUgMsgVsqQONoxg44ry7xedTPx9vIdJ/4SIyyeHIvMXRZLeNf9bKN0pn+XIz8mPmz7ZoAT4QO9j8R/iObFfEd/cyWtpc7deQQXN1KomUbcqoEZwqqSoAx6CvYYr/TjqYsLq6to9XurcTNp8k6NL5fIJCZyVzkEgYzmvKfhrBq0HxS8WpdRarBqB0e1MB1y5juJJP3kwV8w/KseRyo5znpnA9XaSC3Vrq6ign1e3tN0q2ybpSvUqg+9tLA4Hc0Aeb/ALR8s7fADxK1zaraSAwIIlcOAou4wpyB3XBx2ziu/wDAqtH4G8PKwJZdOtgc9f8AVLXnH7TRkl+Bmtyo9wou5LR/JlAHlgyxfIf7vIyc969Q8L2sll4Z0i0ni8qWCzhiePdv2FUAI3d8Y60AagIIyDketeIftG39wPE/wr0iNgkF54ihmdu4aOSNV/D96x/AV7ci7UVck4GMnvXiPx4tRffFX4PQF9mNVlnzjP8Aq2gfH47cfjQB65JqUcMd0dZjhsLYXC20MlxOm24DbQpHPBZmKhTySPcVfXeJtoRRCFGCDznPTHpiqV5HPb2N9L5b6pKCZ4LVvLU5UArGpOAPmHBY8E9cCroBmgXzUaNiAxXdyp64yKAI1lSGZLd5JJJZNzrlc4GfUDAAyBzUF5ZQ6vp9zZ6raBraRijRs+Q6g5B46ZwDipDczjV1tfsUptTAZTeb12BwwHl7c7skHOcY465qssUWsQpJqVjLAbS8Z4llfBJjZlWX5T91h8wB7EZFAFie8sWvRpc11b/bJomkW1MgEjxggMwXOdoJAz71cqhFPaXtnFq2nJBfF7cvbTRFSZUYBgFfphsL3x0qxYyyz2cMtxbtbTOgZ4WYMYz3UlSQce1AE+etFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXB/HXVr/QvhN4h1LSLqS0vreJGimj+8hMqA4/AmvPHm8czz3aaPceLItFuPEWmw21xd2xF3HAwYXb7XT5YQdhBZdo54xQB6V4a+Gfh3w94XvtDs4Hkhvo54bi6kCC5kSUtuUyIqnA3ED04rCs/gl4eg0vVNPm1DWLqHUNPi02QyyQqY4o33Js2RqAwOOSDnHOec834rTx1p3iq5s9MuvE13JAdPTRJVQPaTpkC6a8dVCBvvfexxt21Lf3HjIa34o58UjxCtzdDRIreDOltbiFvILsR5e7PXcQ2/aOmaAOi134M6Nrl1cXOo61r0lxdQ28N1J5sObjyX3IzExcHIGQu0HHTPNbDfDTR28zNzqH7zxCviU/vE/4+V24T7n+r+Ucdf9qvI9NuPiAPCusAaj4pjuJI7Y7bjSriSWGQNiUKxXcVYdfKDBcZXGap6hffEc6NpMkdt4tRgs2bJTcF528zCOLgRbk4Bwk6gAcnOcAA988H+EbTwpNqx068v5bfULp7w21w6tHBI7Mz+XhQwBLc7i3QV0deD6lrvjq21PUdLGneJTO+v2UsFxHbGWBLFvLEieao2kA7t2Omc8c4t/Dm58ZP8UbtNZXXrvS2Ny5uLiOW1ghG7EaGJ08tuOhic+p9wD22iisLV7rxNFeFdG0jRru02jEl1qstu+e42LbyDHvu/KgDdorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6APOvghaQ2fiD4oaBq9vHcTRa79taNkWQOkvzxnaeeNoPIwCRjoa9pZrj7VGFSM25Vi7FjuDcYAGOnWvAfAl7r0Hx6+IkVloukPq0sNnJcxT6tKIkwg5jkFqSwIdMgquCOrdu6aL4j23i+fW5E8ProhsvKfS31mbYsqtnzxIbTI+XjaBjvmgD0OO1igWQWscduZJDLIY0A3sTyT6k9z1rxXxfpsmofHPU2TRNW1dYtAt1P9mat9geItLMQGPmxlw2D3IGBkc8d/p+teL9Rsbe9sdE8L3FpcRrLFLHr85V0YZBB+x9CDXh2u6trmp/GfxdbX/wAPrbxFqdnplvZtDp+syQpDbMPMYFmRTKXMqjhQRs4B5JAO7+GEB074s+K0m0vVNKVNJtG8rUr830sih5fnWTe5C8Y27jyOg6D12W2QST3tpBB/aEkPlrI4xuAyVViBnbkn8zXzz8HNS8R3PxK8ZT6b4NXTrhLe0huLTWNanLQEB2UCRoZGO4MCFAVQoGK9euJPGVxd20z6B4f821YugXxFcqpLKV+ZRZ4bgnGc4PNAHE/tWtcH4TQQlFaS41G1ilRWOw8k49xkCvZ4kCRIgVVCgAKvQewr58/aWuvEs3gjSoNX0jR7aOXWbZITaatLO7yYchSrWyDBAPOeMDg17PpN14olvkXV9H0W1syDultdWlnkBxxhGtkB5/2h+PSgDerxPxoqa3+074I06SV/L0nTZ9RKDgb2LKP1VSfYV7ZXiUgDftdRE87fDeR7fvD/AI0AevRqZLZpdNm5mmEhaYswwGAcAE8cAgAcZ5q1LDFLPC7jMkJLp8xGMgjp34J61BHNDqljFPY3ZMLOrrLCQQwV+R9Dgg/U1O7wx3EYcoJpQVTPVsckUAI1zEiTuxYLBkudp44zx68elQPqVolnbXTSN5FyUETeWx3bx8vGMj8enerbMFzkEKASW7CmLNvSF4V8yOTB3A4wpGQf5fnQBCbPy4rSGxkFnb27L+6hjXayAYCYx8o6dMdKt1Ctui3T3AaTeyhCpc7cD0XoDz1qagAooooAKKKKACiiigAooooAKKKKACiiigAooooAralYWeqWMtlqdpb3lnKAJILiMSRuM55VgQeQDXM/8LD0L+2TpW+5/tEap/ZP2fyTu83y/M34/wCee3ndXX1x8nw80ST4iP4zYXJ1V7Y2xj8wCHO3Z5mMZ37PkznGO2eaAMiL4yeFRd6rbX7X2nS6daveSi6hAJjVgpwFJIbLKNpAbkcUy5+KlhNFJHawXen3tveWNvcwanaMrKLpiEACt1IU85wOM1kTfAnQrbSL23srrULx206awtre9uESFFdw4y0cW7IdQQx3H13U3wp8JL+SXV7vxtq8t1eXt5YXSG3uBKym03FN8jRIGyW5AReB1zzQB00PxV8Py+Io9IEOqKz6lJpH2trNhbC7QkGLzOhJwcYz74rH1f4yaWth4kh0y2uo9b0rTpr9La/i2rII+DnaxI5I+U7WwelbjfDLRWjVGudRKr4gfxJ/rEGbht2U4X/V/OePvdPmrCsPgZ4dsre4gTUtaeCXTp9LVHlhxFDKwZtuIgSwI4LZPrmgCwfitp+mHVZNelRY7SLTtsNtA/mGW6jZgu5jtOdpweAADk13XhrWYtf0iHUbe3ureKUsBHcx7H4OM4BII44IJBrk7z4WaRcHVSuoapC2pR2cc2xoWG22RkQbXjZSCGJYMCMgEYxXQ+B/CmneC/DsOjaN5v2WJ3kzKwLMzMWY8AKOT0UADsKAN+iiigAoBzRRQB4Z4GGP2rviKN3XTrY4H/XO36166ItRtNOMU23V5ZJ33bwsIWF3JAxyDtUhf9rFeQ+BgB+1h8ROQSdNtjx/1zt69at9QgmaOfSg+o293eNbzvHICluUV1ckHsGj2kDuaALcFg1m1hDprW9ppdtEYjaRwAAjACBSCAgXB4AOc9sV8/XcVrqvxl+JlxZ6J4a1WeBbCA/2zeeTh/KKOIvkbkgbCcrgheuSK+gBayWFvZW2jw20VskoEqPn5YsEnZj+LOOvvXzV4ak09PEXxFW/1rwDZC48S3iNZ+J7VZpWCsNrqTKh8sljgEEAqcHk0Aei/s+6ZNpN74+t5Ims4k1solit2LiKA+Uh+RtikjDKBkZCqqkZUk+p2ssc2o3hWG5R4dsLPIpWOTjdlOxxuwT68dq8p+ANpYanoni9ZbXTJLaPxXcTRLZjdbBo1gKPFyeMqGGOhr1a7uXS1mJmtrRxII0klO9ckgLkZXkk4Az1xQB5B+0VcRW/h3wfqmv6Yr/ZvEsAeCGbfmL94eHIXBYIjdOD8ucZNe1kEqQDg+teJftfRM3whEomKSW+oQSDaMbjhlx/49n8K9l0uSSXTLSSf/WvCjPzn5iozQBZrw63nD/te3Kb+U8OhMAdDvVsH8817jXg1lNBbftc69PdNHFFD4dEjSswVUA8olmJ6YGfwoA9bjWLxTodjcIdX0pBcJcCMFrWb93J9yQddjbcFe6mta4luEubVILdZYXZhNIZNpiXaSCBj5ssAMcYzntTdQNlNp8iX7QNZXC+S4lI2SB/l2nPB3ZxjvmpovJi228RRdiDbGuBtXoOPTjFAFczXv8AbCQCzjOnGAu115/zCXcAE8vbyCCTu3dsY5zSy30I1KPTiZBcSwvMpCHAVSqn5ugOWHFTv5jwMFIilIIBI3BT2PvTow4jUSMGkAG4qMAn2GTigDBl0q2PhyDwtc6zqBuJbIwrdfatt7IqBVaXeOd2WXLere9b6KFVVBJAGMk5NVreVjZw3OoQx2s/lgyKZAwiJxld+BkZ78ZxVqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8M8Crn9qr4jyKD8un2q/iYoP8K9ujaTcimEKpQsxDfdbjj36nn2rxf4Z/6Z+0X8UryLd5ccdpb7tuRuEagjPTqh4r2eaKSS2MaztHIQB5qgZB9cHIoAzX024sFhTw+bS3jlvjc3ouFeTzEcs0mz5htcsRgnKjnjpXgnwU8RC50fV9Wi8S6RpS6l4k1DUJYNQtfMVfkjY4k3oAArKS2ccgDHOfeNXv8ASdFtdc1S5ljjNtbCa9YuchFViuR24zjHWvnrwR4gg0H4OGDTvGOrxXNnokt4bCbQR5Ebsu7aHaDDLvfGS53ZzkCgDvP2ZNBgX4ReE7+aLy7qNruZPLym/wAyV13SYPznaFwT0GB2r1o/aokvJG23PJaCFQEOAo+UknBJYHnjr7VwPwR8Oiy+GHgttStZIdQsrR3jUu67PNJJ3LnBJBHBBwemK7m3axgm1GeO6UkPuut0+5YWCDggnCfLg446570AeXftK2aD4H+K7iYSmSZ7Wfy5GDCF/NhTCegwOcdy3rXongS4a88D+HblzlptOt5CfUmJT/WuM/aCtzffAnxKLKQXStbpcLJvDBkEqSEg9CNoJH4V0vwpuI7r4Y+EpYnV1OlWoyOmREoP5EEUAdVXiJAX9roYwPM8N/MPX95/9YV7dXiXxelTw58bPhh4gtrMyXF/cSaNcSchdkhRUyemQZXYDvg+nAB7BYSXk8l6uoWkUMcdxttism/zYwqkORj5Tu3DH+yD3p4eH+1GTyZPtHkgmbyjtK7j8u/GM5525z3pkFpNtvo726a4iuJGMahfLMUZUDYCvJ5BOevPtVnayeUsYHljhsk5Axxj15xQBBbXf2+weazWSJiZI0+0wshDKxXJVsHGRkeowQcEGnW63i6dCtxLA98I1EkiRlY2fA3ELkkDOcDJx6mnn7R9sXBi+y7DuBB378jGD0xjP6UrW6G7S4O/zFQxj5ztwSCfl6E8DnrQAsjxGRYJCC0ikhCM5Axn+Y/OpKginZ7yeEwSIsSqRK2Nr5zkL9Mc/UVPQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUnPelqC/uBaWNxckBhDG0hBOM4GevbpQB4l+z5atqWo/E6ee4mUzeJZMtE5VhscsBn0OQMemRXtAtIJdSj1FZJWlWFoAFmbyypYEkpnaWyo+bGRyM8mvGf2UZJJ/h7qesPCYzqWtXN1O0pIG3YvKHncAwxk4/i9OfadPNq9jA+n+V9kZA8XlABCp5BGO3NAHnv7Qt1BZ/BrxTLOixyTwC3UEqGkZnCrj165x1xXl3xZ8TE+D9d07RvHOuXkspi0yLSbrQkjEpkwpQSNAh5UMd27PHckZ7v9oizS707wlaX13cx2114ns0VrSLM8A8uXJjxklsjrg4z0PSuC1fxVJr3ifwhZ2fxCHii2u/EVlKumf2KLR4Y4nLNIZMAkAqMgjn2GaAPpYNbNeCESRm5gQN5Yf5lVsgEjPQ7TyfQ1FFY2DRXmyyt1S+ZjdKYQPPO0IS4x83yqBzngAdKZAtjc3d5c2SwC/TFrNcLEN42/MEJxkgbyQOnzH1qzLLGPJc3CohfaORhyeAPrmgDB8T6NayeEtWgW18uP+y5rNLaInyhHsICrGPl9AMD2rkP2XpvO+BvholslPtCHJJxi4kx19sV6JEltPrU1xDeSvPbx/ZpbdZyY0J2uCydA+CMHrg15J8AjNonjX4keEryRYjZan9ss7TzAQlvNudSig8DaYyQOhYZ5NAHtded/Hrwhc+M/hvf2enSyx6jZkX9oIk3NJLGrFUHcFskAg5BI6jIPolHegDlPAfjGLxh4Y0LWdPtXeDUIiZ2R1ItZFHzI2SCfmBAwPc4BrormW4h86RIRNEkRZY4z+8dxn5RnC88YyRzXkN+Zvg74zu9TW23fDzXrhZLwwrj+yLxsL5pA/5ZP8oJ7HHT5Q/rUNv5AuZrJzI11Ksx82ZmQfKqnb12jC5AHGST3NAEsc8skVq4tpE80AyJIyhogVzg4JBIOBwTUscSo7spbLnJyxI/D0qCad2umtI4pkZoTItxsBjU5xjr97vj070l1Ztd2C281zOj/KWmgcxMSCDxjoDjkehoAmuZHgtpJEhkuHRSRHHtDOfQZIGfqRUtZus3k2mpJfvhtNtraWW4jjjLzMw2ldgHXgPx6kVoROJIkkCsoZQ2GGCM9iPWgB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcx8UG2/DPxa27bjSLs59P3L109cD8e9XXRfg54tumiMwexa02g4wZyId34eZn8KAMX9mxrmH4K+Do47XfFJ9p852faYl86Zg2P4snaMf7We1emfuXS4tPs0ghiQDaI9qMCOi+v4Vwnwo0+HS/g94Y086hPaKmmw38lygCBVY+awLMCAOSDntnpXbzy3N4mm3Gj3Vm1pJIssrspkE0BQ48tlYAEkoQ3IxnjmgDyL4xSNd+Lfh7dQQ69DJBbX9/BHp1j580MqrBsMkXXaA7AqDySF71m+EL/U9S+NPhe11nW7vWrux0m7umS60X+zpbMS+WBvGTktjGMDHHXNP8b6rcax8dJtOefxTZWei6aIUuvDtv5zK9yFdvPbY4RSqDAK9VDZGK0PhDa2Nx8WfE93bav4g1WbTtJsrFpNbG2ePzGkkKY2KcAIhyRnLMcnOaAPYTcywWkL3cDGZ3WNktwZApZsZ7fKM5J7DNRQadbabpi2ul2NusMTF4rcAIgYsWJHBxySenWs7Tk+wRW/h/T9aa61GyWKa4fUD587wM7ZLEFeW2sobtjoa4D4mfEyz8NeI54PDukrqHiGMW9le6lcFo7DTI5XPl/aZh90bmzjjgn5gRggHp1xJYR3LWLTRWuoaijMBGQsshCgFge5UAc9sCvJPGK2/g34h6H8RbeKWLTLgyaDr888TBwoYJFcNxgLviUFzjI2AA7uKFv8UPG3hrXGTx9H4X+wRzxRPFYSvHNLDKVVLq33sRLEGbDAAEe3NXvFnxWsJtYbwX4P0y68b6u7yJcwlozabH3Bllk2kMil1BGAOAC2QQQD24EEAg5B70V876f8Lvi3p2nSR6Z49sdNSLL2enWyyPbxbjnyg0gLLGvRc7sAdqtN8TPGnwxvBD8XtOi1DR7qUpa6zpKrhGAJKOnHUYIBCnhsbsfKAe739pb6hY3FlewpPa3EbQzROMq6MMMpHoQSK8o8PS3Pw21Sy8IeJnkvvCV1OI9C1Wdi5t3yDHZzccEHOxicEAAYxhfVdMv7TVdPgvtNuYbqznUPFNC4ZHU9wRVXxLoWneJdDvNH1q2W60+7TZLE3GecggjkEEAgjkEA0AX42lM0oeNVjGNjBsluOcjtzTYDE80zoCJAdj5BHTp17c15/8L9a1G1/tLwX4imkuvEehKGinnfB1G0YnyZgSATgYjc4bDLySWrsotUkOo2mn3FheRXM9o1w8scZe3hYFQYzLjG/LHAxyFJ4oAmhF1aRX015Obtd7SxJFBtZExwgwTuPB54zmrcEnnQRybHj3qG2uMMuexHrVSHOm2NlbyyXd442QGZk3u5xje+0ADpknAFXqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvJv2qWI+BviAc8vbD/AMmI69Zrx/8AawcJ8E9XBcLvntwAf4v3qnH6Z/CgDuPAjCTwd4fsZLVntjo9sTI4BjbMYBQj1x+hqe9s7XULLUdF1nS0tdBjEMMD/aAiTrgHACkMm1gFxxnHHFU/Cs9xceCbJHS50+K3sbVo7uLy385REjsUX5jjqmGUHrgdDW/DcRaklsy2zS2c8K3CSyptAzgqCjfMGwc8jjHODQB4TLqC23xl+JtzHrOtaR5b6TDv0zTTerKxgYZlUROQB90YK5z3OK2PhGv9v+JviJqniDUlu7a51qPSrRJlNtL/AKJudVK/KcjzRxjJKsSOa4vwlq1la+O/iPdX3i/xFo+pTeIJIGi07S/tavDCzCLLfZ5cH5mAXI4HINdr+z/d2zaR4vnnR57m48WahJbLdRCOaSTYjfMpAEchAOQQuPQUAdL8W/Glz4b+HcupaTZzJ4h1IrYadbsgE5nkJVcKQdxXJYLg5wB3rh/B9nZaHYQ6Z4G8V2VxqlzvXU9C8TxvC+p3BGZZQkgWZHYDZkBkwOQSGJk+LusW0vxc0C21fV7nw9YaHpcmqf2hZ27TzCWYtFszsdEXCdWHOcDkjF+W31XXXTzbjwP48s44nhk+RYdRcFDlI2DbEYq2TkrjcegoA828dadJeaXpnw50TRbnTNW1i6WeTQb5TdR6NGG3NPaXIAUoxDFhuccsoCHIr6O+HvgnRvAfh2HSNCtwiKAZp2A8y4fu7nuf0A4GBXkP7N2lWup+M/GHiq0tp7WxgkXR7G0vbp7m4tQiq0i7mJwpJXHJ7jPGT9CUAFZniTQtN8S6Jd6TrdpHd2F0myWJ+/oQeoIOCCOQQCK06KAPnT4LanefDf4nap8K9XN5Lps8jXWiXE5HCFWcjnAKsFP3eA6vxljj6Lr5y/amistF8V/D3xhLCoew1OOO5lXJdoo3WVVx04/eH1+avoxGV0V0OVYZB9RQB5r8SAnhnxt4a8bBpUt939i6m4j3olrKSyMQBlcTCMbh/ewa9DaWcX8cItibdo2Zp94wrAgBdvU5BJz04964H9oiGeX4N+I2tE3zQJDdAY7RTxyEn2AQmu00vWLW90jSr9poYl1GON4A0g+cum8KucbjjJ47AmgCXS7KWxW6E1/dXvnXEk6m42/uVY5Ea7VHyr0Gcn1Jq7UcEbRx7XleU5J3MAD16cAdKbZ3CXdrFcRBwki7lDqVbHuDyKAJqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8V/a9Dn4N3Gw/KL2Dfx1GT/AFxXtVeR/tWLu+CGuHbnbLbHPp+/QZ/X9aAO38HxXsfhXRPIktzCukwKkRzgy+WuDu67ccVpvDqFxHpZa9js7iJ1lvIoEEiTjYwaMFhkLvZW3AA/KB3NYng7TIb3wp4KvZZLlZbGwhkjWOUojlrcId6DhuGJGeh6V0cf7l0a9kgM8kjRxMF2kqSWCD1OF5+lAHzx4MurjTNY8f3t14+OgaPH4pvIn02CximmaSR/lcsVZxvwdoAx8h56iuh/Z7vpIPDniZ4INQ1f7T4wu4vtQjRJdrCP/SZkcpt9WAG4Z4WsCPWbfwL8Vfiasut6VoUVze6fc/a7u3MsjJJG7yLHGvLHccZJwOuDniT4KeNrG2vfiNptjLqeryS63PfQXFhpzP5nnAgvkEoozHxvKg8HuQADoLybXtJ+Kmqw6bqmiSamvhmyjln1ljBHcziaYCTZH0H3shemQO9YHiWyuR4X1nVNT0X4ZtNHZXFx/aOj38lvcCTymBKMI9xYnIxvGehNQ+PrXXNT+M+h3dx4N0eb+2dLns7ex15YrsqbcmYvhWKoxDhRhj1Oar/GTQfsXwv8QXMnws8MaLHFDEftlvcRefGzTKuYxHCCdpIzllBBPUZBAPXfgf4Xh8JfC/QdPiRBPJbrdXDhQC8snznJ74yFBPZRXd1znw2ma4+HfheWRZFd9LtmIkbc2TEvU966OgAoGcDPWiigDxH9r+3SX4QSyt5O+K9gZS65bJJGEPY4P5A16/4fdpNB015GLO1tEWJ6k7RzXkP7X999k+DssA2f6bfQQfMATxuk49D+76jtmvXfDoI8P6WCMEWsQI/4AKAOb+NU0cHwk8XtM8UanTJ03SsVGWQqBkdySAB3JAqb4cafEfhr4KTULWNp7PS7N0EsYZoZRbqpZc/dYAsMjnBI71hftGqk/wAJtTsC6ibULi0tIY8jdKzXMXyqO7bQxwPQntXealc2Wj2b6hezNBa20e1jliqqSB90dT0GcZoAeEluLu0vILx1svJfdbiNcSlthRySNw2gNwMZ389BVmGVJ4klibcjDIPqKfRQAUUUUAFFFFABRRUc88UCBp5UjUnGXYKM/jQBJRUcFxDcAmCWOUDglGDY/KpKACioFvLZr17NbiE3aIJGgDjeqk4DFeoBIPNT0AFFFFABRRXHaR8RvD+r+I7rRbBr+S6tbma0nl+xSiCKWIEurS7dgxt7nnI9RQB2NFYt94m0u20++uoLqK+NnGJZYbSVHkCnpxuAGe2SM1U8V+N9E8L2kM2q3SiWZolS1RlM7eY4RWCZBIyeT7GgDpaKxrfxJpz2l7dXkq6fb2l29m8l5Ikas6nGQd2MHtnB9hVbwn4x0fxRoMGrafcCO2mSWQLcMqOEjkaNnIycLuQ89KAOiorPfWtKSaKJ9TsVllKrGhuEDOWGVAGecjketV28Rae02mrZyC9iv5XhjntXSSNWUEncd3sRxnmgDYoqjZavpt/dT21jqFnc3EHEsUM6u8fb5gDkfjVyR0jRnkZURRksxwAPc0AOorlJ/H+gGZoNMuJtaulO0xaTA93tPozoCif8CYVH/afjDUz/AMS7QrLR4T0m1a582Uf9sYSVP4yigDr68l/adudPk+EGv6bcalaW99KkUkMEkyrJKUlRyFUkFuFPSur/AOEQvdQJPiLxNq16p621k/2CD6Dyv3hHs0hqW48CaCvhzV9K0nTrTTTqVpNayXMEK+afMQqWZvvMee5PSgDy74M+Mri8+HHgi3/sGbU9bjjmgsri6litov3ZdCEdiXbEYAJRG4BzXfSWHjK7s2n1jWrKzSN2cQ6HYiecZYgBZZsqSAcZEQPX1wOC/ZW1ObSvA2v6Lrt9Dt0HVpLNeRiIMQMA/wB0yF8E+pr3FY/svlR2lunlPIzSYbbtzli2O5LfzoA+dfFXhEaB8XL03+saVBYavpgvYtW8R24vys1ttR0VWdEDbZA2SDgDCgc1r+DL63uviobI3cniHw34n0RYRdXtuI4ZZbTIZYF2hfKxKxKgfeYnJxk7Xx9jv9N0jRPGsGmw3d/4X1T7QAJSoNm42yAj1J8vJwSNuRxmuO+JepvDqeieIZ9bn8T+IfDF+LqeHw9ZkWtpZEjzxMwZ9rlYyPmkzjGVxlqAOr+LMEF7ceBvEmmzSarYf2u1qIo7owsxu08hWilH3AjAHHf1Fc9r/hd1+Hfi2wvfB3iWKebTpLljPrK3UReJ2aNt+/JcYD42njjmu6+MWnWHiz4SeL7j7RNJZDTvtlrLDMrxSeSnnpJH1GGPyse4HGODXnXhO00e4tYtUsPBMlvYX+nx6ff6v4Y1dryWFJIoy0bWq7nHJAOAzjG7J60Aelfs33hvvgn4XkOwFIZIcJ/sSug/HCjNelV87/so65FY3HirwOy3sTadfSXVpHfHZKLdiF2mMgFSCAx4xmToCefoigAooooA+cf2rZLXXPE/w88HyTqGv9RVrhE/1kcbukSsPY5k/FfavoyKNYokjjG1EAVR6AV8w+Hpm+KX7Uk2sJa2t74f8NJ5CTHIC7d5jbB+83mlyOMYXPYZ+nZ4Y7iGSGeNJYZFKOjqGVlIwQQeoNAHmvjuX+2fix4G0C2tlml09pNdupJCNsUKq0KEA8ljI4xjpjPqR31vd2HlXV6pjhUSNFNK42ZZGKck9eRgGvFfhn4F0TxO3iLxfa6DokNnqd2tvpVoFDQwW8DeVI67AADIyO2AODg5Oc16UPAfhkztHHp91C6gNviuriPI9NyuM/TNAHVtLtuEi8uQ7lZt4HyjBHBPqc8fQ1JXHReB9JN3PEv/AAkNvCgUq8XiC+RHJznCrMORgdu9TDwRbqB5WueJUYfxf2tM/wCjEj9KAOrorlP+EQnU/ufFfiWNfT7RE/6vGTR/wjGsIB5XjnxASOglt7Bl/HFsCfzoA6uiuV/sHxIh/d+Mbhwf+e2n27EfTaq/1pP7K8YIP3fijTGx087Ri2f97bOufwxQB1dcp8UdAs/EXgXWLW902PUZI7Waa1iaLzGE4icIyD+98xAxzzWrdX8uheGbjUNdlS6eygee5ksrZowyqCxKRl2PQdNx6fhXPH4maC9pqFxZLe30djBa3Mxt4QQEuFDR4JIH3SGOSMA80AeeeHdO1PwL4L+G93o+galBG7IfEFrp9kWuJSYCAZYwNxw+Mk9O9UNKHxA19LaHUbvxZpcTWGpzs0UJhk81bg/Z0YlDg7MYAwSBwSOvo9l8XPDl/pumXOnJqN5c6hdTWkFjBb77gvEAZeAcbVBUkgkYYdapx/F3RJHTUUnP9hnRJNXwbZ/P2pcCEnrjGTjbjPfOKAOGN18R5tMubq2tdVTU38NacZJPsYSXzvOP2gJuUAzBMnaeh6DOKf4uvPEH9iWdv4XX4hGB57k/bLyG486NhFGUUxqgkZC27azkKG35yMY9Is/ijo13a63JHY60k2krDJPazWRimeOU4SRVYj5TySSRgAk4rHT4uWerT+HH8Oxh7S/1C50+7+1IQ8DxQGXA2nB/h5BIwaAOy+HVxql14D8Pz+IFnXV3sojdiePy5PN2jduXAwc9RgV0VeX2Xxg0ZNO0EXa3V9qmp2QvhDp1q3+rLlAwV2zyQQFBZuOnSvUKACvCtI+GWv6F4l8X6vLbaVdW2pXWpXkUsN/d/aESZH2Ri3CiJmyRknJ5OCcCvdaKAPmzw58JfEWs+Bkee30rRbqXwyukwW4Ekcsjs6SM91mMFSNuNoDHJJzXQ+KfhPr+oa1q81k2hTQajcafcm6u3kFzb/ZtgaJMRkFTtJHI64I7j3KigDxWb4W65HdpfRNot9JD4m1DWUsb15Ps80NwpVd5CEiROo+UjPeuV174Va5ZeGfAWgwM39pyXF5puqXOnRu8A0+eZppNzlRtwNoAIGWJAzX0pRQB4p4x+Ds2uaz4lu4INE8q9fShYCdSWt4rY4mT7h2hlwAASDjnFTaX8KtT07X7e6t5NKhsIPEl7q8cEbOoS3mtliRAoQAMGBJAIGOhzXstFAHknwc+G+s+Ctau572fTo9MNr9ngs7dzcMjF9xYSvEjqmBjYS+ScluBXql9Z22oWslrf28NzbSYDxTIHRsHIyDweQKnooAZBFHBEsUEaRxKMKiKAAPYCn0UUAFFFFAHzvoxPgv9rHVdOexjh0vxZbCaAq4C+Yqb2cj1Mkcox1y4I68/QixkTO5kchgAEONo9xxXin7U3hm4ufDOneL9GgR9X8NXKXW4IzO0IYEj5eoVtrnOMKHOR377wPq2ja/4Rj8WRypFHrVvHJeO1y/lI6r5bIu44TawK/KBkjPJ5oA2bjS47i2udJvoZtQ02/W4Nw1zIrBQ5H7rHB24ZgMdAvXpXh2lXF3osd98PfHF/baToekWxeI2sAFx4gsAGURjGQDtGHCDzG3AArhmb6A0yxt9M061sLJGS1tolhiVnZyqKMAFmJJ4HUkmsDxp4a0fxpayaVqKzR3lpsuba8gDRzWchJ2Swy44YFM4B7DI5FAHzlrPhnxVb+GpdD8P6zceHU1GWEXnhed2mgsLe9n8iFEnKknc+5nAxw5+XKnd1fh+0sbm58OR6de3mlebA9h4b8SRoFffASj2V3GPkkBaJnXdjeBgEMMmPX9O8beE7ZofEOnX/imN/EtlrbazpcYZ5I4nQNHJbjlSFiXaFynPUY5W38SG9j8b6N4Y8N6/qc2o6ot9o7rYva21vJtiKzlpNuzbcIXPHzHnGC2ADi/EMfijw94x8R/FZ7jSrjV9C1eLTtRsLJGW3eBreOPzAzPu5LouzBKtz2r6l8GeKdJ8ZeHrbWdBuRPZzjvw8bDqjjsw9PxGQQa8os9FsvCqeH/CN9fLqGpRSTeKvEzvGXF3EFkzIwYYf9/5QUdf3YbAIzXnOn+GJpfEF5r3w/8AGTWHim8dbue1UmKCaa8Y3FpCqOgVk+z+Y7Bt2CuAOuAD65ryL46ePmsNOHg/wpH/AGn4u14SWMNvbTDfahlAaR8MChCtlScAYLE4U15rJqXxqvtU8PaMPFdgG1m5uvIubW1jObWIr/pJYR48og5TBBbcOuRj2n4Y/CvQfh+bq6sTcX+s3n/H1qd62+aTJyQD/CpbkjqTjcTgYAE+Cfw8g+G/guLSy8c+pTt599cRjh5SANqk87FAwM4zycDJFR/FzVLm4t7HwbocpXWvELmBnjdQ1rZjmeY5Bx8gZVOPvMMcgCui8aeL9K8H6al3q0kjSzN5drZ26eZcXcnaOKMcsxyPYZ5Irmvhz4euotX1HxF4sRIvGuqw5eKJ2kXT7TICW6MSVOCu5iOrE9QASAdDaaC9voUmgafI+i6baiGGwnsXXzRGgUnO9SMkhlPByCT1Oa3b8XRtJBp7QJdY+Rp1LIDnuAQeme9TKCAoJ3YHU9TTZZ4oWiWV1UytsQE/ebBOB+AJ/CgBxcCRUO7LAkcHHGO/brVfS7GHTdPt7O2MhhgQInmOXbA9WPJ/GrCKERUXoowMnPFEe/Yvmbd/fb0oAdRRRQAUUUUANljSWN45VDxuCrKwyCD1BrzSy+C3hqy8HSeHbW41RLd7+PUVuTMjzJLHgIMshVkUKAFZSMe/Nem0UAePaz8JLjTrSwk8GX0/9rW+o3V/9tvb4QyK1woEoBSB1ZTtX5SoPHDCptC+CemQeE7TTNX1G9kul0R9EnktWVEMbzidmUMpO4MMAnjHbNet0UAcB4h+Feh69Pqc13c6kkl/FaRsYpEHl/ZmLRsoKEE5PIbcD6CodJ+EmiabJbyLf6tPLDqU+qb5ZIsvNNCIXztjA27RkAY59uK9FooA8u1H4J+HdR0XSNJu77VpNN022W1jgZ4SJFDlsljEWVjnBaMoSAB2r0T+y7T/AJ5t/wB/G/xq7RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQelABRRRQBHcRJcQyQzLujkUow6ZBGCK+dfhvMnwx+Jmq/DbxJEjeG9YmN1oc1y5eLJb5YcNkZPTsd6jrvBr6OrgPjT8O7f4jeE/sQlFrqto/2iwugozHIB90nqFbjOD1CnnaBQB3RaOWUx7zviIYhWIxnOM46jrxUUk0kyg2LRMyTBJPMzgAH5gMd8dO1eU/Ar4lXWumbwh4xhns/G+kxkXKTJj7SikDzAem7BXPZs7lyCdvpupeVfeHrn7ZJd6dDLA3mOkphmhGOSGU5Vh6g0AadUDfTRaNLfXNjcLLFE8rWsQEsrbcnaoHDMccD3q47lZUURu27OWGMLj1riNa8SzancR6Z4LnL6xdqPMnkQtFp0AdgZnQ8biQwROCxGfuqTQB5fezaj4k1PUtLuM6d4p8RIlzqMoII8O6THtIgdyeWkC5aP5RmZiQBya+r3llpn2jxlBZu1/NJP4higi+SE2liwsbYKuM7XhufN3g4OOPlIx7zoPhzTtF0I6VDF59vJva5a5xI907/6x5SfvFsnOeO3AAFS22i6QlxbXFtYWiSWls1hCY4woihyuYlA4C/IvHtQBwWs+GNW8O23grVvCKprB8OWI02azcKsl5aMsSs8TEgCUeUrAE4OSM9mtnxb431dnt9B8DPp0ygk3WvXaRwqewCw72f8MDjrXa2OqW2p2t22jTQ3LWs0lq4yVVJYztZDxxgjFXyW3qAoKnOTnpQB574W8CXun36+I9d1OHxH4tdkUXlynlw2cJIEiW0a5CfJuGRgseuMmu8E7m/Nv9mlEYiEn2j5dhOSNnXOeM9Mc9alSJI41jjURovRU+UDnPajaxkYlsxlcbcdD65oASBHSPEshkbJO4gDgkkDj0GB+FV5ryCH7U94v2e3s1ErXM+FjA2klgxPAAzknGK5/wAbeOtA8F6CNX8SzPaRh3SCFk3TTOuRhFHXOOCcDBBJFeWxeGvFXxrv4NT8Ym68PeA1YNa6GjlZ75QQRJOR0BIGM8gD5QM+YwBqXXxa1bxpq8+i/B7S49RMQ23GuX4aO0ticYIGNzn73GOoyAwzXU/C/wAG+JPD93qGp+MfF11r+pXyIvlfMlvbYznYmdvPHIVeh45Ndpo+l2Wi6dBp+lWsNpYW67IoIUCqg68Y9Sc/XJq7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAgzjmloooAKKKKAPI/jd8JR4zNvr3hqddL8YWDCSC6U7PO28qrsOQwwNrduh46ZHw8+OkUt1N4b+JNvH4b8VWgZXe7Pk20xAyCWP+rJHPOVIwVJ3Ba9zrzP426D4d8S6XbaTqekJqniC8DQ6YkbeXNETjdL5gBKRpwzEgjoMMSAQDo/F+v3Vnd2uj6AsVx4gvY3aGGQExwoMAzykdI1J6dXOFHci14L0OLRdLbIlk1C5kM17dXGDNcy9N7EcdAMKOFXAGAK8Hsfh18TvhIxvPAOoWXie1liVLmyu4QjAqMLty4JVcnADjGT8pratfj/AKK6Lp3xM8M6v4ZuzJHKsVxBJIjBWDLJ91XGHXptPQcnkAA96hMjJmZFR8nhW3DGeOcDtUN5byTyWrR3MsAhl8x1TGJRtI2NntyDx6CuKsPip8PNVMF3D4t0hGjBKfaLn7OQCOcq+0/mK1rrxl4Uu7eSGPxdo8LEKxeHUYQ6g8g8k9R+lAGxq1o+q2N7p5nvLFZY9i3dpKElXOclDg4Ix1x3q1e3EVpaS3NzPHb28KmWWWUgKiKMsSTwBgHntXIX/wAR/AxjjLeNtEiCSBj5OoxEtjnacE8GuJ1z9orwqsyWXhOz1PxTqEobZb2Vs6AkdjuXdg+qq1AHtQIYAggg8givLfiZ8V9B8H6wunaday654xnTyIdPsRvdSeVWUj7uSc4ALc5xg5rkreH4vfFENFqZXwB4ebcf3KFryYHjYcsGHfn5OvRq9O+HPw38OfD+zeLQLVjdSjE99cMJLibnPzNgcewAHGcZ5oA5DwH8M9Q1TXR4z+Kxg1HxI4H2bT8BrbTVByFQZILD15wcnLH5q9hOeMYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACikCgMxGcnrkk0tABRRRQBh+LPEMWgWcQjge91S6YxWNhEcSXMuM4H91R1Zzwo5Poa/hHw9Lpr3OqaxMl54hvwpu7hRhEUfdhiB+7GuTjuSSx5NT6X4djttevdavrhr7UpyY4ZHXAtbfORDGvYcAs3VjyeAoG7QAVS1XStO1e38jVrC1voP+edzCsi/kwNXaKAPN9S+B3w41GeWa48L2qSSnLeRLLCAfZUYAfgKxb39m/wCHFwAIdMvLXDBsw3shyAOV+ctwe/f0Ir2KigDy6z+Afw1tVwvhpJGxgtLdTvn83x+Vd9oWg6RoFqLfRNNs7CEKF228KpkDpkgc/U1p0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8vR+IvsPixh4nt9RvvF0/iQ2ph/tee0ezt/MXyHghVSksO3dn1753ZH1DRQB4ZpfxW1K48Q6Xoc9xAurN4nuNNvLY2xVktFDmM8jAJAXnPPPvXGfCTx34h0/wjo9l4euovETRaJf3Vzpy2+XsJYyWh3ODuYyEkbScnsBxX1NRQB81aV8VfF82lF49Y0i7mnurCFH8lWe2aaTZIkkaEYHIwCQwwQfWtvxz4u8caJc+LIbXXrAnw3ptpfOf7MGLt3Zty4LnYuB6k+4r3qigD5/174qa3b/FOw0yxvY0spNWsdPn0+5hRW2Tqm54+rsuWJDkgcgYPU19Q+JniVPDPiDUk1y1h8SWn2g/8IydO3PaxxzbQ7N94/INxY/Kd3GMV9EUUAfOnjDx+fFuoanBpd6lxodjrWgNZSxIyFhM7mTJOCRlBWxpfxW1K48Q6Xoc9xAurN4nuNNvLY2xVktFDmM8jAJAXnPPPvXudFAHzVY/ELx7qGmafdpr1hCNS0zVLxVGmKxgNnKwGCX+YsFwSRgDtnmvevA+qz674K8P6tdqi3N/p9vdSrGMKGkjViB7ZNbdFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A patent processus vaginalis allows open communication between the peritoneal cavity and the scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Langman, J. Urogenital system. In: Medical Embryology, 4th ed, Williams and Wilkins, Baltimore 1981. p.264.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Indirect inguinal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse section of the anterior abdominal wall illustrates the herniation of peritoneal contents into the inguinal canal through the internal inguinal ring, along the course of the spermatic cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9367=[""].join("\n");
var outline_f9_9_9367=null;
var title_f9_9_9368="Intraatrial reentrant tachycardia";
var content_f9_9_9368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraatrial reentrant tachycardia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9368/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9368/contributors\">",
"     Munther K Homoud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9368/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9368/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9368/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/9/9368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardias have traditionally been characterized as automatic, triggered, or reentrant. However, the European Society of Cardiology and the North American Society of Pacing and Electrophysiology in 2001 proposed a classification that takes into consideration both anatomic features and electrophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/1\">",
"     1",
"    </a>",
"    ]. Atrial tachycardia is the overriding term that includes two major categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal atrial tachycardia due to an automatic, triggered, or microreentrant mechanism",
"     </li>",
"     <li>",
"      Macroreentrant atrial tachycardia, including typical atrial flutter and other well-characterized macroreentrant circuits in the right and left atrium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intraatrial reentrant tachycardia (IART) falls into the latter group. This topic will discuss the mechanisms, clinical manifestations, and treatment of IART. Discussions of other specific atrial arrhythmias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=see_link\">",
"     \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION, PREVALENCE, AND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraatrial reentrant tachycardia (IART) refers to any macroreentrant atrial tachycardia that does not utilize the cavotricuspid isthmus (",
"    <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"     figure 1",
"    </a>",
"    ) as a critical pathway for the reentry to perpetuate. IART generally occurs in one of three settings: post surgical repair of congenital heart disease (incidence of 16 to 50 percent post Fontan procedure, 15 to 48 percent post Mustard or Senning procedures, 12 to 34 percent post Tetralogy of Fallot repair), post surgical scar (incisional tachycardia), or post catheter based or surgical management of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. With the increase in atrial fibrillation ablation, an increase in IART is arising due to the surgical maze and catheter based procedures in the left atrium. IART has also been reported in the absence of surgical or catheter intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reentry refers to a circuit in which previously excited tissue is re-excited, producing an extra beat or a sustained rhythm. Sinoatrial (SA) nodal reentrant tachycardia and IART (also called reentrant atrial tachycardia) are the two major types of paroxysmal reentrant supraventricular tachycardias in which the reentrant circuit does not involve the atrioventricular (AV) node or accessory pathways (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"UTD.htm?38/33/39441\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=see_link\">",
"     \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reentry pathways are usually defined by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two discrete but connected pathways",
"     </li>",
"     <li>",
"      Slow conduction in one of the pathways and unidirectional block in the other pathway",
"     </li>",
"     <li>",
"      Block in the pathway with unidirectional block following a premature beat, with conduction through the slower pathway allowing the pathway with unidirectional block to recover conduction and conduct the impulse back to the first pathway, hence initiating reentry",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Block may be anatomical (accessory bypass tract, slow or fast AVN pathway), functional (ischemia, electrolyte imbalance or anti arrhythmic agents), or both.",
"   </p>",
"   <p>",
"    IART has a different activation sequence of atrial depolarization, leading to a P wave morphology that differs from that of normal sinus rhythm. In comparison, SA nodal reentrant tachycardia has an activation sequence similar to that of normal sinus rhythm so that the P waves on the surface ECG appear to be normal. Only the abrupt onset and termination of this arrhythmia distinguish it clinically from sinus tachycardia. (See",
"    <a class=\"local\" href=\"#H1013571688\">",
"     'Electrophysiological features'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=see_link\">",
"     \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IART was responsible for approximately 6 percent of atrial tachycardias in patients referred for electrophysiologic studies to an active electrophysiologic group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/5\">",
"     5",
"    </a>",
"    ]. Organic heart disease is common in adults with this arrhythmia. In children, intraatrial tachycardia is often associated with surgery that involves the atrium, such as the repair of an atrial septal defect or correction of transposition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/6\">",
"     6",
"    </a>",
"    ], but may occur with any repair that includes an atrial scar. Intraatrial reentrant tachycardia (IART) may be quite detrimental because of the elevated heart rate and the frequent loss of normal AV synchrony. It has been suggested that there is an increased rate of right and atrial thrombosis with IART.",
"   </p>",
"   <p>",
"    IART most often begins with an atrial premature depolarization that tends to occur quite early [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/5,7-9\">",
"     5,7-9",
"    </a>",
"    ]. The initiating beat may arise in either atrium, and an intraatrial conduction delay is necessary for the induction and maintenance of the arrhythmia. Ventricular premature beats very rarely initiate intraatrial reentrant tachycardia, and, if they do, it is usually due to rapid retrograde conduction through an accessory bypass tract, which results in the early prematurity usually required to initiate reentry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13989262\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and significance of intraatrial reentrant tachycardia (IART) are variable, depending upon the hemodynamic effects of the increase in heart rate and the heart rate achieved. Some patients are asymptomatic, while others have symptoms that range from palpitations and lightheadedness to, in rare cases, syncope. If a patient is examined during an episode of arrhythmia, they will have a regular heart rate greater than 100 beats per minute.",
"   </p>",
"   <p>",
"    Most episodes of IART do not precipitate hemodynamic compromise or limiting symptoms. However, higher ventricular rates associated with IART in a patient with underlying advanced cardiac or pulmonary disease can sometimes exacerbate their disease, leading to signs and symptoms of angina, heart failure, or worsening systemic oxygenation.",
"   </p>",
"   <p>",
"    In the face of persistently elevated ventricular rates (eg, for weeks to months), particularly if baseline ventricular dysfunction exists, heart failure (tachycardia-mediated cardiomyopathy) may ensue. The atrial rates tend to be slower than the atrial rates in isthmus dependent atrial flutter, allowing 1:1 conduction from the atria to the ventricles and, subsequently, more potentially detrimental hemodynamic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13989352\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of intraatrial reentrant tachycardia (IART) should be considered in the presence of a regular but rapid pulse and heartbeat on physical examination. The diagnosis cannot be confirmed, however, without an electrocardiogram or, in most cases, invasive electrophysiologic studies.",
"   </p>",
"   <p>",
"    The suspicion for IART rests on the patient's history combined with the electrocardiogram. A patient with a cardiac surgical history, particularly for correction of a congenital heart defect, presenting with what looks like atrial flutter should be considered to suffer from IART. Like other reentrant tachycardias, the onset is sudden, and vagal maneuvers may help slow the ventricular rate but will not change the atrial rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Electrocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an arrhythmic episode, the electrocardiographic (ECG) findings in IART are similar to those of most other regular supraventricular tachycardias (SVT), with evidence of atrial activity (P waves) associated with ventricular activity (QRS complexes) in a 1:1 fashion. In the appropriate clinical setting (eg, prior cardiac surgery, prior ablation, etc), the surface ECG can be highly suggestive of IART. However, the surface ECG alone cannot reliably distinguish between IART and other types of SVT, most notably focal atrial tachycardia. (See",
"    <a class=\"local\" href=\"#H1013571688\">",
"     'Electrophysiological features'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13989360\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As noted above, P wave morphology in IART is different from that in normal subjects due to a difference in the activation sequence of atrial depolarization. The sequence depends upon the reentrant circuit (",
"    <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"     figure 1",
"    </a>",
"    ) which, in turn, may involve an anatomical obstacle or result from functional changes in refractoriness. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition, prevalence, and mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinically, the P wave morphology in aVL and V1 are useful clues in identifying the site of origin of the arrhythmia. A positive P wave in V1 and a negative P wave in aVL suggest a left atrial origin (",
"    <a class=\"graphic graphic_waveform graphicRef73578 \" href=\"UTD.htm?7/58/8110\">",
"     waveform 1",
"    </a>",
"    ), while a negative P wave in V1 and a positive P wave in aVL suggests a right atrial origin. These changes reflect the vectorial sequence. The left atrium is posterior and to the left, so the sequence of the activation for an impulse arising in the left atrium usually is anterior towards V1 (leading to a positive P wave) and rightward away from aVL (leading to a negative P wave); the sequence is reversed with a right atrial origin. Both reentrant and automatic atrial tachycardias will show these morphologies.",
"   </p>",
"   <p>",
"    However, the electrocardiogram can be misleading in non-isthmus dependent macro reentrant tachycardias, particularly after catheter ablation for atrial fibrillation where the index of suspicion is always high that the atrial tachyarrhythmia is left sided [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/11\">",
"     11",
"    </a>",
"    ]. Counterclockwise isthmus dependent atrial flutter characteristically displays upright flutter waves in V1 and negative flutter waves in leads II, III, and aVF. If the isthmus dependent flutter is clockwise, leads II, III, and aVF will display upright flutter waves. V1 will remain upright as well. Any departure from this pattern, particularly in the appropriate setting (post surgical procedure, catheter, or surgical ablation) should lead one to suspect a non isthmus dependent IART. Left sided IART can display similar electrocardiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1013571688\">",
"    <span class=\"h2\">",
"     Electrophysiological features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, it is important to distinguish intraatrial reentrant tachycardia (IART) from other supraventricular tachycardias (SVT), particularly focal atrial tachycardia. Since the surface electrocardiogram alone is not reliable in distinguishing IART from other types of SVT, invasive electrophysiological studies (EPS) are employed to help make this distinction. Since macroreentrant atrial arrhythmias, including IART, are reentrant, they can be entrained during EPS with manifest and concealed fusion, and upon cessation of atrial pacing, the post pacing interval should be within 30 milliseconds of the tachycardia cycle length. The use of newer mapping techniques such as electroanatomical mapping further helps to make this distinction where focal mechanisms display centrifugal activation patterns, reentry displays an \"early meets late\", and the entire cycle length of the tachycardia can be mapped to the chamber containing the tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The behavior of reentrant and triggered activity atrial rhythms may be quite similar (",
"    <a class=\"graphic graphic_table graphicRef53347 \" href=\"UTD.htm?6/56/7052\">",
"     table 1",
"    </a>",
"    ), and intracardiac recordings are usually necessary to make the diagnosis with certainty. The following criteria have been used to help identify the type of arrhythmia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial tachycardia has conventionally been called reentry when the arrhythmia is abrupt in onset and termination and can be started or stopped by spontaneous or programmed premature beats. However, triggered activity can show the same features [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      has been thought to be quite specific for atrial tachycardias due to cyclic AMP-mediated triggered activity and to enhanced automaticity. In several small cohort studies, adenosine was ineffective in terminating IART [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Although some studies have provided conflicting data [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/12,16,17\">",
"       12,16,17",
"      </a>",
"      ], the criteria used to define macroreentry did not exclude triggered activity as the cause of the arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison to the atrial abnormalities, conduction through the AV node, the specialized infranodal conduction system (His bundle, fascicles and bundle branches, terminal Purkinje fibers), and the ventricles is not directly impaired in intraatrial reentrant tachycardia. Thus, the QRS pattern and duration should not be abnormal unless the rapid rate causes some type of functional conduction disturbance.",
"   </p>",
"   <p>",
"    Dual-loop figure-8 intraatrial reentry has been described that electrocardiographically mimics atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/18\">",
"     18",
"    </a>",
"    ]. All such patients had undergone surgery for ostium secundum atrial septal defect (ASD) closure. The arrhythmias were quite resistant to antiarrhythmic therapy, and ablation of both loops may be required. This mechanism should be kept in mind in patients with corrected secundum ASD surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13989360\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for intraatrial reentrant tachycardia (IART) is similar to that for other narrow QRS complex tachycardias (assuming there is normal AV conduction without bundle branch block) and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial flutter",
"     </li>",
"     <li>",
"      Atrioventricular reciprocating tachycardia",
"     </li>",
"     <li>",
"      Focal atrial tachycardia",
"     </li>",
"     <li>",
"      Sinoatrial nodal reentrant tachycardia",
"     </li>",
"     <li>",
"      Sinus tachycardia, including inappropriate sinus tachycardia",
"     </li>",
"     <li>",
"      Atrioventricular nodal reentrant tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more in-depth discussion of the differential diagnosis of narrow QRS complex tachycardias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Types of narrow QRS complex tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While intraatrial reentrant tachycardia (IART) can be transient and asymptomatic, persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic IART requires treatment to relieve symptoms and to prevent long-term sequelae such as tachycardia-mediated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts to acutely terminate IART should begin with vagal maneuvers. If vagal maneuvers are unsuccessful, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    can be administered. Catheter ablation of IART is generally the treatment of choice for chronic management of this arrhythmia, given its efficacy combined with the relatively poor efficacy of pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694418\">",
"    <span class=\"h2\">",
"     Acute termination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694500\">",
"    <span class=\"h3\">",
"     Autonomic maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autonomic innervation of the atria is less than that of the specialized myocardial areas which comprise the sinoatrial and atrioventricular nodes. Thus, vagal stimulation has a variable and often negligible effect on reentrant intraatrial rhythms. However, it has been estimated that this arrhythmia can be terminated by carotid sinus massage in about one-fourth of cases, particularly those arising in the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As such, for the acute termination of symptomatic IART, we suggest carotid sinus massage or another vagal maneuver as the initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694545\">",
"    <span class=\"h3\">",
"     IV adenosine and verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is controversy as to the specificity and efficacy of calcium channel blockers, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    have been reported to be effective in 30 to 50 percent or more of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/12,13,16,19\">",
"     12,13,16,19",
"    </a>",
"    ]. For symptomatic IART that is persistent in spite of vagal maneuvers, we suggest using adenosine via intravenous push for acute termination of the arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Intravenous adenosine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    is unsuccessful and symptomatic IART persists, we then use intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    . We typically give a 1 mg test dose and, if the dose is tolerated, an additional 4 mg is administered over 5 minutes. If IART persists and high-degree AV block is not present, an additional 5 mg is given over 5 minutes, with two additional 5 mg doses over 5 minutes administered if needed to a maximum IV loading dose of 20 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694425\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have been published regarding chronic pharmacologic therapy in IART, which appears limited in many cases by lack of efficacy and drug toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/10\">",
"     10",
"    </a>",
"    ]. Catheter ablation, however, has relatively high success rates for the acute termination of IART and for the long-term prevention of recurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For IART that is symptomatic or persistent, thereby requiring long-term preventive therapy, we suggest catheter ablation as initial therapy rather than treatment with an antiarrhythmic agent. This is particularly true in younger patients who might be subject to the long-term side effect of years or decades of antiarrhythmic therapy.",
"   </p>",
"   <p>",
"    Catheter ablation of macroreentrant atrial arrhythmias, including IART, has become the preferred treatment modality, with rates of acute success in terminating IART exceeding 80 percent in several cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. However, ablation does require specialized expertise and background knowledge of the predisposing factors. Electroanatomical mapping and irrigated tipped catheters have further improved the outcomes after these ablations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excitable gaps are critical for all reentrant arrhythmias. An excitable gap allows a reentrant arrhythmia to be entrained, and if entrainment is achieved with concealed conduction, the critical pathway is identified. This feature is used therapeutically when overdrive atrial pacing is employed to terminate these arrhythmias. This was employed in the management of IART complicating surgically corrected transposition of the great arteries. The problem was that if it fails or if overdrive pacing accelerates the heart rate, it may lead to hemodynamic compromise and, in turn, death [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since an excitable gap is usually present in IART, an atrial premature depolarization or atrial pacing can usually cause a beat to be inserted in the reentrant pathway, thereby terminating the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Radiofrequency catheter ablation is extremely effective in patients with recurrent arrhythmias and has largely replaced chronic pacemaker therapy or surgery (",
"    <a class=\"graphic graphic_waveform graphicRef58120 graphicRef50219 graphicRef82052 \" href=\"UTD.htm?39/40/40586\">",
"     waveform 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/5,20-22\">",
"     5,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraatrial reentrant tachycardia is common after surgery for congenital heart disease. Radiofrequency ablation is successful, but the recurrence rate is high [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. The reentrant circuit for intraatrial reentrant tachycardia often involves the tricuspid valve isthmus following the",
"    <span class=\"nowrap\">",
"     Mustard/Senning",
"    </span>",
"    procedure and in other types of repaired congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/32\">",
"     32",
"    </a>",
"    ]. The circuits in patients after the Fontan procedures differ, with the lateral right atrial wall being the more common area for successful radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ablation or pacing for typical atrial flutter may give rise to macroreentrant tachycardias arising in the right atrium, with such arrhythmias occurring more frequently as the use of ablation and devices becomes more common. The term \"lower loop reentry\" has been used to describe counterclockwise reentry around the inferior vena cava where the anterior portion of the reentrant circuit is the IVC-tricuspid valve isthmus and the posterior arm is the low posterior right atrial wall across the crista terminalis, making it a variant of typical atrial flutter in which the superior pivot point is lower [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/33\">",
"     33",
"    </a>",
"    ]. At other times, circuits may involve the free wall of the right atrium. The ECG usually shows negative atrial deflections in the inferior leads [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroanatomic mapping (EAD) has proven useful in ablating right macro-reentrant tachycardias including IART, particularly when the mid-diastolically activated isthmus can be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of invasive cardiac electrophysiology studies\", section on 'Mapping and ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694652\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available pharmacologic options for the prevention of IART include calcium channel blockers, sodium channel blockers, beta blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , all of which have been tried with some success at preventing IART recurrences. However, many patients with IART have structural heart disease, which limits the choice of available antiarrhythmic agents. If IART cannot be prevented, rate control can be attempted with non-dihydropyridine calcium channel blockers or beta adrenergic blockers.",
"   </p>",
"   <p>",
"    For chronic therapy of IART when ablation is not an option or has been unsuccessful in preventing recurrent IART, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    as first-line therapy rather than a beta blocker or antiarrhythmic agent. This suggestion is based on the efficacy of verapamil in the acute termination of IART in addition to it generally being well-tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/19\">",
"     19",
"    </a>",
"    ]. Beta blockers are also effective in some cases but have a larger spectrum of side effects. The use of calcium channel modulators, particularly class IC antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 2",
"    </a>",
"    ) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , is limited by major toxicities and proarrhythmic actions, especially in patients with coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694829\">",
"    <span class=\"h3\">",
"     Permanent pacemaker insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare circumstances, such as when IART persists following an unsuccessful ablation and standard pharmacologic therapy, insertion of a permanent pacemaker may be considered. Pacemaker insertion allows for the more aggressive use of rate controlling medications, especially in patients with sinus node dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pacemakers with anti-tachycardia features have been used to successfully terminate IART but have been associated with sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9368/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456745\">",
"    <span class=\"h2\">",
"     Our approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the available evidence, we take the following approach to treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the acute termination of symptomatic IART, we suggest carotid sinus massage or another vagal maneuver as the initial therapy.",
"     </li>",
"     <li>",
"      For symptomatic IART that is persistent in spite of vagal maneuvers, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      via intravenous push rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      for acute termination of the arrhythmia. If adenosine is unsuccessful and symptomatic IART persists, we then use intravenous verapamil.",
"     </li>",
"     <li>",
"      For IART that is symptomatic or persistent, thereby requiring long-term preventive therapy, we suggest catheter ablation as initial therapy rather than treatment with an antiarrhythmic agent.",
"     </li>",
"     <li>",
"      For chronic therapy of IART when ablation is not an option or has been unsuccessful in preventing recurrent IART, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      as first-line therapy rather than a beta blocker or antiarrhythmic agent. If verapamil is unsuccessful or not tolerated, beta blockers or antiarrhythmic agents can be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694871\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraatrial reentrant tachycardia (IART) refers to any macroreentrant atrial tachycardia that does not utilize the cavotricuspid isthmus (",
"      <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"       figure 1",
"      </a>",
"      ) as a critical pathway for the reentry to perpetuate. IART generally occurs in one of three settings: post surgical repair of congenital heart disease, post surgical scar (incisional tachycardia), or post catheter based or surgical management of atrial fibrillation, although it has also been reported in the absence of surgical or catheter intervention. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition, prevalence, and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IART, which is responsible for approximately 6 percent of atrial tachycardias in patients referred for electrophysiologic studies, has a different activation sequence of atrial depolarization, leading to a P wave morphology that differs from that of normal sinus rhythm. IART most often begins with an atrial premature depolarization and is perpetuated via a reentry circuit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition, prevalence, and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations and significance of IART are variable, depending upon the hemodynamic effects of the increase in heart rate and the heart rate achieved. Some patients are asymptomatic, while others have symptoms that range from palpitations and lightheadedness to, in rare cases, syncope. (See",
"      <a class=\"local\" href=\"#H13989262\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During an arrhythmic episode, the electrocardiographic (ECG) findings in IART are similar to those of most other regular supraventricular tachycardias (SVT), with evidence of atrial activity (P waves) associated with ventricular activity (QRS complexes) in a 1:1 fashion. In the appropriate clinical setting (eg, prior cardiac surgery, prior ablation, etc), the surface ECG can be highly suggestive of IART. However, the surface ECG alone cannot reliably distinguish between IART and other types of SVT, most notably focal atrial tachycardia. Because the surface electrocardiogram alone is not reliable in distinguishing IART from other types of SVT, invasive electrophysiological studies (EPS) are employed to help make this distinction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Electrocardiographic findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1013571688\">",
"       'Electrophysiological features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for intraatrial reentrant tachycardia (IART) is similar to that for other narrow QRS complex tachycardias (assuming there is normal AV conduction without bundle branch block). (See",
"      <a class=\"local\" href=\"#H13989360\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Types of narrow QRS complex tachycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While intraatrial reentrant tachycardia (IART) can be transient and asymptomatic, persistent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptomatic IART requires treatment to relieve symptoms and to prevent long-term sequelae such as tachycardia-mediated cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the acute termination of symptomatic IART, we suggest carotid sinus massage or another vagal maneuver as the initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4694500\">",
"       'Autonomic maneuvers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"       \"Vagal maneuvers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For symptomatic IART that is persistent in spite of vagal maneuvers, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      via intravenous push rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      for acute termination of the arrhythmia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If adenosine is unsuccessful and symptomatic IART persists, we then use intravenous verapamil. (See",
"      <a class=\"local\" href=\"#H4694545\">",
"       'IV adenosine and verapamil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For IART that is symptomatic or persistent, thereby requiring long-term preventive therapy, we suggest catheter ablation as initial therapy rather than treatment with an antiarrhythmic agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Catheter ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For chronic therapy of IART when ablation is not an option or has been unsuccessful in preventing recurrent IART, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      as first-line therapy rather than a beta blocker or antiarrhythmic agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If verapamil is unsuccessful or not tolerated, beta blockers or antiarrhythmic agents can be used. (See",
"      <a class=\"local\" href=\"#H4694652\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/1\">",
"      Saoudi N, Cos&iacute;o F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/2\">",
"      Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol 2002; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/3\">",
"      Chae S, Oral H, Good E, et al. Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence. J Am Coll Cardiol 2007; 50:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/4\">",
"      Fiala M, Chovanc&iacute;k J, Neuwirth R, et al. Atrial macroreentry tachycardia in patients without obvious structural heart disease or previous cardiac surgical or catheter intervention: characterization of arrhythmogenic substrates, reentry circuits, and results of catheter ablation. J Cardiovasc Electrophysiol 2007; 18:824.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Supraventricular Tachycardias. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations, 4th, Lippincott, Williams, and Wilkins, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/6\">",
"      Gillette PC. Supraventricular arrhythmias in children. J Am Coll Cardiol 1985; 5:122B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/7\">",
"      Wu D, Amat-y-leon F, Denes P, et al. Demonstration of sustained sinus and atrial re-entry as a mechanism of paroxysmal supraventricular tachycardia. Circulation 1975; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/8\">",
"      Josephson ME. Paroxysmal supraventricular tachycardia: an electrophysiologic approach. Am J Cardiol 1978; 41:1123.",
"     </a>",
"    </li>",
"    <li>",
"     Akhtar M. Supraventricular tachycardias. Electrophysiologic mechanisms, diagnosis and pharmacologic therapy. In: Tachycardias: Mechanisms, Diagnosis, Treatment, Josephson ME, Wellens HJJ (Eds), Lea &amp; Febiger, Philadelphia 1984. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/10\">",
"      Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol 1985; 6:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/11\">",
"      Medi C, Kalman JM. Prediction of the atrial flutter circuit location from the surface electrocardiogram. Europace 2008; 10:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/12\">",
"      Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation 1994; 90:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/13\">",
"      Engelstein ED, Lippman N, Stein KM, Lerman BB. Mechanism-specific effects of adenosine on atrial tachycardia. Circulation 1994; 89:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/14\">",
"      Iwai S, Markowitz SM, Stein KM, et al. Response to adenosine differentiates focal from macroreentrant atrial tachycardia: validation using three-dimensional electroanatomic mapping. Circulation 2002; 106:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/15\">",
"      Markowitz SM, Nemirovksy D, Stein KM, et al. Adenosine-insensitive focal atrial tachycardia: evidence for de novo micro-re-entry in the human atrium. J Am Coll Cardiol 2007; 49:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/16\">",
"      Kall JG, Kopp D, Olshansky B, et al. Adenosine-sensitive atrial tachycardia. Pacing Clin Electrophysiol 1995; 18:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/17\">",
"      Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/18\">",
"      Shah D, Ja&iuml;s P, Takahashi A, et al. Dual-loop intra-atrial reentry in humans. Circulation 2000; 101:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/19\">",
"      Garratt C, Linker N, Griffith M, et al. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol 1989; 64:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/20\">",
"      Kay GN, Chong F, Epstein AE, et al. Radiofrequency ablation for treatment of primary atrial tachycardias. J Am Coll Cardiol 1993; 21:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/21\">",
"      Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994; 89:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/22\">",
"      Baker BM, Lindsay BD, Bromberg BI, et al. Catheter ablation of clinical intraatrial reentrant tachycardias resulting from previous atrial surgery: localizing and transecting the critical isthmus. J Am Coll Cardiol 1996; 28:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/23\">",
"      Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial maco-re-entry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping. J Am Coll Cardiol 2001; 37:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/24\">",
"      Ja&iuml;s P, Shah DC, Ha&iuml;ssaguerre M, et al. Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter. Circulation 2000; 101:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/25\">",
"      Triedman JK, Alexander ME, Berul CI, et al. Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial reentrant tachycardia. Circulation 2001; 103:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/26\">",
"      Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol 2002; 39:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/27\">",
"      Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol 2003; 92:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/28\">",
"      Triedman JK, Saul JP, Weindling SN, Walsh EP. Radiofrequency ablation of intra-atrial reentrant tachycardia after surgical palliation of congenital heart disease. Circulation 1995; 91:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/29\">",
"      Van Hare GF, Lesh MD, Ross BA, et al. Mapping and radiofrequency ablation of intraatrial reentrant tachycardia after the Senning or Mustard procedure for transposition ofthe great arteries. Am J Cardiol 1996; 77:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/30\">",
"      Triedman JK, Bergau DM, Saul JP, et al. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol 1997; 30:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/31\">",
"      Dorostkar PC, Cheng J, Scheinman MM. Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease. Pacing Clin Electrophysiol 1998; 21:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/32\">",
"      Collins KK, Love BA, Walsh EP, et al. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease. Am J Cardiol 2000; 86:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/33\">",
"      Cheng J, Cabeen WR Jr, Scheinman MM. Right atrial flutter due to lower loop reentry: mechanism and anatomic substrates. Circulation 1999; 99:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/34\">",
"      Kall JG, Rubenstein DS, Kopp DE, et al. Atypical atrial flutter originating in the right atrial free wall. Circulation 2000; 101:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/35\">",
"      DePonti R, Verlato R, Bertaglia, et al. Treatment of macro-re-entrant atrial tachycardia based on electroanatomic mapping: Identification and ablation of the mid-diastolic isthmus. Europace 2007; 9:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9368/abstract/36\">",
"      Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol 1995; 18:1005.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 937 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-6ABA7822FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9368=[""].join("\n");
var outline_f9_9_9368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4694871\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION, PREVALENCE, AND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13989262\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13989352\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Electrocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1013571688\">",
"      Electrophysiological features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13989360\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4694418\">",
"      Acute termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4694500\">",
"      - Autonomic maneuvers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4694545\">",
"      - IV adenosine and verapamil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4694425\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4694652\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4694829\">",
"      - Permanent pacemaker insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456745\">",
"      Our approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4694871\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/937\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/937|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/10/27811\" title=\"figure 1\">",
"      Flutter circuit right atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/33/39441\" title=\"figure 2\">",
"      Sites of reentry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/937|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/56/7052\" title=\"table 1\">",
"      Electrophysiology in SVTach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 2\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/937|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/58/8110\" title=\"waveform 1\">",
"      ECG in atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/49/17176\" title=\"waveform 2A\">",
"      EP study tracings during atrial tachycardia mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/9/8341\" title=\"waveform 2B\">",
"      EP study tracing showing VPB during atrial tachycardia mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/15/8438\" title=\"waveform 2C\">",
"      EP study tracing RF ablation atrial tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34166?source=related_link\">",
"      Sinoatrial nodal reentrant tachycardia (SANRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_9_9369="Organic foods and children";
var content_f9_9_9369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Organic foods and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Debby Demory-Luce, PhD, RD, LD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9369/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/9/9369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organically grown foods are foods that are grown or processed without the use of synthetic fertilizers or pesticides [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Organic farmers attempt to protect the environment by using natural matter (eg, aged manure, humus, and compost) for fertilizer and biological methods of pest control (eg, crop rotation and natural insect predators like lady bugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/2,4,6\">",
"     2,4,6",
"    </a>",
"    ]. Livestock and poultry used for egg, dairy, and meat production are raised on organically grown feed, without antibiotics or hormones, and provided with access to the outdoors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standards for growing and labeling organic food may vary depending upon the certifying organization or agency. The World Health Organization (WHO) and the Food and Agriculture Organization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/7\">",
"     7",
"    </a>",
"    ], as well as the Environmental Protection Agency (EPA) of the United States have adopted or proposed guidelines for the production, processing, labeling, and marketing of organic foods in an attempt to ensure that all foods that are labeled organic meet the same minimum standards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11115603\">",
"    <span class=\"h2\">",
"     Labeling requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of April, 2008, food that is labeled &ldquo;100 percent organic&rdquo; or \"organic\" in the United States must meet the standards of the United States Department of Agriculture (USDA), with the following labeling requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/8\">",
"     8",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To be labeled as &ldquo;100 percent organic,&rdquo; all ingredients must be certified as organically produced and processed (excluding water and salt).",
"     </li>",
"     <li>",
"      To be labeled &ldquo;organic,&rdquo; foods must consist of at least 95 percent certified organically processed ingredients (excluding water and salt); the remaining 5 percent of ingredients may be non-organically produced but must be on the USDA&rsquo;s National List.",
"     </li>",
"     <li>",
"      Products at least 70 percent certified organic ingredients (excluding water and salt) can use the claim &ldquo;made with organic ingredients&rdquo; and may list up to three individual organically produced ingredients on the side panel, but may not claim to be organic on the front of the package.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11115610\">",
"    <span class=\"h2\">",
"     Market growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumer demand for organic foods has grown steadily during the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/9\">",
"     9",
"    </a>",
"    ]. Organic foods, including organic infant formulas, are available increasingly in supermarkets and chain food stores [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. Producers, exporters, and retailers are struggling to meet consumer demand for a wide range of organic food products [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/12\">",
"     12",
"    </a>",
"    ]. In 2011, organic food sales represented 4.2 percent of total retail food sales in the United States, up from 1.4 percent in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      According to the USDA, the area of farmland devoted to organic crop production more than doubled between 2000 and 2008, increasing from 1.2 million acres to 2.7 million acres. During the same time period, the area of farmland devoted to organic pasture more than quadrupled, increasing from 567 thousand acres to 2.2 million acres. Currently, certified organic farmland is found in all 50 US states [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several large food companies (eg, Sunrise cereal from General Mills Company) have begun to market organic products.",
"     </li>",
"     <li>",
"      Retail sales of organic foods in the United States have grown from approximately $1 billion in 1990 to $6 billion in 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/9\">",
"       9",
"      </a>",
"      ]. Sales of organic foods increased to $31.5 billion in 2011 (a 9.5 percent increase over 2010 sales) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/12\">",
"       12",
"      </a>",
"      ]. Fresh produce (fruits and vegetables) are the top-selling organic category followed by organic dairy products; organic products now represent 12 percent and 6 percent of all United States fruit and vegetable sales and dairy sales, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased demand for organically grown food can be attributed to [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/1,2,4,5,11,15-17\">",
"     1,2,4,5,11,15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concern about the nutritional adequacy of foods grown by conventional agriculture",
"     </li>",
"     <li>",
"      Concern that pesticides and chemical fertilizers have adverse health effects",
"     </li>",
"     <li>",
"      Concern about environmental effects of pesticides and chemical fertilizers",
"     </li>",
"     <li>",
"      Concern about adverse developmental and health effects from ingesting meat from animals treated with antibiotics, sex steroids, and hormone supplementation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Demand for food purity has increased despite governmental assurances that the American food supply is one of the safest in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Organically grown foods are promoted as and perceived by consumers to be healthier than conventionally grown foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/15,19,20\">",
"     15,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric healthcare providers should be prepared to help the parents of their patients make informed decisions regarding the purchase and consumption of organic foods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advocates of organic foods claim that organically grown foods are nutritionally superior to foods grown with conventional agriculture methods that use chemical fertilizers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/2,11,15,21\">",
"     2,11,15,21",
"    </a>",
"    ]. Many people believe that commercial fertilizers lack some nutrients that are present in \"natural\" organic fertilizers. They argue that \"natural\" fertilizers are better able to nourish plants and thus result in more nutritious foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nutrient content of a plant is determined by several factors, including the genetic makeup, climate and soil conditions, maturity at harvest, storage, and distribution time [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/2,22\">",
"     2,22",
"    </a>",
"    ]. Nitrogen, potassium, and phosphorous, the main soil nutrients required by crops, must be present in sufficient amounts for plants to grow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fertilization enriches soil by providing the necessary nutrients. It does not matter whether organic or synthetic fertilizers are used as long as all of the essential nutrients are provided [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/23\">",
"     23",
"    </a>",
"    ]. Synthetic fertilizers are formulated to meet this requirement. Organic fertilizers may or may not. Organic fertilizers (typically manure) must be converted to soluble mineral salts by soil bacteria before they can be utilized by plants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/23\">",
"     23",
"    </a>",
"    ]. Manure breakdown cannot be synchronized with crop growth. In addition, the nutrient benefit of manure is unpredictable because its composition varies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nutrient-deficient soil affects crop yields to a greater extent than it affects nutritional value [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/22\">",
"     22",
"    </a>",
"    ]. The nutritional content of organically and conventionally grown foods usually are similar regarding carbohydrate or vitamins and minerals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17,24,25\">",
"     17,24,25",
"    </a>",
"    ]; however, organic vegetables may have lower nitrate and protein content than conventionally grown foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/1,5,26,27\">",
"     1,5,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nutritional composition of milk and dairy products may vary because of dietary components of feed, time of year, and whether the farms are conventional or organic. However, milk produced by both organically and conventionally reared cows has similar protein, vitamin, total lipids, and trace mineral content [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"     17",
"    </a>",
"    ]. One study in England comparing milk obtained from conventional and organic farms found significantly higher levels of total polyunsaturated fatty acids including conjugated linoleic acid and -linolenic acid in the milk from the organic farms compared with milk from the conventional farms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organically grown foods may cost 10 to 50 percent more than conventionally grown foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17,29\">",
"     17,29",
"    </a>",
"    ], the reasons for which include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/3,30\">",
"     3,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The smaller supply; organic farmers are fewer and crop yields and smaller",
"     </li>",
"     <li>",
"      The increased cost of certification and labor intensity of growing food without synthetic pesticides and chemicals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FOOD SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three areas of food safety to consider when comparing organic and conventionally grown foods are microbial infection, natural toxins, and pesticide use. Additional information about food safety is available from the",
"    <a class=\"external\" href=\"file://www.foodsafety.gov/\">",
"     United States Government Food Safety",
"    </a>",
"    web site [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/31\">",
"     31",
"    </a>",
"    ] and the",
"    <a class=\"external\" href=\"file://extoxnet.orst.edu/faqs/\">",
"     Extension toxicology network",
"    </a>",
"    (Extoxnet) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microbial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbial infection is the main cause of food-related illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/33\">",
"     33",
"    </a>",
"    ]. Young children are particularly vulnerable because of the immaturity of their immune systems [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Escherichia coli (E. coli) 0157:H7, Salmonella, Listeria monocytogenes, and Campylobacter jejuni are the major pathogens of foodborne illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=see_link&amp;anchor=H8#H8\">",
"     \"Food poisoning in children\", section on 'Common and emerging microbial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Foods can become contaminated by fertilization with raw manure, irrigation of crops with contaminated water, or inadvertent contact with fecal matter during handling or processing. The risk of contamination with bacteria resistant to",
"    <strong>",
"     multiple",
"    </strong>",
"    antibiotics is higher in conventional as compared to organic farming methods, but the overall risk of bacterial contamination is not different [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/24\">",
"     24",
"    </a>",
"    ]. Illness caused by E. coli O157:H7, for example, has been linked to fresh-pressed apple juice and cider [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. Pasteurization, canning, and freezing help to prevent illness caused by Salmonella, E. coli, Campylobacter, and Listeria monocytogenes contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. An increasing number of major food-borne disease outbreaks have been linked to consumption of fecal contamination of fresh or minimally processed produce [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11,39-42\">",
"     11,39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention of foodborne illness requires safe food handling practices for both organic and conventional foods. These measures include (",
"    <a class=\"graphic graphic_table graphicRef73216 \" href=\"UTD.htm?4/17/4381\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thoroughly cooking meat",
"     </li>",
"     <li>",
"      Storing foods at appropriate temperatures",
"     </li>",
"     <li>",
"      Preventing cross-contamination from meats and poultry to other foods",
"     </li>",
"     <li>",
"      Keeping hands, tools, and kitchen surfaces clean",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Natural toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some foods, whether organically or conventionally grown, contain naturally occurring toxins: aflatoxins in peanuts and grains, solanine in green parts of potatoes, goitrogens in some raw vegetables, and other poisons in mushrooms and herbs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of these naturally occurring toxins are harmless when eaten in small amounts as part of a healthy diet [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11\">",
"     11",
"    </a>",
"    ]. As with pesticides, \"poison\" is a matter of dose [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pesticides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the debate about organic and conventional agriculture centers on the use of pesticides. Promoters of organic foods suggest that the pesticides used in commercial farming are detrimental to food safety and health [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/16\">",
"     16",
"    </a>",
"    ]. Surveys show that individuals who purchase organic foods believe that pesticides, at any level of exposure, are hazardous to health, food safety, and the environment, and that something must be done to reduce this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/33,44,45\">",
"     33,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many people are frightened by reports of pesticides in conventionally-grown foods, although the reports often lack scientific peer review. Media attention may perpetuate this misinformation. In 1989, for example, the media portrayed alar, a growth regulator used mainly on apples, as a potent cancer-causing threat to children. As a result, apples and apple products treated with alar were destroyed and alar was voluntarily withdrawn from the domestic market. However, many health authorities, including the Surgeon General and the American Medical Association, issued statements that alar poses no risk to the public's health when used in the approved, regulated fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although organic farmers avoid the use of synthetic pesticides, organic foods sometimes contain synthetic pesticide residues, probably because of cross-contamination by wind and groundwater [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11,18,46,47\">",
"     11,18,46,47",
"    </a>",
"    ]. The frequency and amount of pesticide residue in organic foods are usually lower than in conventionally grown foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/5,24,48,49\">",
"     5,24,48,49",
"    </a>",
"    ]. In a systematic review, detectable residues were found in 7 percent of organic produce samples, as compared with 38 percent of conventional produce samples [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the risk of pesticide contamination exceeding maximum allowed limits was small for both farming methods. Of note, all plants produce toxins (\"natural pesticides\") that protect them from fungi, insects, and predators [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11,50,51\">",
"     11,50,51",
"    </a>",
"    ]. Plant varieties that have been developed to be naturally pest-resistant may contain increased amounts of natural pesticides and have adverse health effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11,52\">",
"     11,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful and judicious use of pesticides permits a more abundant food supply. Pesticides increase crop yields and affordability of fruits and vegetables throughout the year. They also may prolong shelf life and retard mold growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential adverse effects from too much exposure to a pesticide range from mild symptoms of dizziness and nausea to serious, long-term neurologic, developmental, and reproductive disorders.",
"   </p>",
"   <p>",
"    Compared to adults, infants and young children have different levels of risk for adverse effects of pesticides. Several reasons are [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/13,33,54-57\">",
"     13,33,54-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children eat relatively more food (particularly fruits and vegetables) per unit of body weight than do adults",
"     </li>",
"     <li>",
"      Children tend to eat large quantities of single foods for days or weeks on end",
"     </li>",
"     <li>",
"      Children's behaviors, such as playing on the floor and placing hands and objects in their mouths, may increase exposures to pesticides",
"     </li>",
"     <li>",
"      A child's developing organ systems may be more susceptible to the effects of pesticides (eg, nervous system) or less able to clear the metabolites (eg, renal)",
"     </li>",
"     <li>",
"      Infants and children may have unique exposure pathways such as through the placenta and through breast milk",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Exposure in utero",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effects of pesticides may depend on the developmental stage when exposure occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/58\">",
"     58",
"    </a>",
"    ]. There is some evidence from animal studies that in utero exposure to organophosphate (OP) pesticides at high doses may affect neurodevelopment and growth in the offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The few studies that have focused specifically on pesticide exposure of children in utero indicate that OP pesticides are transferred to the developing fetus during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. No prospective studies to date have examined the causal relationship between exposure to dietary pesticides and adverse neurodevelopmental health outcomes in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies about associations between maternal pesticide exposure and fetal growth have conflicting results. In one study of an urban cohort of pregnant women and newborns in Manhattan, measurements of OP pesticides (chlorpyrifos and diazinon) were inversely associated with both birth weight and length prior to 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The adverse association between OP exposure and fetal growth disappeared within a year of the EPA regulatory action to phase out these pesticides. Conversely, in a birth cohort in California, maternal organochlorine exposure was not associated with birth weight, length, or length of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women living in agricultural communities appear to have higher levels of exposure to pesticides. Urinary metabolites of OP pesticides were measured during pregnancy and after delivery in 600 women residing in an agricultural community in California [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/62\">",
"     62",
"    </a>",
"    ]. Metabolite levels during pregnancy and postpartum were higher in this population than in a sample of women of childbearing age in the general US population. The differences were more pronounced at the post-partum measurement, when levels were 2.5 times higher than in the reference population. These findings may have implications for estimating dose of exposure during pregnancy and lactation.",
"   </p>",
"   <p>",
"    There is some evidence supporting an association between OP exposure and alterations in neonatal neurobehavior [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/60\">",
"     60",
"    </a>",
"    ]. In the cohort described above, neonatal neurobehavior was assessed with the Brazelton Neonatal Behavioral Assessment Scale (BNBAS), and in utero and early postnatal OP exposure was measured by urinary OP metabolites. The study revealed a correlation between prenatal urinary metabolite levels and abnormal reflexes in the infants. However, no detrimental associations were found between postnatal urinary metabolite levels and any of the neurodevelopmental measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Exposure in childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most evidence indicates that traces of pesticide residues in foods are not a problem for most people [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/68\">",
"     68",
"    </a>",
"    ]. However, data are limited regarding the toxicologic consequences of exposure to pesticide residue during infancy and early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who live in agricultural settings may be exposed to higher levels of OP pesticides than their urban counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Children of farm workers may be exposed to pesticides tracked into their homes by household members, by pesticide drift, by playing in contaminated areas, or through breast milk from their farm worker mother [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/58\">",
"     58",
"    </a>",
"    ]. Researchers in Washington State found that the median metabolite pesticide levels in 109 preschool children of agricultural workers were five times higher than in those in a reference population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/74\">",
"     74",
"    </a>",
"    ]. Studies are currently examining the effectiveness of interventions to reduce pesticide exposure to this population, including education of parents in pesticide safety and to remove contaminated shoes and clothing before entering the home, and to keep children away from pesticide-treated areas [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/72,75\">",
"     72,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pesticide regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of pesticide is regulated strictly by three federal agencies: the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA), and the United States Department of Agriculture (USDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EPA establishes a tolerance for all pesticides that are registered and approved for use in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/77\">",
"     77",
"    </a>",
"    ]. Tolerance is defined as the legal limit of a pesticide residue allowed in or on a raw agricultural commodity and, in appropriate cases, on processed foods [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/69\">",
"     69",
"    </a>",
"    ]. The pesticide tolerance for various crops or chemicals can be obtained from the",
"    <a class=\"external\" href=\"file://www.epa.gov/pesticides/food/viewtols.htm\">",
"     EPA's Web site",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    The EPA uses toxicity data from animal studies that attempt to mimic human exposure (eg, continuous low-level ingestion) to determine tolerance levels. Multigenerational animal studies are used to determine the pesticide's effects on reproduction, pregnancy, and lactation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If studies suggest that children may be harmed by exposure to a pesticide, the EPA does not approve the pesticide's use or it requires action to reduce the potential risks. Examples for which consideration for the health of infants and children affected decisions include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tolerances for the pesticide pydrin on alfalfa and sorghum were not approved in 1985 because of concern regarding risks to children from secondary residues in milk.",
"     </li>",
"     <li>",
"      The EPA limited the use of two organophosphate pesticides, methyl parathion and azinphos methyl, in 1999.",
"     </li>",
"     <li>",
"      Another organophosphate pesticide, chlorpyrifos (Dursban), was banned in 2000.",
"     </li>",
"     <li>",
"      In 2001, the EPA began to phase out diazinon, one of the most widely used organophosphate pesticides [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 1993, the National Research Council (NRC) issued a report on pesticides in the diets of infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/69\">",
"     69",
"    </a>",
"    ]. The report concluded that children may be exposed to relatively larger amounts of certain pesticide residues than are adults and that the exposure occurs at a vulnerable point in their development. It acknowledged the need for reassessment of pesticide tolerances that would apply specifically to infants and children and recommended the collection of data that would more accurately reflect the dietary patterns of children and the effects of pesticide exposure in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/54,56,69\">",
"     54,56,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NRC report triggered passage of the Food Quality Protection Act (FQPA) in 1996. The FQPA required the EPA to review and reassess all existing pesticide tolerances to make them safer for infants and children by 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The FQPA required the EPA to apply an additional 10-fold margin of safety to its pesticide assessments to address the potential for pre- and postnatal toxicity and to compensate for gaps or inadequacies in the available database regarding potential health risks to infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. The EPA is required to apply the 10-fold safety factor unless there are reliable data to support use of a different safety factor to protect infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/56,84,86\">",
"     56,84,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As of August 3, 2006, the EPA had completed 9637, or more than 99 percent, of the planned tolerance reassessments; the remaining tolerance reassessment cases were completed in September, 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/87\">",
"     87",
"    </a>",
"    ]. The tolerance reassessment process has led to EPA decisions to revoke or modify thousands of existing tolerances (3200 and 1200, respectively), and to require the establishment of many new tolerances, improving food safety and health protection. The new tolerances also ensure that pesticides used on foods meet the stringent FQPA safety standards [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tolerance levels are enforced by the USDA for meat and poultry and by the FDA for all other foods. The FDA specifically analyzes for pesticide residues all foods eaten by infants and children. As an example, pesticide residues on apples, bananas, oranges, pears, grape and orange juice, and milk were monitored by the FDA between 1985 and 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/76,89,90\">",
"     76,89,90",
"    </a>",
"    ]. More than 10,000 food samples were analyzed before processing and without washing or peeling. Fifty samples (0.5 percent) were in violation (0.3 percent of domestic products and 0.6 percent of imports). The majority of these violations occurred because the pesticide was not approved for use on that particular food.",
"   </p>",
"   <p>",
"    The FDA monitors nutritional concerns, including pesticide exposure, through the Total Diet Study. This study examines 234 foods selected to typify the American diet. Between 1985 and 1991, analysis of these foods revealed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No residues were found in infant formulas",
"     </li>",
"     <li>",
"      No residues over the EPA tolerance or FDA action level were found in any of the \"market basket\" foods",
"     </li>",
"     <li>",
"      Low levels of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/23/10611?source=see_link\">",
"       malathion",
"      </a>",
"      were found in some cereals",
"     </li>",
"     <li>",
"      Low levels of thiabendazole, a post-harvest fungicide, were found on some fruits and fruit products",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Total Diet Study findings for 2003 were consistent with previous FDA reports in that pesticide residues were below regulatory standards. An adjunct survey of baby foods also provided evidence of only small amounts of pesticide residues between 1991 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reduction of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pesticides begin to break down soon after application with exposure to sunlight and rain; they continue to break down after harvest [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/92\">",
"     92",
"    </a>",
"    ]. Additional pesticide reduction can be achieved through washing, peeling, cooking, or processing of foodstuffs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the FDA monitoring described above, the highest residue level of the fungicide thiabendazole in raw apples was 2 parts per million (ppm), in apple juice was 0.08 ppm, and in applesauce was 0.06 ppm. The established tolerance is 10 ppm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Canned or frozen fruits and vegetables are alternatives to fresh fruits and vegetables for individuals concerned about pesticide residues. Most current food preservation techniques minimize the loss of nutritive value and are safe and well standardized. One comparative analysis of fresh, frozen, and canned vegetables conducted by the University of Illinois found that canned foods are nutritionally equivalent to their fresh and frozen counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organic diets appear to reduce OP exposure in children. In one study of a group of 39 preschool-aged children in Washington State, children consuming a conventional diet had urinary dimethyl OP metabolites six to nine times higher than children consuming an organic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/94\">",
"     94",
"    </a>",
"    ]. In another study, the short-term effects of changing to an organic diet were measured in 23 school-aged children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/95\">",
"     95",
"    </a>",
"    ]. After only 24 to 48 hours of the organic diet, urinary OP metabolites (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/23/10611?source=see_link\">",
"     malathion",
"    </a>",
"    and chlorpyrifos) decreased to nondetectable levels. However, whether this reduction of urinary OP metabolites has any relevance to health outcomes has not been shown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11115752\">",
"    <span class=\"h2\">",
"     Hormone, sex-steroid, and antibiotic treatment of livestock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major reasons why consumers choose organic foods are concerns about hormone supplementation and treatment with sex-steroids and antibiotics used in conventional livestock farming [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormones &ndash; Hormone injections, especially with bovine recombinant growth hormone (rBGH), are given to cows to increase milk yield by 10 to 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"       17",
"      </a>",
"      ]. Studies show that conventional milk does not contain significantly higher levels of bovine growth hormone (GH) compared to organic milk. In addition, 90 percent of bovine GH is destroyed by pasteurization. Bovine GH is biologically inactive in humans, so even if it were absorbed from drinking conventional milk, it would not be expected to cause adverse health effects [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sex steroids &ndash; Treatment of cattle with sex-steroids accelerates the rate of growth, an efficient way to increase meat yield. It has been postulated that ingested estrogen in food derived from sex-hormone-treated animals may lead to earlier development of puberty. Limited studies have not supported this hypothesis in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17,96\">",
"       17,96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibiotics &ndash; On conventional livestock farms, antibiotics are administered in nontherapeutic doses to enhance growth and prevent disease. Many of these antibiotics are identical or similar to antibiotic drugs given to humans [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/97\">",
"       97",
"      </a>",
"      ]. A recent review suggests that the presence of antibiotic-resistant bacteria in non-organic foods may be related to the routine use of antibiotics. Organic farming that prohibits the use of non-therapeutic antibiotics may contribute to a reduction in disease caused by drug-resistant organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Organically grown\" refers to the methods used to grow and process agricultural products (eg, fruits, vegetables, dairy, meat, and poultry) and is not related to nutritional quality or food safety [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/1,5,11\">",
"     1,5,11",
"    </a>",
"    ]. Both organic and conventional farming supply nutritious foods when selected as part of a well-balanced diet [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/11,18,98\">",
"     11,18,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors to consider when deciding whether to use organic products include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Organic foods are not free of synthetic pesticide residues, but typically contain smaller amounts than are present on conventionally grown foods. Thus, organically grown foods provide an alternative source of fruits and vegetables for individuals who are concerned about synthetic pesticides. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reduction of exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children may be more susceptible to the adverse effects of pesticides than are adults. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Exposure in utero'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Exposure in childhood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the traces of pesticide residue that are found in food pose little threat to human health. Potential adverse effects of pesticide exposure on special populations include neurologic, developmental, and reproductive disorders. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Exposure in utero'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Populations involved in agricultural work have higher levels of pesticide exposure, but evidence of adverse effects of such exposure levels is limited. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Exposure in utero'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Exposure in childhood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pesticides help to maintain an abundant and varied food supply. Pesticide use is regulated by the EPA and enforced by the USDA and the FDA. Efforts are being made to ensure that these regulations are appropriate for infants and children. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pesticide regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to pesticide residue in either organic or conventionally grown food can be reduced through washing, peeling, cooking, or processing of foods. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reduction of exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organic food production does not eliminate the risk of foodborne illness, and \"organic\" should not be interpreted as meaning \"safe\". (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organic farming is typically performed by smaller, family-owned farms and may be more environmentally friendly [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because organic farming prohibits nontherapeutic antibiotics, it may reduce the risk of disease attributed to organisms that are resistant to multiple antibiotics. (See",
"      <a class=\"local\" href=\"#H11115752\">",
"       'Hormone, sex-steroid, and antibiotic treatment of livestock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It has been postulated that ingested estrogen in food derived from sex-hormone-treated animals may lead to earlier development of puberty, but limited studies have not supported this hypothesis in humans. (See",
"      <a class=\"local\" href=\"#H11115752\">",
"       'Hormone, sex-steroid, and antibiotic treatment of livestock'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regardless of the increased cost of organically grown produce and possible risks of pesticide residues, the American Academy of Pediatrics, American Dietetic Association, the American Medical Society, and the American Cancer Society recommend a diet that is rich in fruits and vegetables, with between five and nine servings of these foods daily [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9369/abstract/17,99-101\">",
"       17,99-101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Irrespective of the food production system, food safety measures are important. The following steps can be taken to reduce exposure to foodborne pathogens and pesticides: (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reduction of exposure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Buy the freshest foods available. They will have the best taste and highest nutrient (ie, vitamin) content.",
"     </li>",
"     <li>",
"      Consider using frozen or canned fruits and vegetables as an alternative or supplement to fresh produce. These foods maintain most of their nutritional value and may also reduce pesticide exposure as compared to fresh produce.",
"     </li>",
"     <li>",
"      Eat a variety of foods to ensure a balanced nutritional intake and to lessen contamination from any one source.",
"     </li>",
"     <li>",
"      Select produce that is free of dirt, insect holes, mold, or decay. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Natural toxins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Always wash fruits and vegetables thoroughly with a dish brush, but do not use soap or other detergents.",
"     </li>",
"     <li>",
"      Peel fruits and vegetables before eating and throw away the outer leaves of leafy vegetables. Some nutrients and fiber may be lost when produce is peeled.",
"     </li>",
"     <li>",
"      Trim fat from meat and skin from poultry and fish because some pesticide residues are concentrated in fat.",
"     </li>",
"     <li>",
"      Make sure that apple juice and cider are pasteurized, to reduce the risk of food-borne illness such as E.Coli 0157. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbial infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92754734\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Craig Jensen, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/1\">",
"      Fisher BE. Organic: What's in a name? Environ Health Perspect 1999; 107:A150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/2\">",
"      Worthington V. Effect of agricultural methods on nutritional quality: a comparison of organic with conventional crops. Altern Ther Health Med 1998; 4:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/3\">",
"      Trewavas A. Urban myths of organic farming. Nature 2001; 410:409.",
"     </a>",
"    </li>",
"    <li>",
"     Dimitri C, Greene C. Recent growth patterns in the U.S. organic foods market. US Department of Agriculture, Economic Research Service. Agricultural Information Bulletin (AIB) Number 777, September, 2002 www.ers.usda.gov/publications/aib777/aib777.pdf (Accessed on April 25, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/5\">",
"      Bourn D, Prescott J. A comparison of the nutritional value, sensory qualities, and food safety of organically and conventionally produced foods. Crit Rev Food Sci Nutr 2002; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Agriculture. Agricultural Marketing Service. National organic program. file://www.ams.usda.gov/AMSv1.0/nop (Accessed on October 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/7\">",
"      Kapp C. International food committee agrees on organic food guidelines. Lancet 1999; 354:314.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Agriculture. Agricultural Marketing Service. National organic program. Labeling organic products. file://www.ams.usda.gov/AMSv1.0/getfile?dDocName=STELDEV3004446&amp;acct=nopgeninfo (Accessed on October 30, 2012).",
"    </li>",
"    <li>",
"     U.S. Organic Industry Overview. Organic Trade Association&rsquo;s 2011 Organic Industry Survey. file://www.ota.com/pics/documents/2011OrganicIndustrySurvey.pdf (Accessed on October 02, 2012).",
"    </li>",
"    <li>",
"     Greene C. US organic agriculture gaining ground. Nutrition Weekly, Community Nutrition Institute, Washington, DC, April 14, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/11\">",
"      Magkos F, Arvaniti F, Zampelas A. Putting the safety of organic food into perspective. Nutr Res Rev 2003; 16:211.",
"     </a>",
"    </li>",
"    <li>",
"     Organic Trade Association. Organic Trade Association&rsquo;s 2012 Organic Industry Survey shows continued growth. file://www.organicnewsroom.com/2012/04/us_consumerdriven_organic_mark.html (Accessed on October 02, 2012).",
"    </li>",
"    <li>",
"     United States Department of Agriculture. Economic Research Service. Organic production. Available at: www.ers.usda.gov/Data/Organic/ (Accessed on October 02, 2012).",
"    </li>",
"    <li>",
"     Organic Trade Association. Industry statistics and projected growth. Organic facts. file://www.ota.com/organic/mt/business.html (Accessed on October 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/15\">",
"      Williams PR, Hammitt JK. A comparison of organic and conventional fresh produce buyers in the Boston area. Risk Anal 2000; 20:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/16\">",
"      Williams PR, Hammitt JK. Perceived risks of conventional and organic produce: pesticides, pathogens, and natural toxins. Risk Anal 2001; 21:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/17\">",
"      Forman J, Silverstein J, Committee on Nutrition, et al. Organic foods: health and environmental advantages and disadvantages. Pediatrics 2012; 130:e1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/18\">",
"      Organic foods: are they better? J Am Diet Assoc 1990; 90:367, 370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/19\">",
"      Magkos F, Arvaniti F, Zampelas A. Organic food: buying more safety or just peace of mind? A critical review of the literature. Crit Rev Food Sci Nutr 2006; 46:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/20\">",
"      Brandt K, Molgaard JP. Organic agriculture: does it enhance or reduce the nutritional value of plant foods? J Sci Food Agric 2001; 81:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/21\">",
"      M&oslash;rkeberg A, Porter JR. Organic movement reveals a shift in the social position of science. Nature 2001; 412:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/22\">",
"      Hornick SB. Factors affecting the nutritional quality of crops. Am J Altern Agric 1992; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     Whiting D, Wilson C, Card A. Plant nutrition. Colorado State University Cooperative Extension No. 7.730. March, 2005. cmg.colostate.edu/gardennotes/231.pdf (Accessed on April 25, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/24\">",
"      Smith-Spangler C, Brandeau ML, Hunter GE, et al. Are organic foods safer or healthier than conventional alternatives?: a systematic review. Ann Intern Med 2012; 157:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/25\">",
"      Williams CM. Nutritional quality of organic food: shades of grey or shades of green? Proc Nutr Soc 2002; 61:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/26\">",
"      Woese K, Lange D, Boess C, Bogl KW. A comparison of organically and conventionally grown foods-Results of a review of the relevant literature. J Sci Food Agric 1997; 74:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/27\">",
"      Dangour AD, Dodhia SK, Hayter A, et al. Nutritional quality of organic foods: a systematic review. Am J Clin Nutr 2009; 90:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/28\">",
"      Butler G, Stergiadis S, Seal C, et al. Fat composition of organic and conventional retail milk in northeast England. J Dairy Sci 2011; 94:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/29\">",
"      Winter CK, Davis SF. Organic foods. J Food Sci 2006; 71:R117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/30\">",
"      Leckie J. Is organic food production feasible? Nutr Health 1999; 13:109.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food Safety Agency (sponsored by the Food and Drug Administration and United States Department of Agriculture). Available at:  file://www.foodsafety.gov/.",
"    </li>",
"    <li>",
"     EXTOX FAQs. Questions about pesticides in foods. January, 1998. Available at: extoxnet.orst.edu/faqs/index.htm (Accessed on September 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/33\">",
"      Position of the American Dietetic Association: food and water safety. J Am Diet Assoc 1997; 97:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of Escherichia coli O157:H7 infection and cryptosporidiosis associated with drinking unpasteurized apple cider--Connecticut and New York, October 1996. MMWR Morb Mortal Wkly Rep 1997; 46:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/35\">",
"      McCabe-Sellers BJ, Beattie SE. Food safety: emerging trends in foodborne illness surveillance and prevention. J Am Diet Assoc 2004; 104:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/36\">",
"      Besser RE, Lett SM, Weber JT, et al. An outbreak of diarrhea and hemolytic uremic syndrome from Escherichia coli O157:H7 in fresh-pressed apple cider. JAMA 1993; 269:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/37\">",
"      Oliver SP, Jayarao BM, Almeida RA. Foodborne pathogens in milk and the dairy farm environment: food safety and public health implications. Foodborne Pathog Dis 2005; 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     Finley JW, Deming DM, Smith RE. Food processing: nutrition, safety, and quality. In: Modern Nutrition in Health and Disease, 10th ed, Shils ME, Shike M, Ross AC (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/39\">",
"      Keene WE. Lessons from investigations of foodborne disease outbreaks. JAMA 1999; 281:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/40\">",
"      Pell AN. Manure and microbes: public and animal health problem? J Dairy Sci 1997; 80:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/41\">",
"      Beuchat LR, Ryu JH. Produce handling and processing practices. Emerg Infect Dis 1997; 3:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/42\">",
"      Hilborn ED, Mermin JH, Mshar PA, et al. A multistate outbreak of Escherichia coli O157:H7 infections associated with consumption of mesclun lettuce. Arch Intern Med 1999; 159:1758.",
"     </a>",
"    </li>",
"    <li>",
"     US Food &amp; Drug Administration. FDA pesticide program pesticide monitoring 1993-2003. June 2005. www.cfsan.fda.gov/~dms/pesrpts.html (Accessed on January 07, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/44\">",
"      Hammitt JK. Risk perceptions and food choice: an exploratory analysis of organic- versus conventional-produce buyers. Risk Anal 1990; 10:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/45\">",
"      Williams JL, Hillers VN. Influences of pesticide residue and environmental concerns on organic food preference among food cooperative members and non-members in Washington State. J Nutr Educ 1994; 26:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/46\">",
"      Gonzalez M, Miglioranza KS, Aizp&uacute;n de Moreno JE, Moreno VJ. Occurrence and distribution of organochlorine pesticides (OCPs) in tomato (Lycopersicon esculentum) crops from organic production. J Agric Food Chem 2003; 51:1353.",
"     </a>",
"    </li>",
"    <li>",
"     Wardlow GM. Contemporary nutrition: Issues and insights, 3rd ed, Brown &amp; Benchmark Publishers, Dubuque 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/48\">",
"      Baker BP, Benbrook CM, Groth E 3rd, Lutz Benbrook K. Pesticide residues in conventional, integrated pest management (IPM)-grown and organic foods: insights from three US data sets. Food Addit Contam 2002; 19:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/49\">",
"      M&auml;der P, Fliessbach A, Dubois D, et al. Soil fertility and biodiversity in organic farming. Science 2002; 296:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/50\">",
"      Harborne JB. Role of secondary metabolites in chemical defense mechanisms in plants. Clin Foundation Symposium 1990; 150:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/51\">",
"      Ames BN, Gold LS. Pesticides, risk, and applesauce. Science 1989; 244:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/52\">",
"      Jadhav SJ, Sharma RP, Salunkhe DK. Naturally occurring toxic alkaloids in foods. Crit Rev Toxicol 1981; 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     University of California Division of Agriculture and Natural Resources. Beyond pesticides&mdash; Biological approaches to pest management in California, Agriculture and Natural Resources Publications, Oakland, CA 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/54\">",
"      Reigart JR. Pesticides and children. Pediatr Ann 1995; 24:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/55\">",
"      Koletzko B, Aggett PJ, Agostoni C, et al. Pesticides in dietary foods for infants and young children. Report of the Working Group on Pesticides in Baby Foods of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Arch Dis Child 1999; 80:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/56\">",
"      Bruckner JV. Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report. Regul Toxicol Pharmacol 2000; 31:280.",
"     </a>",
"    </li>",
"    <li>",
"     US Environmental Pesticides Protection Acency. Childrens' environmental health: 2006 report. yosemite.epa.gov/ochp/ochpweb.nsf/content/CEH06_Final.htm/$file/CEH06_Final.pdf (Accessed on January 30, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/58\">",
"      Eskenazi B, Bradman A, Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect 1999; 107 Suppl 3:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/59\">",
"      Brimijoin S, Koenigsberger C. Cholinesterases in neural development: new findings and toxicologic implications. Environ Health Perspect 1999; 107 Suppl 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/60\">",
"      Young JG, Eskenazi B, Gladstone EA, et al. Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology 2005; 26:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/61\">",
"      Whyatt RM, Camann DE, Kinney PL, et al. Residential pesticide use during pregnancy among a cohort of urban minority women. Environ Health Perspect 2002; 110:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/62\">",
"      Bradman A, Eskenazi B, Barr DB, et al. Organophosphate urinary metabolite levels during pregnancy and after delivery in women living in an agricultural community. Environ Health Perspect 2005; 113:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/63\">",
"      Richardson RJ. Assessment of the neurotoxic potential of chlorpyrifos relative to other organophosphorus compounds: a critical review of the literature. J Toxicol Environ Health 1995; 44:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/64\">",
"      Whyatt RM, Barr DB, Camann DE, et al. Contemporary-use pesticides in personal air samples during pregnancy and blood samples at delivery among urban minority mothers and newborns. Environ Health Perspect 2003; 111:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/65\">",
"      Whyatt RM, Camann D, Perera FP, et al. Biomarkers in assessing residential insecticide exposures during pregnancy and effects on fetal growth. Toxicol Appl Pharmacol 2005; 206:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/66\">",
"      Whyatt RM, Rauh V, Barr DB, et al. Prenatal insecticide exposures and birth weight and length among an urban minority cohort. Environ Health Perspect 2004; 112:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/67\">",
"      Fenster L, Eskenazi B, Anderson M, et al. Association of in utero organochlorine pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect 2006; 114:597.",
"     </a>",
"    </li>",
"    <li>",
"     Taylor SL. Food additives, contaminants, and natural toxicants and their risk assessment. In: Modern nutrition in health and disease, 10th ed, Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006.",
"    </li>",
"    <li>",
"     National Research Council. Pesticides in the diets of infants and children. In: National Academy Press, National Academy Press, Washington, DC 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/70\">",
"      Bouvier G, Seta N, Vigouroux-Villard A, et al. Insecticide urinary metabolites in nonoccupationally exposed populations. J Toxicol Environ Health B Crit Rev 2005; 8:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/71\">",
"      Harnly M, McLaughlin R, Bradman A, et al. Correlating agricultural use of organophosphates with outdoor air concentrations: a particular concern for children. Environ Health Perspect 2005; 113:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/72\">",
"      Fenske RA, Lu C, Simcox NJ, et al. Strategies for assessing children's organophosphorus pesticide exposures in agricultural communities. J Expo Anal Environ Epidemiol 2000; 10:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/73\">",
"      Fenske RA, Lu C, Curl CL, et al. Biologic monitoring to characterize organophosphorus pesticide exposure among children and workers: an analysis of recent studies in Washington State. Environ Health Perspect 2005; 113:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/74\">",
"      Lu C, Fenske RA, Simcox NJ, Kalman D. Pesticide exposure of children in an agricultural community: evidence of household proximity to farmland and take home exposure pathways. Environ Res 2000; 84:290.",
"     </a>",
"    </li>",
"    <li>",
"     US Environmental Pesticides Protection Acency. Childrens' environmental health: 2006 report. Available at: www.epa.gov/envirohealth/children (Accessed on January 01, 2007).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA Reports on Pesticides in Foods. FDA Consumer, 1993. Available at: www.cfsan.fda.gov/~lrd/pesticid.html (Accessed on April 25, 2007).",
"    </li>",
"    <li>",
"     Chaisson CF, Peterson B, Douglass JS. Pesticides in food: A guide for professionals, American Dietetic Association, Chicago 1991.",
"    </li>",
"    <li>",
"     United States Environmental Protection Agency, Prevention, Pesticides and Toxic Substances. For your information: Protecting the public from pesticide residues in foods. EPA Pesticide Programs, Washington, DC 1993.",
"    </li>",
"    <li>",
"     Cornell University Cooperative Extension, Pesticide Management Education Program. Available at:  file://pmep.cce.cornell.edu/profiles/ (Accessed on October 05, 2010).",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. EPA announces elimination of all indoor uses of widely used pesticide diazinon. December 2000. Available at: yosemite.epa.gov/opa/admpress.nsf/016bcfb1deb9fecd85256aca005d74df/c8cdc9ea7d5ff585852569ac0077bd31!OpenDocument (Accessed on February 28, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/81\">",
"      Wagner JM. Food Quality Protection Act: its impact on the pesticide industry. Qual Assur 1997; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. Pesticides: regulating pesticides. Accomplishments under the Food Quality Protection Act (FQPA), August 3, 2006, Available at: hwww.epa.gov/pesticides/regulating/laws/fqpa/fqpa_accomplishments.htm (Accessed on January 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/83\">",
"      Lefferts LY. Pesticide residues variability and acute dietary risk assessment: a consumer perspective. Food Addit Contam 2000; 17:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/84\">",
"      Renwick AG, Dorne JL, Walton K. An analysis of the need for an additional uncertainty factor for infants and children. Regul Toxicol Pharmacol 2000; 31:286.",
"     </a>",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. Protecting children from pesticides. January 2002. Available at: www.epa.gov/pesticides/factsheets/kidpesticide.htm (Accessed on January 04, 2007).",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. Determination of the appropriate FQPA safety factor(s) in tolerance assessment. Washington, DC. February 2002. Available at: www.epa.gov/oppfead1/trac/science/determ.pdf (Accessed on January 14, 2007).",
"    </li>",
"    <li>",
"     United States Environmental Protection Agency. Pesticides: regulating pesticides. Tolerance reassessment. file://www.epa.gov/pesticides/tolerance/reassessment.html (Accessed on October 02, 2012).",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. Accomplishments under the Food Quality Protection Act (FQPA). Available at: www.epa.gov/pesticides/regulating/laws/fqpa/fqpa_accomplishments.htm (Accessed on January 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/89\">",
"      Foulke JE, Ames BN, Gold LS. Pesticide residues in your children's food. Consumers' Research Magazine 1993; 76:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/90\">",
"      Yess NJ, Gunderson EL, Roy RR. U.S. Food and Drug Administration monitoring of pesticide residues in infant foods and adult foods eaten by infants/children. J AOAC Int 1993; 76:492.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Pesticide program residue monitoring 2003. May 2005. Available at: www.cfsan.fda.gov/~dms/pes03rep.html (Accessed on January 07, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/92\">",
"      Hotchkiss JH. Pesticide residue controls to ensure food safety. Crit Rev Food Sci Nutr 1992; 31:191.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign. Nutrient conservation in canned, frozen, and fresh foods. Available at: www.aces.uiuc.edu/~nutrican/studyfinal.html (Accessed on April 08, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/94\">",
"      Curl CL, Fenske RA, Elgethun K. Organophosphorus pesticide exposure of urban and suburban preschool children with organic and conventional diets. Environ Health Perspect 2003; 111:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/95\">",
"      Lu C, Barr DB, Pearson MA, Waller LA. Dietary intake and its contribution to longitudinal organophosphorus pesticide exposure in urban/suburban children. Environ Health Perspect 2008; 116:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/96\">",
"      Partsch CJ, Sippell WG. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Update 2001; 7:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/97\">",
"      Shea KM, American Academy of Pediatrics Committee on Environmental Health, American Academy of Pediatrics Committee on Infectious Diseases. Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics. Pediatrics 2004; 114:862.",
"     </a>",
"    </li>",
"    <li>",
"     Duyff RL. The American Dietetic Association's complete food and nutrition guide, Chronimed Publishing, Minneapolis, MN 1996.",
"    </li>",
"    <li>",
"     National Cancer Institute. Eat 5 to 9 a day for better health. Available at: www.5aday.gov (Accessed on December 25, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/100\">",
"      Van Duyn MA, Pivonka E. Overview of the health benefits of fruit and vegetable consumption for the dietetics professional: selected literature. J Am Diet Assoc 2000; 100:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9369/abstract/101\">",
"      American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5362 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9369=[""].join("\n");
var outline_f9_9_9369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11115603\">",
"      Labeling requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11115610\">",
"      Market growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FOOD SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microbial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Natural toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pesticides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Exposure in utero",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Exposure in childhood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pesticide regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reduction of exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11115752\">",
"      Hormone, sex-steroid, and antibiotic treatment of livestock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92754734\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5362|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/17/4381\" title=\"table 1\">",
"      Safe food handling practices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=related_link\">",
"      Food poisoning in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_9_9370="Laser and light therapy for cutaneous hyperpigmentation";
var content_f9_9_9370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laser and light therapy for cutaneous hyperpigmentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Andrei Metelitsa, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Thomas Rohrer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Kenneth A Arndt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/9/9370/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/9/9370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11132301\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers and intense pulsed light are useful for the treatment of a wide variety of disorders characterized by the presence of cutaneous hyperpigmentation. The mechanisms through which these therapies improve hyperpigmentation include photothermal, photomechanical, and ablative effects.",
"   </p>",
"   <p>",
"    Thorough knowledge of the principles that govern the interaction between light and skin is essential for the successful and safe clinical application of lasers and intense pulsed light. Knowledge of the lesion type and lesional histopathologic characteristics are critical for the selection of an appropriate light-based therapy.",
"   </p>",
"   <p>",
"    The principles of laser and intense pulsed light therapy for hyperpigmented skin lesions, the lasers used for this indication, and the therapeutic options for select disorders of hyperpigmentation will be discussed here. The general principles of medical lasers and more information on the principles of treatment of cutaneous lesions with laser and intense pulsed light are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044410\">",
"    <span class=\"h1\">",
"     PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of laser and intense pulsed light therapy for cutaneous hyperpigmentation is based upon the clinical application of the theory of selective photothermolysis, a theory that describes the mechanism through which light can be used to exert specific effects on the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999074#H31999074\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Selective photothermolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The basic principles of selective photothermolysis are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The wavelength of light delivered should be preferentially absorbed by the target molecule (also known as a chromophore)",
"     </li>",
"     <li>",
"      Light must be delivered within a period of time that limits damage to adjacent cutaneous structures",
"     </li>",
"     <li>",
"      The light energy transferred to the target chromophore must be sufficient to exert the desired therapeutic effect while minimizing damage to adjacent tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since an excess of melanin in the skin is responsible for the darkened appearance of most cutaneous disorders of hyperpigmentation, melanin frequently is the chromophore targeted during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4137973\">",
"    <span class=\"h2\">",
"     Light wavelength",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strong light absorption by melanin occurs in the ultraviolet range of the electromagnetic spectrum and the molecule&rsquo;s affinity for light decreases progressively as wavelengths rise (",
"    <a class=\"graphic graphic_figure graphicRef74419 \" href=\"UTD.htm?21/34/22048\">",
"     figure 1",
"    </a>",
"    ). Although one might interpret this to mean that lasers that emit ultraviolet light or short wavelengths of visible light would be preferred for the treatment of hyperpigmentation, additional factors such as competition with hemoglobin (a chromophore with peak light absorption between 400 and 600 nm) and the limited depth of penetration of very short wavelengths of light narrow the spectrum of optimal clinical use.",
"   </p>",
"   <p>",
"    Thus, the ideal wavelengths of light for absorption by melanin in the skin fall between 600 and 1100 nm. The Q-switched (QS) lasers, nonablative pulsed lasers, and intense pulsed light sources most commonly used for the treatment of cutaneous hyperpigmentation emit wavelengths of light within this range. In contrast, the efficacy of ablative lasers and fractionated lasers for hyperpigmented skin lesions is not based upon melanin as a target chromophore; these lasers target water in the skin. Wavelengths between 1550 and 10,600 nm are strongly absorbed by water and are utilized for ablative and fractional therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999082#H31999082\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Wavelength'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of water-targeting ablative lasers, in which strong absorption of light by water in the skin limits the amount of light transmitted to the dermis, the depth of light penetration into the skin generally increases with increasing laser wavelength. Thus, knowledge of the site of abnormal melanin deposition within the skin is critical for device selection. While some disorders, such as lentigines are characterized by increased melanin in the epidermis, dermal hyperpigmentation is a significant feature in other skin diseases (see",
"    <a class=\"local\" href=\"#H11132338\">",
"     'Indications'",
"    </a>",
"    below). Lasers with relatively short wavelengths (eg, 532 nm frequency doubled QS Nd:YAG lasers) are well-suited for the elimination of epidermal melanin, and longer wavelength lasers (eg, 694 nm QS ruby, 755 nm QS alexandrite, and 1064 nm QS neodynium:yttrium aluminum garnet [Nd:YAG] lasers) are typically employed for the treatment of lesions in which melanin deposits are deeper. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999082#H31999082\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Wavelength'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4137883\">",
"    <span class=\"h2\">",
"     Pulse duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulse duration of a device (length of time over which light is delivered) is an additional factor that has a significant impact on the efficacy of treatment. When light emitted from a laser or intense pulsed light device is absorbed by the target chromophore (eg, melanin), a photothermal effect, resulting from the conversion of light energy into heat, leads to the coagulation of the target tissue. The delivery of light in a period shorter than a target&rsquo;s thermal relaxation time (the time necessary for a target to cool by 50 percent) allows for the destruction of the target while limiting the transfer of heat to adjacent tissues. As an example, the thermal relaxation time of an individual melanosome is between 50 and 500 ns, and the pulse durations of the QS lasers commonly used for the treatment of pigmented lesions are in the nanosecond range.",
"   </p>",
"   <p>",
"    Extending the pulse duration can be beneficial for the treatment of large structures. Because large structures have longer thermal relaxation times and lose heat more slowly than small structures, long pulse durations lead to relatively greater accumulation of heat in large structures. In this way, larger structures (eg, a large nest of pigment-containing nevomelanocytes) can be preferentially destroyed while sparing smaller, unintended targets that also contain melanin or other light-absorbing chromophores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999090#H31999090\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Pulse duration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to photothermal effects, lasers can also remove melanin via photomechanical effects (also referred to as photoacoustic effects). Very rapid delivery of high energy pulses of light that is highly absorbed by melanin can lead to the creation of shock waves within melanosomes, resulting in melanosome rupture. The QS lasers take advantage of this feature. (See",
"    <a class=\"local\" href=\"#H3044579\">",
"     'Q-switched lasers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4137890\">",
"    <span class=\"h2\">",
"     Fluence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lastly, the fluence (the amount of light energy delivered per unit of space) is a key determinant for achieving the desired clinical effect. Fluence settings that are too high can lead to adverse effects such as dyspigmentation and scarring, and fluence settings that are too low result in inadequate treatment. Excessive fluence settings are particularly detrimental in individuals with dark skin pigmentation, as permanent hypopigmentation may result from treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999097#H31999097\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Fluence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044417\">",
"    <span class=\"h1\">",
"     DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of light-emitting devices are useful for the treatment of pigmented skin lesions. As described above, the wavelength and pulse duration of a particular device are important determinants of the clinical scenarios for which it is most useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044579\">",
"    <span class=\"h2\">",
"     Q-switched lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Q-switched (QS) lasers deliver exceptionally high energy laser pulses with pulse durations in the nanosecond range. Absorption of light emitted in this fashion by melanin can lead to the removal of melanin via the creation of acoustic shock waves within melanosomes. Q-switched lasers also operate via photothermal effects. (See",
"    <a class=\"local\" href=\"#H3044410\">",
"     'Principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    QS lasers are available in a variety of wavelengths. Commonly used varieties include the 694 nm QS ruby, 755 nm QS alexandrite, 1064 QS Nd:YAG, and 532 nm frequency doubled QS Nd:YAG lasers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044586\">",
"    <span class=\"h2\">",
"     Long-pulsed lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers with pulse durations in the millisecond range are also useful for the treatment of pigmented lesions. The relatively slow delivery of light energy facilitates the treatment of larger targets in the skin. (See",
"    <a class=\"local\" href=\"#H3044410\">",
"     'Principles'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H2286670#H2286670\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Large versus small structures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-pulsed 694 nm ruby, 755 nm alexandrite, and 1064 nm Nd:YAG lasers have been used for the treatment of pigmented lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044593\">",
"    <span class=\"h2\">",
"     Traditional ablative lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional ablative lasers eliminate superficial skin pigmentation in a nonselective manner through the vaporization of the epidermis and superficial dermis. The 10,600 nm carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ), 2940 nm erbium:yttrium aluminum garnet (Er:YAG) and 2790 nm yttrium scandium gallium garnet (YSGG) lasers can be used to ablate pigment-containing skin. Water is the target chromophore for these lasers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link&amp;anchor=H832338#H832338\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Traditional ablative lasers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044600\">",
"    <span class=\"h2\">",
"     Fractionated lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonablative fractionated lasers (eg, 1550 nm erbium-doped laser, 1927 nm thulium fiber laser) and ablative fractionated lasers (eg, 10,600 nm CO",
"    <sub>",
"     2",
"    </sub>",
"    , 2940 nm Er:YAG, 2790 nm YSGG) create numerous microscopic vertical columns of thermally damaged skin in the epidermis and dermis called microthermal zones (",
"    <a class=\"graphic graphic_figure graphicRef53757 \" href=\"UTD.htm?38/15/39153\">",
"     figure 2",
"    </a>",
"    ). After treatment, the wound-healing response leads to repopulation of the damaged epidermis and dermal remodeling. The efficacy of fractional lasers in hyperpigmented skin disorders is thought to arise from the elimination of epidermal and dermal melanocytes through a compromised dermal-epidermal junction (the &ldquo;melanin shuttle&rdquo; hypothesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999193#H31999193\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Fractionated lasers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link&amp;anchor=H7559191#H7559191\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Ablative fractional lasers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1325109\">",
"    <span class=\"h2\">",
"     Intense pulsed light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intense pulsed light sources are non-laser devices that emit polychromatic light ranging from 515 to 1200 nm. Filters can be used to limit the range of wavelengths emitted. Wavelengths towards the shorter end of this range, which are more highly absorbed my melanin, are favored for the treatment of hyperpigmentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999201#H31999201\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Intense pulsed light'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132308\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to treatment, patients must be evaluated for factors that may affect treatment selection and treatment response. Lesion characteristics, baseline skin color, and risk factors for adverse events should be assessed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lesion characteristics &ndash;",
"      </strong>",
"      Selection of the most appropriate laser device and treatment parameters requires full understanding of the skin disorder, including the site of pigmentation within the skin and the origin of pigmentation (eg, melanin, iron, foreign body).",
"      <br/>",
"      <br/>",
"      Depending on the disorder, excess pigment may reside in the epidermis, papillary dermis, or reticular dermis. The laser selected must be of an appropriate wavelength to reach the site of pigmentation. In melasma, which may present with epidermal or dermal pigment deposition, examination with a Wood&rsquo;s lamp prior to treatment can be useful for estimating the depth of pigmentation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33092?source=see_link&amp;anchor=H3#H3\">",
"       \"Melasma\", section on 'Clinical features and diagnosis'",
"      </a>",
"      ). A small (eg, 2 mm) punch biopsy can also be helpful for determining the location of pigment, but is typically avoided due to scarring.",
"     </li>",
"     <li>",
"      <strong>",
"       Patient skin color &ndash;",
"      </strong>",
"      Because melanin is frequently used as the target chromophore in the treatment of cutaneous hyperpigmentation, the normal distribution of melanin in the epidermis may be adversely affected during treatment. This risk is greatest when epidermal melanin is in abundance, such as in individuals with baseline dark skin pigmentation (eg, Fitzpatrick skin phototype IV to VI (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"       table 1",
"      </a>",
"      )) or suntanned skin.",
"      <br/>",
"      <br/>",
"      In general, treatment with lasers that target melanin in skin should be avoided until a suntan fades completely. For individuals with dark baseline skin pigmentation, additional caution is necessary. Treatment of a small, inconspicuous area (a test spot) prior to treatment of a larger area is recommended. In addition, lower fluence settings and lasers with longer wavelengths (eg, 1064 nm QS Nd:YAG) are generally preferred, as they minimize damage to epidermal pigment.",
"     </li>",
"     <li>",
"      <strong>",
"       Risk for adverse outcomes &ndash;",
"      </strong>",
"      The risk of treatment-induced scarring should be discussed thoroughly with all patients, particularly those with a history of keloidal or hypertrophic scar formation. In addition, laser therapy should not be performed for at least six months after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      due to a possible increased risk for poor wound healing.",
"      <br/>",
"      <br/>",
"      Treatment with QS lasers should be avoided in patients with a history of parenteral gold therapy, as localized chrysiasis, manifesting as permanent skin discoloration may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Possibility for melanocytic atypia &ndash;",
"      </strong>",
"      Benign and atypical melanocytic lesions cannot always be easily distinguished on clinical examination. Lesions that exhibit any features concerning for an atypical or malignant melanocytic disorder should be biopsied prior to treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when laser or intense pulsed light therapy is performed appropriately, treatment can be ineffective, or adverse effects such as permanent hypopigmentation or hyperpigmentation and scarring may occur. Patients should be well-informed of the various potential outcomes of treatment and associated risks prior to proceeding with therapy. The use of an informed consent document prior to treatment is advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132338\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple disorders of cutaneous hyperpigmentation can be improved with laser or intense pulsed light therapy. A select group of disorders characterized by epidermal, dermal, and mixed epidermal or dermal pigmentation is reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132347\">",
"    <span class=\"h2\">",
"     Epidermal pigmented lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of pigmented lesions characterized by increased melanin in the epidermis that can be treated with light-emitting devices include lentigines, caf&eacute;-au-lait macules (CALM), and Becker&rsquo;s nevus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044621\">",
"    <span class=\"h3\">",
"     Lentigines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigines are small, well circumscribed, pigmented macules that are characterized by melanocyte proliferation in the basal layer of the epidermis (",
"    <a class=\"graphic graphic_picture graphicRef61452 \" href=\"UTD.htm?6/10/6306\">",
"     picture 1",
"    </a>",
"    ). Various clinical subtypes exist, including solar lentigines, lentigo simplex, and labial melanotic macules. Lentigines may also occur in association with genetic syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H2#H2\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Lentigo'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple lasers are effective for the treatment of lentigines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/4\">",
"     4",
"    </a>",
"    ]. Continuous wave CO",
"    <sub>",
"     2",
"    </sub>",
"    and argon lasers were among the initial lasers used for pigment disorders, but are no longer used due to an unacceptably high risk for adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/5\">",
"     5",
"    </a>",
"    ]. Due to the superficial location of pigment in lentigines (epidermis), lasers with relatively short wavelengths are well-suited for treatment.",
"   </p>",
"   <p>",
"    Q-switched (QS) lasers are frequently employed for the treatment of lentigines. The 694 nm QS ruby, 755 nm QS alexandrite, and 532 nm frequency-doubled QS Nd:YAG lasers have yielded excellent results. Treatment with a frequency-doubled Nd:YAG laser was superior to liquid nitrogen cryotherapy in a small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/6\">",
"     6",
"    </a>",
"    ], and benefit of QS lasers has been documented in small case series and uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Complete clearing of lesions can often be attained with two to three treatments (",
"    <a class=\"graphic graphic_picture graphicRef75757 graphicRef55782 \" href=\"UTD.htm?18/59/19384\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In our experience, lentigines rarely recur after complete clearance. However, partially resolved solar lentigines may darken due to subsequent ultraviolet light exposure, and the development of new solar lentigines in areas of actinically damaged skin is common.",
"   </p>",
"   <p>",
"    We typically use the following laser settings when treating lentigines with QS lasers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       694 nm QS ruby &ndash;",
"      </strong>",
"      3 to 6",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      5 to 6.5 mm spot size",
"     </li>",
"     <li>",
"      <strong>",
"       755 nm QS alexandrite &ndash;",
"      </strong>",
"      3 to5",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      4 mm spot size",
"     </li>",
"     <li>",
"      <strong>",
"       532 nm frequency-doubled QS Nd:YAG &ndash;",
"      </strong>",
"      0.7 to 2.5",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      3 mm spot size",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other options for the treatment of lentigines include intense pulsed light devices [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/13-16\">",
"     13-16",
"    </a>",
"    ] and pulsed dye lasers used with compression handpieces [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/13,17-21\">",
"     13,17-21",
"    </a>",
"    ]. Unlike QS lasers, which are utilized to target individual lentigines, these devices can be utilized to treat large areas, such as an entire cosmetic unit or the entire face.",
"   </p>",
"   <p>",
"    Fractionated lasers offer a newer option for the treatment of dyschromia related to cutaneous photodamage, in which solar lentigines are often a prominent manifestation. An uncontrolled study of 50 patients with facial and nonfacial signs of photodamage (including dyspigmentation) found improvement in photodamage following three treatment sessions with a 1550 nm erbium-doped fractionated laser (six to eight passes, 8",
"    <span class=\"nowrap\">",
"     mJ/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    250 MTZs) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the more recently developed 1927 thulium fiber fractionated laser, which has a higher affinity for water than the 1550 nm fractionated laser, also has shown promise for the treatment of lentigines. In an uncontrolled study of nine patients with nonfacial photodamage treated with this laser, lentigines were improved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2010, a consensus panel of experts released recommendations for the use of the 1550 nm erbium-doped fractionated laser that included a protocol for the treatment of lentigines. Three to five treatments separated by one month with energy settings between 10 to 20 mJ and treatment levels of 7 to 11 (total density of 1576 to 2704",
"    <span class=\"nowrap\">",
"     MTZ/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    at eight passes) were recommended for patients with skin phototype I to III (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/23\">",
"     23",
"    </a>",
"    ]. Lower energy settings of 4 to 6 were recommended for patients with darker skin pigmentation. The longevity of treatment effect after fractionated laser therapy is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044628\">",
"    <span class=\"h3\">",
"     Cafe-au-lait macules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caf&eacute;-au-lait macules (CALM) are sharply demarcated light tan to dark brown macules that may occur in the presence or absence of an associated syndrome (",
"    <a class=\"graphic graphic_picture graphicRef73651 graphicRef50599 \" href=\"UTD.htm?20/25/20890\">",
"     picture 3A-B",
"    </a>",
"    ). Histologically, lesions demonstrate increased melanin within the epidermis and giant melanosomes. Occasionally, an increased number of melanocytes is detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H8#H8\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Caf&eacute;-au-lait macule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response of CALM to laser treatments is variable. Retrospective and uncontrolled studies of the use of QS ruby, QS alexandrite and QS Nd:YAG lasers for these lesions have yielded inconsistent results, and complete clearance of CALM with these interventions is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/8,24,25\">",
"     8,24,25",
"    </a>",
"    ]. In one series of 22 patients with pigmented skin lesions (including 12 patients with CALM) treated with a QS ruby laser and followed for an average of 14 months, the four patients with the best responses in CALM achieved only 50 to 75 percent clearance, and 50 percent of all patients with CALM exhibited repigmentation within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/26\">",
"     26",
"    </a>",
"    ]. Clearance of CALM with an ablative Er:YAG laser has been reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically utilize a QS alexandrite laser as initial therapy when attempting to treat CALM, and if treatment is not effective, our next choice for therapy is a QS ruby laser.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044635\">",
"    <span class=\"h3\">",
"     Becker's nevus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Becker&rsquo;s nevus is an organoid hamartoma that typically presents as a unilateral hyperpigmented and hypertrichotic plaque on the trunk or shoulder. Histologically, there is an increased number of melanosomes in keratinocytes and a normal to slightly increased number of epidermal melanocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H11#H11\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Becker nevus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lasers that have been reported to be moderately effective for Becker&rsquo;s nevus include the 694 nm QS ruby, 532 nm QS frequency-doubled Nd:YAG, 1064 nm QS Nd:YAG, 2940 nm Er:YAG, long-pulsed ruby, long pulsed alexandrite, and fractional lasers. Although partial improvement in Becker&rsquo;s nevus after treatment with a 694 nm QS ruby and a 532 nm QS frequency-doubled Nd:YAG laser has been reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/24\">",
"     24",
"    </a>",
"    ], these lasers are not effective for hypertrichosis, and up to 50 percent of lesions may recur within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of long-pulsed ruby and long-pulsed alexandrite lasers for Becker&rsquo;s nevus may offer the dual benefit of the reduction of both pigment and hair. In an uncontrolled study of 11 patients with skin phototype III to V (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ), treatment with 2 to 12 sessions with a long-pulsed (3 ms) alexandrite laser (20 to 25",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    spot size 15 to 18 mm) led to more than 75 percent improvement in pigmentation in two patients (18 percent) and more than 50 percent improvement in five patients (45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/28\">",
"     28",
"    </a>",
"    ]. Hair density was reduced in all patients in the study. Improvement in pigment and hair in a Becker&rsquo;s nevus after treatment with a long-pulse ruby laser also has been reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of ablative laser resurfacing with an Er:YAG laser is suggested by the results of a prospective comparative study of 22 patients with Becker&rsquo;s nevus and skin phototypes ranging from II to IV [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/30\">",
"     30",
"    </a>",
"    ]. The study, which compared the efficacy of a single treatment with a 2940 nm Er:YAG laser (single pass, 28",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    3 mm spot size) to three treatment sessions with a 1064 nm QS Nd:YAG laser (10",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    3 mm spot size), found that in 6 out of 11 patients treated with the Er:YAG laser, complete clearance of hyperpigmentation persisted for at least two years after treatment. In contrast, only 1 out of 11 patients treated with the QS Nd:YAG laser had greater than 50 percent improvement in hyperpigmentation after two years. Hair growth was not affected in either group.",
"   </p>",
"   <p>",
"    Fractional lasers may also have promise for the treatment of Becker&rsquo;s nevus. A randomized single-blind split-lesion trial of 11 patients with Becker&rsquo;s nevus (skin types II to V) found significantly greater improvement in hyperpigmentation in the sides of lesions treated with one to three sessions with an ablative 10,600 nm CO",
"    <sub>",
"     2",
"    </sub>",
"    fractionated laser (4 passes, 10 mJ per microbeam) compared with the sides that did not receive laser therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/31\">",
"     31",
"    </a>",
"    ]. Treatment with a nonablative 1550 nm erbium-doped fiber fractionated laser (8 to 10 passes, 6 to 10 mJ, 250 to 254",
"    <span class=\"nowrap\">",
"     MTZs/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per pass) has also been associated with more than 75 percent improvement in hyperpigmentation in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/32\">",
"     32",
"    </a>",
"    ]. Improvement in hypertrichosis did not occur.",
"   </p>",
"   <p>",
"    Our preferred approach to Becker&rsquo;s nevus usually involves the use of a QS alexandrite laser. If this is not effective, we often next attempt treatment with a QS ruby laser.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3137461\">",
"    <span class=\"h3\">",
"     Ephelides (freckles)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ephelides (also known as freckles) are small, light brown macules that develop in areas of sun-exposed skin. Histopathologically, these lesions demonstrate increased epidermal melanin. The number of melanocytes is normal.",
"   </p>",
"   <p>",
"    While our experience indicates that QS alexandrite lasers, QS ruby lasers, and intense pulsed light devices are effective for the treatment of ephelides, studies focused on laser therapy for ephelides are limited. In a Korean series of 197 patients treated with a QS alexandrite laser (7",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    3 mm spot size), 64 percent of patients had greater than 75 percent clearance of treated lesions after a single treatment, and 100 percent had clearance after an average of 1.5 treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/33\">",
"     33",
"    </a>",
"    ]. Postinflammatory dyspigmentation occurred in 10 patients, and resolved within several months. Recurrences were common, occurring in 28 patients (14 percent) within one year. However, recurrent lesions responded well to retreatment.",
"   </p>",
"   <p>",
"    Three to eight treatments with a quasi-continuous 532 nm frequency-doubled Nd:YAG administered every 4 to 12 weeks also was effective for ephelides in a study that included 14 patients with ephelides (skin phototype IV (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/34\">",
"     34",
"    </a>",
"    ]. Greater than 50 percent improvement occurred in 10 out of 14 patients (71 percent). Recurrence occurred within two years in 4 out of 10 patients who achieved 50 percent improvement.",
"   </p>",
"   <p>",
"    Compared to pulsed lasers, quasi-continuous lasers have an increased risk for adverse effects. Transient hypopigmentation, mild textural changes, and hyperpigmentation occurred in 25, 15, and 10 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132354\">",
"    <span class=\"h2\">",
"     Dermal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of skin disorders in which excess pigment is primarily localized in the dermis include melanocytic nevi, Nevus of Ota, and postinflammatory hyperpigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044642\">",
"    <span class=\"h3\">",
"     Melanocytic nevi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the standard of care for the removal of nevi is surgical excision, treatment of nevi with laser therapy is occasionally considered for the cosmetic removal of benign nevi in locations in which an excisional scar is undesirable. Theoretical concerns for the promotion of malignant transformation of melanocytes have made laser therapy for nevi controversial. A study of eight patients in which biopsy specimens were taken from treated sites an average of 4.75 years after treatment with a ruby laser (mean period 4.75 years) found no evidence for malignant changes in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/35\">",
"     35",
"    </a>",
"    ]. However, pending further data on the risk of malignancy, we favor surgical removal of melanocytic nevi over laser therapy.",
"   </p>",
"   <p>",
"    Laser treatment should only be performed on nevi that lack clinical signs of atypia, and if any signs of atypia are present, a biopsy should be performed prior to treatment. In general, laser treatment of nevi should be avoided in patients with personal histories of melanoma or who have first-degree relatives with melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk factors for the development of melanoma\", section on 'History of melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevi that are predominantly localized to the epidermis and superficial dermis, such as junctional or slightly raised compound nevi (",
"    <a class=\"graphic graphic_picture graphicRef57022 graphicRef81931 \" href=\"UTD.htm?0/35/567\">",
"     picture 4A-B",
"    </a>",
"    ) have been successfully treated with 694 nm QS ruby, 755 nm QS alexandrite and 1064 nm QS Nd:YAG lasers in small uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Since some nevus cells typically remain, recurrence is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital melanocytic nevi often extend into the deep reticular dermis, and repigmentation is likely to occur following laser treatment (",
"    <a class=\"graphic graphic_picture graphicRef62970 \" href=\"UTD.htm?18/8/18562\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Treatment with a normal-mode ruby laser, which has a longer pulse duration than QS lasers (and therefore may be better suited for the treatment of the deep, large nests of nevomelanocytes seen in congenital nevi) was effective for significantly improving the appearance of congenital nevi in a series of three patients for at least 18 to 39 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/43\">",
"     43",
"    </a>",
"    ]. Combining therapy with a normal-mode and a QS ruby laser may offer additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ablative resurfacing with CO",
"    <sub>",
"     2",
"    </sub>",
"    or Er:YAG lasers also has been used for the treatment of melanocytic nevi, but these procedures carry a risk for significant scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/42,45\">",
"     42,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044649\">",
"    <span class=\"h3\">",
"     Nevus of Ota",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nevus of Ota is a dermal melanocytic hamartoma that presents with blue-brown patches in the distribution of the first and second branches of the trigeminal nerve (",
"    <a class=\"graphic graphic_picture graphicRef77921 \" href=\"UTD.htm?1/55/1909\">",
"     picture 6",
"    </a>",
"    ). Histology shows dendritic melanocytes within the papillary and reticular dermis.",
"   </p>",
"   <p>",
"    QS lasers, particularly QS ruby lasers, are the most common lasers used for the treatment of nevus of Ota. The beneficial effects of treatment have been documented in multiple case series and uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/4,46,47\">",
"     4,46,47",
"    </a>",
"    ]. The response to treatment ranges from lesion lightening to complete clearance, and three or more treatment sessions are often necessary.",
"   </p>",
"   <p>",
"    Data are limited on the comparative efficacy of specific QS lasers for nevus of Ota, and the relative efficacy of these lasers remains uncertain. One retrospective study of 94 patients found that estimates of the dermal melanin fraction were significantly lower after treatment with a 694 nm QS ruby laser compared with treatment with a 1064 nm QS Nd:YAG laser at similar fluence settings (7 to 10",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, a prospective split-lesion study of 40 patients found that treatment with a 1064 nm QS Nd:YAG laser (7 to 9",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    2 mm spot size, 6 ns pulse duration) was superior to a 755 nm alexandrite (6 to 9",
"    <span class=\"nowrap\">",
"     J/cm&sup2;,",
"    </span>",
"    2 mm spot size, 75 ns pulse duration) for lesion lightening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/49\">",
"     49",
"    </a>",
"    ]. Complication rates were not statistically different (4 with QS alexandrite versus 2 with QS Nd:YAG). However, the results of another split-lesion study suggested that treatment with the QS Nd:YAG laser may be better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Responses to treatment are usually maintained over time. Repigmentation occurs in occasional patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of fractional lasers for nevus of Ota remains to be determined. One lesion refractory to treatment with a 1064 nm QS Nd:YAG laser resolved after two treatments with a 1440 nm fractionated Nd:YAG laser [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically treat nevus of Ota with QS ruby, QS alexandrite, or 1064 nm QS Nd:YAG lasers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132361\">",
"    <span class=\"h2\">",
"     Postinflammatory hyperpigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postinflammatory hyperpigmentation (PIH) represents acquired hypermelanosis of the skin that can develop following any cutaneous injury or inflammation. This disorder occurs most commonly in individuals with moderately or deeply pigmented skin (skin phototype IV to VI (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    )). The excess pigment may be present in both the epidermis and dermis.",
"   </p>",
"   <p>",
"    Since spontaneous improvement in postinflammatory hyperpigmentation may take several months or longer, accelerating clearance of hyperpigmentation is of value. Case reports have documented improvement following treatment with a 1550 nm erbium-doped fractionated laser [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, a three-month uncontrolled study that included six patients with postinflammatory hyperpigmentation and eight patients with erythema dyschromicum perstans found a lack of improvement in postinflammatory hyperpigmentation with the same laser. Moreover, laser-induced postinflammatory hyperpigmentation occurred in 3 out of 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 1064 nm QS Nd:YAG laser may have benefit for postinflammatory hyperpigmentation. In a nonrandomized comparison study of 40 Korean patients with acne and postinflammatory hyperpigmentation, 11 out of 20 patients given five weekly treatments with a 1064 nm Nd:YAG laser (5 to 10 passes, 3.3 to 5.8",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    had more than 50 percent improvement in hyperpigmentation, while no patients who were excluded from laser therapy achieved similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/57\">",
"     57",
"    </a>",
"    ]. The QS ruby laser was poorly effective for postinflammatory hyperpigmentation in a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the risk for laser-induced worsening of hyperpigmentation, we typically do not utilize lasers for the treatment of postinflammatory hyperpigmentation. Additional studies are necessary to evaluate the efficacy and safety of different types of laser therapy for this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132368\">",
"    <span class=\"h2\">",
"     Melasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melasma is a common, acquired disorder that usually presents with symmetric hyperpigmented patches on the face (",
"    <a class=\"graphic graphic_picture graphicRef64109 graphicRef75884 \" href=\"UTD.htm?38/2/38952\">",
"     picture 7A-B",
"    </a>",
"    ). Multiple laser modalities have been used for melasma, but treatment results are highly variable and recurrence after treatment is common. Worsening of hyperpigmentation or mottled hypopigmentation may also occur as a result of laser therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33092?source=see_link\">",
"     \"Melasma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with a low-fluence 1064 nm QS Nd:YAG laser can be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. In a retrospective study of 25 women with melasma, 11 out of 25 patients had marked improvement with this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term efficacy of fractional lasers for melasma is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. Although small case series and an open label study have reported improvement with a 1550 nm erbium-doped fractional laser [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/62\">",
"     62",
"    </a>",
"    ], worsening of hyperpigmentation following laser treatment was noted in 9 out of 29 patients in a split-faced randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/63\">",
"     63",
"    </a>",
"    ]. A single treatment with an ablative fractionated CO",
"    <sub>",
"     2",
"    </sub>",
"    laser used in combination with topical therapy appeared to be beneficial for lengthening the duration of response in one prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/67\">",
"     67",
"    </a>",
"    ]. The efficacy of the 1927 nm thulium fiber laser in melasma remains to be determined.",
"   </p>",
"   <p>",
"    Additional treatment options include intense pulsed light [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/68-71\">",
"     68-71",
"    </a>",
"    ] and ablative laser resurfacing with traditional Er:YAG or CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Traditional ablative laser therapy of melasma is often complicated by postinflammatory hyperpigmentation.",
"   </p>",
"   <p>",
"    Daily use of broad-spectrum sunscreens after laser therapy is typically recommended to minimize the risk of recurrence after laser therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132375\">",
"    <span class=\"h2\">",
"     Drug-induced hyperpigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drugs may cause hyperpigmentation of the skin. While discontinuation of the inciting drug leads to improvement in some cases, dyspigmentation can be persistent. Pigment deposits related to drug therapy may consist of melanin, iron, or other substances.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Different variants of minocycline-induced pigmentation have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. Type I pigmentation is seen in sites of previous inflammation, trauma or scarring, is blue-black in color, and histological assessment shows pigment within dermal macrophages that stains positively for iron. Type II pigmentation usually presents with blue-black discoloration on the extensor surfaces, especially the shins, with characteristic staining for both iron and melanin in the dermis (",
"      <a class=\"graphic graphic_picture graphicRef79772 \" href=\"UTD.htm?34/1/34834\">",
"       picture 8",
"      </a>",
"      ). Type III pigmentation is often very persistent and presents as a muddy-brown discoloration in sun-exposed areas. Histological examination of type III pigmentation reveals increased epidermal and superficial dermal pigment that stains only for melanin.",
"      <br/>",
"      <br/>",
"      The 694 nm QS ruby, 755 nm QS alexandrite, 1064 nm QS Nd:YAG, and 532 nm frequency-doubled QS Nd:YAG lasers have been used successfully for the treatment of minocycline-associated pigmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/78-85\">",
"       78-85",
"      </a>",
"      ]. Treatment with a 1550 nm fractionated laser has also been effective in a patient [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       Imipramine",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Imipramine hyperpigmentation has responded to QS ruby or QS alexandrite lasers in individual patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. Of note, paradoxical darkening of hyperpigmentation has occurred in a patient following treatment with a 1064 nm QS Nd:YAG and QS ruby laser [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Topical",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Exogenous ochronosis due to topical hydroquinone presents on histology with yellow-brown banana-shaped deposits in the papillary dermis. Reports have documented successful treatment with QS ruby and QS alexandrite lasers [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Amiodarone-induced hyperpigmentation can be associated with granular, yellow-brown pigment deposits in the cytoplasm of dermal histiocytes. QS ruby laser treatment has induced clearing of pigmentation in a single treatment session [",
"      <a class=\"abstract\" href=\"UTD.htm?9/9/9370/abstract/92,93\">",
"       92,93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044464\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implementation of practices focused on safety is of paramount importance for the administration of laser therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Eye protection &ndash;",
"      </strong>",
"      Lasers used to treat pigmentary disorders can induce severe retinal injury and blindness. All individuals in the treatment room, including both clinical personnel and patients, must wear protective eyewear. Safety goggles are specific to the laser wavelength, and selection of the correct goggles should be confirmed prior to the start of treatment. In addition, application of metal eye shields to the eyes of patients is recommended during the treatment of periocular areas.",
"     </li>",
"     <li>",
"      <strong>",
"       Fire prevention &ndash;",
"      </strong>",
"      To prevent accidental fires, complete removal of flammable products (makeup, creams, and topical anesthetics) should be performed prior to treatment and the treatment site must be free of alcohol residue. In addition, care should be taken to remove any drapes, towels, plastics, or clothing from the treatment area to prevent accidental ignition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3044471\">",
"    <span class=\"h1\">",
"     ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients treated with lasers for pigmented lesions in limited areas do not require anesthesia. The level of discomfort during treatment with QS lasers is often likened to a rubber band snapping against the skin surface.",
"   </p>",
"   <p>",
"    Factors that can determine the need for anesthesia include the size of the lesion, anatomical location, depth of pigment, type of laser device, and the patient&rsquo;s pain threshold. Children, patients with lesions characterized by a large amount of dermal pigment (eg, Nevus of Ota), and patients treated with fractionated laser devices often require some form of anesthesia.",
"   </p>",
"   <p>",
"    Topical anesthesia with agents, such as topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    5 percent cream (LMX-5), are the most commonly used anesthetic agents in laser therapy. Occasionally, infiltrative anesthesia, regional nerve blocks, and oral or intramuscular sedation are used. The need for general anesthesia is primarily limited to children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132382\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expected side effects of treatment vary with treatment type. Sensations of pain or stinging are common immediately after laser treatment. Postoperative use of ice packs, cool compresses and occlusive dressings can reduce these symptoms.",
"   </p>",
"   <p>",
"    With the use of QS lasers, immediate skin whitening is the appropriate treatment endpoint, and typically fades within 20 to 30 minutes (",
"    <a class=\"graphic graphic_picture graphicRef69289 \" href=\"UTD.htm?5/42/5798\">",
"     picture 9",
"    </a>",
"    ). Treated lesions subsequently become darker and form superficial crusts that fall off in 7 to 10 days. Daily application of occlusive ointments and gentle cleansing of treated areas with soap and water optimizes the healing process and allows crusts to slough on their own.",
"   </p>",
"   <p>",
"    In some patients, urticarial reactions can develop following QS laser treatment, presenting with edema, itching and stinging. If these symptoms do not subside within an hour, oral antihistamines may be administered.",
"   </p>",
"   <p>",
"    Blistering, bruising, dyspigmentation, and scarring are complications that may occur as a result of treatment with lasers or intense pulsed light. Greater detail on the adverse effects of treatment with pulsed and ablative fractional lasers is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link&amp;anchor=H832338#H832338\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Traditional ablative lasers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link&amp;anchor=H7559191#H7559191\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Ablative fractional lasers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H368860500#H368860500\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since treatment-induced hyperpigmentation is a risk of laser and intense pulsed light therapy, patients should be instructed to engage in sun-protective practices, including the daily use of sunscreen after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11132389\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laser and intense pulsed light therapy can be effective for the treatment of a wide variety of hyperpigmented skin lesions. A thorough understanding of laser principles and the characteristics of the lesion to be treated is essential for the effective and safe use of light-based therapies. (See",
"      <a class=\"local\" href=\"#H3044410\">",
"       'Principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11132338\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different classes of light-emitting devices, including Q-switched lasers, long-pulsed lasers, traditional ablative lasers, fractionated lasers, and intense pulsed light are used for the treatment of pigmented lesions. The wavelength, pulse duration, energy setting, and mode of light delivery determine the effects of a device on tissue. (See",
"      <a class=\"local\" href=\"#H3044417\">",
"       'Devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be carefully evaluated prior to laser or intense pulsed light therapy for hyperpigmented skin lesions. Factors that influence the efficacy and safety of treatment such as specific lesion characteristics, patient skin color, and risk factors for adverse events should be assessed. In addition, patients should be well-informed of the possible treatment outcomes and potential adverse effects. (See",
"      <a class=\"local\" href=\"#H11132308\">",
"       'Patient evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11132382\">",
"       'Postoperative care and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevention of eye injury and accidental fire is an important component of the safe administration of laser therapy. All individuals in the treatment room must wear protective eyewear and flammable substances or products should be removed from the treatment site. (See",
"      <a class=\"local\" href=\"#H3044464\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/1\">",
"      Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/2\">",
"      Hantash BM, Bedi VP, Sudireddy V, et al. Laser-induced transepidermal elimination of dermal content by fractional photothermolysis. J Biomed Opt 2006; 11:041115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/3\">",
"      Trotter MJ, Tron VA, Hollingdale J, Rivers JK. Localized chrysiasis induced by laser therapy. Arch Dermatol 1995; 131:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/4\">",
"      Polder KD, Landau JM, Vergilis-Kalner IJ, et al. Laser eradication of pigmented lesions: a review. Dermatol Surg 2011; 37:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/5\">",
"      Polder KD, Harrison A, Eubanks LE, Bruce S. 1,927-nm fractional thulium fiber laser for the treatment of nonfacial photodamage: a pilot study. Dermatol Surg 2011; 37:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/6\">",
"      Todd MM, Rallis TM, Gerwels JW, Hata TR. A comparison of 3 lasers and liquid nitrogen in the treatment of solar lentigines: a randomized, controlled, comparative trial. Arch Dermatol 2000; 136:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/7\">",
"      Taylor CR, Anderson RR. Treatment of benign pigmented epidermal lesions by Q-switched ruby laser. Int J Dermatol 1993; 32:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/8\">",
"      Kagami S, Asahina A, Watanabe R, et al. Treatment of 153 Japanese patients with Q-switched alexandrite laser. Lasers Med Sci 2007; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/9\">",
"      Sadighha A, Saatee S, Muhaghegh-Zahed G. Efficacy and adverse effects of Q-switched ruby laser on solar lentigines: a prospective study of 91 patients with Fitzpatrick skin type II, III, and IV. Dermatol Surg 2008; 34:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/10\">",
"      Suh DH, Han KH, Chung JH. The use of Q-switched Nd:YAG laser in the treatment of superficial pigmented lesions in Koreans. J Dermatolog Treat 2001; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/11\">",
"      Rosenbach A, Lee SJ, Johr RH. Treatment of medium-brown solar lentigines using an alexandrite laser designed for hair reduction. Arch Dermatol 2002; 138:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/12\">",
"      Kilmer SL, Wheeland RG, Goldberg DJ, Anderson RR. Treatment of epidermal pigmented lesions with the frequency-doubled Q-switched Nd:YAG laser. A controlled, single-impact, dose-response, multicenter trial. Arch Dermatol 1994; 130:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/13\">",
"      Galeckas KJ, Collins M, Ross EV, Uebelhoer NS. Split-face treatment of facial dyschromia: pulsed dye laser with a compression handpiece versus intense pulsed light. Dermatol Surg 2008; 34:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/14\">",
"      Konishi N, Kawada A, Kawara S, et al. Clinical effectiveness of a novel intense pulsed light source on facial pigmentary lesions. Arch Dermatol Res 2008; 300 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/15\">",
"      Kawada A, Shiraishi H, Asai M, et al. Clinical improvement of solar lentigines and ephelides with an intense pulsed light source. Dermatol Surg 2002; 28:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/16\">",
"      Kawada A, Asai M, Kameyama H, et al. Videomicroscopic and histopathological investigation of intense pulsed light therapy for solar lentigines. J Dermatol Sci 2002; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/17\">",
"      Kono T, Manstein D, Chan HH, et al. Q-switched ruby versus long-pulsed dye laser delivered with compression for treatment of facial lentigines in Asians. Lasers Surg Med 2006; 38:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/18\">",
"      Kono T, Groff WF, Sakurai H, et al. Comparison study of intense pulsed light versus a long-pulse pulsed dye laser in the treatment of facial skin rejuvenation. Ann Plast Surg 2007; 59:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/19\">",
"      Kono T, Chan HH, Groff WF, et al. Long-pulse pulsed dye laser delivered with compression for treatment of facial lentigines. Dermatol Surg 2007; 33:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/20\">",
"      Kauvar AN, Rosen N, Khrom T. A newly modified 595-nm pulsed dye laser with compression handpiece for the treatment of photodamaged skin. Lasers Surg Med 2006; 38:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/21\">",
"      Galeckas KJ, Ross EV, Uebelhoer NS. A pulsed dye laser with a 10-mm beam diameter and a pigmented lesion window for purpura-free photorejuvenation. Dermatol Surg 2008; 34:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/22\">",
"      Wanner M, Tanzi EL, Alster TS. Fractional photothermolysis: treatment of facial and nonfacial cutaneous photodamage with a 1,550-nm erbium-doped fiber laser. Dermatol Surg 2007; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/23\">",
"      Sherling M, Friedman PM, Adrian R, et al. Consensus recommendations on the use of an erbium-doped 1,550-nm fractionated laser and its applications in dermatologic laser surgery. Dermatol Surg 2010; 36:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/24\">",
"      Tse Y, Levine VJ, McClain SA, Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. A comparative study. J Dermatol Surg Oncol 1994; 20:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/25\">",
"      Wang Y, Qian H, Lu Z. Treatment of caf&eacute; au lait macules in Chinese patients with a Q-switched 755-nm alexandrite laser. J Dermatolog Treat 2012; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/26\">",
"      Shimbashi T, Kamide R, Hashimoto T. Long-term follow-up in treatment of solar lentigo and caf&eacute;-au-lait macules with Q-switched ruby laser. Aesthetic Plast Surg 1997; 21:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/27\">",
"      Alora MB, Arndt KA. Treatment of a caf&eacute;-au-lait macule with the erbium:YAG laser. J Am Acad Dermatol 2001; 45:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/28\">",
"      Choi JE, Kim JW, Seo SH, et al. Treatment of Becker's nevi with a long-pulse alexandrite laser. Dermatol Surg 2009; 35:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/29\">",
"      Nanni CA, Alster TS. Treatment of a Becker's nevus using a 694-nm long-pulsed ruby laser. Dermatol Surg 1998; 24:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/30\">",
"      Trelles MA, Allones I, Moreno-Arias GA, V&eacute;lez M. Becker's naevus: a comparative study between erbium: YAG and Q-switched neodymium:YAG; clinical and histopathological findings. Br J Dermatol 2005; 152:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/31\">",
"      Meesters AA, Wind BS, Kroon MW, et al. Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol 2011; 65:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/32\">",
"      Glaich AS, Goldberg LH, Dai T, et al. Fractional resurfacing: a new therapeutic modality for Becker's nevus. Arch Dermatol 2007; 143:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/33\">",
"      Jang KA, Chung EC, Choi JH, et al. Successful removal of freckles in Asian skin with a Q-switched alexandrite laser. Dermatol Surg 2000; 26:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/34\">",
"      Rashid T, Hussain I, Haider M, Haroon TS. Laser therapy of freckles and lentigines with quasi-continuous, frequency-doubled, Nd:YAG (532 nm) laser in Fitzpatrick skin type IV: a 24-month follow-up. J Cosmet Laser Ther 2002; 4:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/35\">",
"      Imayama S, Ueda S. Long- and short-term histological observations of congenital nevi treated with the normal-mode ruby laser. Arch Dermatol 1999; 135:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/36\">",
"      Vibhagool C, Byers HR, Grevelink JM. Treatment of small nevomelanocytic nevi with a Q-switched ruby laser. J Am Acad Dermatol 1997; 36:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/37\">",
"      Rosenbach A, Williams CM, Alster TS. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg 1997; 23:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/38\">",
"      Duke D, Byers HR, Sober AJ, et al. Treatment of benign and atypical nevi with the normal-mode ruby laser and the Q-switched ruby laser: clinical improvement but failure to completely eliminate nevomelanocytes. Arch Dermatol 1999; 135:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/39\">",
"      Grevelink JM, van Leeuwen RL, Anderson RR, Byers HR. Clinical and histological responses of congenital melanocytic nevi after single treatment with Q-switched lasers. Arch Dermatol 1997; 133:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/40\">",
"      Waldorf HA, Kauvar AN, Geronemus RG. Treatment of small and medium congenital nevi with the Q-switched ruby laser. Arch Dermatol 1996; 132:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/41\">",
"      Kishi K, Okabe K, Ninomiya R, et al. Early serial Q-switched ruby laser therapy for medium-sized to giant congenital melanocytic naevi. Br J Dermatol 2009; 161:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/42\">",
"      August PJ, Ferguson JE, Madan V. A study of the efficacy of carbon dioxide and pigment-specific lasers in the treatment of medium-sized congenital melanocytic naevi. Br J Dermatol 2011; 164:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/43\">",
"      Ueda S, Imayama S. Normal-mode ruby laser for treating congenital nevi. Arch Dermatol 1997; 133:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/44\">",
"      Kono T, Er&ccedil;&ouml;&ccedil;en AR, Chan HH, et al. Effectiveness of the normal-mode ruby laser and the combined (normal-mode plus q-switched) ruby laser in the treatment of congenital melanocytic nevi: a comparative study. Ann Plast Surg 2002; 49:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/45\">",
"      Horner BM, El-Muttardi NS, Mayou BJ. Treatment of congenital melanocytic naevi with CO2 laser. Ann Plast Surg 2005; 55:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/46\">",
"      Kono T, Chan HH, Er&ccedil;&ouml;&ccedil;en AR, et al. Use of Q-switched ruby laser in the treatment of nevus of ota in different age groups. Lasers Surg Med 2003; 32:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/47\">",
"      Watanabe S, Takahashi H. Treatment of nevus of Ota with the Q-switched ruby laser. N Engl J Med 1994; 331:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/48\">",
"      Chang CJ, Kou CS. Comparing the effectiveness of Q-switched Ruby laser treatment with that of Q-switched Nd:YAG laser for oculodermal melanosis (Nevus of Ota). J Plast Reconstr Aesthet Surg 2011; 64:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/49\">",
"      Chan HH, Ying SY, Ho WS, et al. An in vivo trial comparing the clinical efficacy and complications of Q-switched 755 nm alexandrite and Q-switched 1064 nm Nd:YAG lasers in the treatment of nevus of Ota. Dermatol Surg 2000; 26:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/50\">",
"      Chan HH, King WW, Chan ES, et al. In vivo trial comparing patients' tolerance of Q-switched Alexandrite (QS Alex) and Q-switched neodymium:yttrium-aluminum-garnet (QS Nd:YAG) lasers in the treatment of nevus of Ota. Lasers Surg Med 1999; 24:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/51\">",
"      Chan HH, Leung RS, Ying SY, et al. Recurrence of nevus of Ota after successful treatment with Q-switched lasers. Arch Dermatol 2000; 136:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/52\">",
"      Kouba DJ, Fincher EF, Moy RL. Nevus of Ota successfully treated by fractional photothermolysis using a fractionated 1440-nm Nd:YAG laser. Arch Dermatol 2008; 144:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/53\">",
"      Katz TM, Goldberg LH, Firoz BF, Friedman PM. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation. Dermatol Surg 2009; 35:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/54\">",
"      Rokhsar CK, Ciocon DH. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation after carbon dioxide laser resurfacing. Dermatol Surg 2009; 35:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/55\">",
"      Schmitt L, Raulin C, Karsai S. [Fractional photothermolysis. Treatment of post-inflammatory hyperpigmentation following meadow grass dermatitis]. Hautarzt 2009; 60:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/56\">",
"      Kroon MW, Wind BS, Meesters AA, et al. Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat 2012; 23:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/57\">",
"      Kim S, Cho KH. Treatment of facial postinflammatory hyperpigmentation with facial acne in Asian patients using a Q-switched neodymium-doped yttrium aluminum garnet laser. Dermatol Surg 2010; 36:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/58\">",
"      Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994; 20:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/59\">",
"      Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol 2009; 34:e847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/60\">",
"      Chan NP, Ho SG, Shek SY, et al. A case series of facial depigmentation associated with low fluence Q-switched 1,064&thinsp;nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med 2010; 42:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/61\">",
"      Jeong SY, Shin JB, Yeo UC, et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg 2010; 36:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/62\">",
"      Lee HS, Won CH, Lee DH, et al. Treatment of melasma in Asian skin using a fractional 1,550-nm laser: an open clinical study. Dermatol Surg 2009; 35:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/63\">",
"      Wind BS, Kroon MW, Meesters AA, et al. Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med 2010; 42:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/64\">",
"      Karsai S, Fischer T, Pohl L, et al. Is non-ablative 1550-nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single-blinded trial in 51 patients. J Eur Acad Dermatol Venereol 2012; 26:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/65\">",
"      Katz TM, Glaich AS, Goldberg LH, et al. Treatment of melasma using fractional photothermolysis: a report of eight cases with long-term follow-up. Dermatol Surg 2010; 36:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/66\">",
"      Naito SK. Fractional photothermolysis treatment for resistant melasma in Chinese females. J Cosmet Laser Ther 2007; 9:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/67\">",
"      Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol 2010; 9:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/68\">",
"      Wang CC, Hui CY, Sue YM, et al. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg 2004; 30:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/69\">",
"      Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense pulsed light. Aesthetic Plast Surg 2010; 34:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/70\">",
"      Goldman MP, Gold MH, Palm MD, et al. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma. Dermatol Surg 2011; 37:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/71\">",
"      Li YH, Chen JZ, Wei HC, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg 2008; 34:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/72\">",
"      Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/73\">",
"      Nouri K, Bowes L, Chartier T, et al. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999; 25:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/74\">",
"      Wanitphakdeedecha R, Manuskiatti W, Siriphukpong S, Chen TM. Treatment of melasma using variable square pulse Er:YAG laser resurfacing. Dermatol Surg 2009; 35:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/75\">",
"      Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006; 55:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/76\">",
"      Basler RS. Minocycline-related hyperpigmentation. Arch Dermatol 1985; 121:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/77\">",
"      Wasel NR, Schloss EH, Lin AN. Minocycline-induced cutaneous pigmentation. J Cutan Med Surg 1998; 3:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/78\">",
"      Tsao H, Busam K, Barnhill RL, Dover JS. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol 1996; 132:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/79\">",
"      Wilde JL, English JC 3rd, Finley EM. Minocycline-induced hyperpigmentation. Treatment with the neodymium:YAG laser. Arch Dermatol 1997; 133:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/80\">",
"      Wood B, Munro CS, Bilsland D. Treatment of minocycline-induced pigmentation with the neodymium-Yag laser. Br J Dermatol 1998; 139:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/81\">",
"      Collins P, Cotterill JA. Minocycline-induced pigmentation resolves after treatment with the Q-switched ruby laser. Br J Dermatol 1996; 135:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/82\">",
"      Alster TS, Gupta SN. Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser. Dermatol Surg 2004; 30:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/83\">",
"      Green D, Friedman KJ. Treatment of minocycline-induced cutaneous pigmentation with the Q-switched Alexandrite laser and a review of the literature. J Am Acad Dermatol 2001; 44:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/84\">",
"      Greve B, Sch&ouml;nermark MP, Raulin C. Minocycline-induced hyperpigmentation: treatment with the Q-switched Nd:YAG laser. Lasers Surg Med 1998; 22:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/85\">",
"      Knoell KA, Milgraum SS, Kutenplon M. Q-switched ruby laser treatment of minocycline-induced cutaneous hyperpigmentation. Arch Dermatol 1996; 132:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/86\">",
"      Izikson L, Anderson RR. Resolution of blue minocycline pigmentation of the face after fractional photothermolysis. Lasers Surg Med 2008; 40:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/87\">",
"      Orringer JS, Lowe L, Cha KB. Treatment of imipramine-induced dyspigmentation with Q-switched alexandrite laser therapy. Dermatol Surg 2010; 36:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/88\">",
"      Atkin DH, Fitzpatrick RE. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol 2000; 43:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/89\">",
"      Izikson L, Anderson RR. Delayed darkening of imipramine-induced hyperpigmentation after treatment with a Q-switched Nd:YAG laser followed by a Q-switched ruby laser. Dermatol Surg 2009; 35:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/90\">",
"      Kramer KE, Lopez A, Stefanato CM, Phillips TJ. Exogenous ochronosis. J Am Acad Dermatol 2000; 42:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/91\">",
"      Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg 2004; 30:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/92\">",
"      Karrer S, Hohenleutner U, Szeimies RM, Landthaler M. Amiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser. Arch Dermatol 1999; 135:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/9/9370/abstract/93\">",
"      Wiper A, Roberts DH, Schmitt M. Amiodarone-induced skin pigmentation: Q-switched laser therapy, an effective treatment option. Heart 2007; 93:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13637 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9370=[""].join("\n");
var outline_f9_9_9370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11132389\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11132301\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3044410\">",
"      PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4137973\">",
"      Light wavelength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4137883\">",
"      Pulse duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4137890\">",
"      Fluence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3044417\">",
"      DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3044579\">",
"      Q-switched lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3044586\">",
"      Long-pulsed lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3044593\">",
"      Traditional ablative lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3044600\">",
"      Fractionated lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1325109\">",
"      Intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11132308\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11132338\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11132347\">",
"      Epidermal pigmented lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3044621\">",
"      - Lentigines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3044628\">",
"      - Cafe-au-lait macules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3044635\">",
"      - Becker's nevus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3137461\">",
"      - Ephelides (freckles)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11132354\">",
"      Dermal lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3044642\">",
"      - Melanocytic nevi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3044649\">",
"      - Nevus of Ota",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11132361\">",
"      Postinflammatory hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11132368\">",
"      Melasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11132375\">",
"      Drug-induced hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3044464\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3044471\">",
"      ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11132382\">",
"      POSTOPERATIVE CARE AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11132389\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13637|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/34/22048\" title=\"figure 1\">",
"      Chromophore absorption spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/15/39153\" title=\"figure 2\">",
"      Fractionated photothermolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13637|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/10/6306\" title=\"picture 1\">",
"      Solar lentigo hand 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/31/38386\" title=\"picture 2A\">",
"      Lentigines before laser therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/60/38851\" title=\"picture 2B\">",
"      Lentigines after laser therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/8/33928\" title=\"picture 3A\">",
"      Cafe-au-lait macule 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/46/29411\" title=\"picture 3B\">",
"      Cafe-au-lait macule 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/55/19313\" title=\"picture 4A\">",
"      Junctional nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/52/42817\" title=\"picture 4B\">",
"      Compound nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/8/18562\" title=\"picture 5\">",
"      Medium CMN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/55/1909\" title=\"picture 6\">",
"      Nevus of Ota",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/53/35666\" title=\"picture 7A\">",
"      Melasma cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/56/3973\" title=\"picture 7B\">",
"      Melasma forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/1/34834\" title=\"picture 8\">",
"      Minocycline pigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/42/5798\" title=\"picture 9\">",
"      Q-switched laser skin whitening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=related_link\">",
"      Ablative laser resurfacing for skin rejuvenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33092?source=related_link\">",
"      Melasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=related_link\">",
"      Principles of laser and intense pulsed light for cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_9_9371="Cytokine genes with GRE";
var content_f9_9_9371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cytokines suppressed by glucocorticoids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Interleukin (IL)-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GM-CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor necrosis factor alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon gamma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Genes for the above cytokines are suppressed by steroid-bound glucocorticoid receptors.",
"    <div class=\"footnotes\">",
"     GM-CSF: Granulocyte macrophage colony stimulating factor",
"    </div>",
"    <div class=\"reference\">",
"     See text for references",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9371=[""].join("\n");
var outline_f9_9_9371=null;
var title_f9_9_9372="Diarrhea causes PI";
var content_f9_9_9372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible causes of sudden onset (acute) diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Infectious diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral infection",
"       </td>",
"       <td>",
"        Loose stool, low-grade fever, feel ill",
"       </td>",
"       <td>",
"        None, usually resolves within 48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial infection",
"       </td>",
"       <td>",
"        Fever (temperature &gt;101&deg;F or 38.4&deg;C), bloody stools",
"       </td>",
"       <td>",
"        Usually none, antibiotics in selected situations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parasite",
"       </td>",
"       <td>",
"        Not common in developed countries, may be seen in returning traveler or camper",
"       </td>",
"       <td>",
"        Antibiotics in most cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Non-infectious diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antibiotics",
"       </td>",
"       <td>",
"        Loose stool begins after antibiotic started, usually resolves with a few days after stopped",
"       </td>",
"       <td>",
"        Usually none",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Food intolerance (eg, lactose intolerance)",
"       </td>",
"       <td>",
"        Diarrhea, abdominal pain, and/or gas after consuming food",
"       </td>",
"       <td>",
"        Determine if food intolerance is the cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)",
"       </td>",
"       <td>",
"        Mouth sores, diarrhea, abdominal pain, weight loss, and fever",
"       </td>",
"       <td>",
"        See a healthcare provider for full evaluation and treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Irritable bowel syndrome",
"       </td>",
"       <td>",
"        Chronic lower abdominal pain, diarrhea and/or constipation",
"       </td>",
"       <td>",
"        Symptomatic treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celiac disease (gluten sensitivity)",
"       </td>",
"       <td>",
"        None to diarrhea, weight loss, abdominal pain, gas",
"       </td>",
"       <td>",
"        Complete avoidance of wheat, rye, barley",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9372=[""].join("\n");
var outline_f9_9_9372=null;
var title_f9_9_9373="Risk factors for lead exposure in pregnancy and lactation";
var content_f9_9_9373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for lead exposure in pregnancy and during lactation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recent emigration from or residency in areas where ambient lead contamination is high",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women from countries where leaded gasoline is still being used (or was recently phased out) or where industrial emissions are not well controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Living near a point source of lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examples include lead mines, smelters, or battery recycling plants (even if the establishment is closed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Working with lead or living with someone who does",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who work in or who have family members who work in an industry that uses lead (eg, lead production, battery manufacturing, paint manufacturing, ship building, ammunition production, or plastic manufacturing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Using lead-glazed ceramic pottery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who cook, store, or serve food in lead-glazed ceramic pottery made in a traditional process and usually imported by individuals outside the normal commercial channels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Eating nonfood substances (pica)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who eat or mouth nonfood items that may be contaminated with lead, such as soil or lead-glazed ceramic pottery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Using alternative or complementary substances, herbs, or therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who use imported home remedies or certain therapeutic herbs traditionally used by East Indian, Indian, Middle Eastern, West Asian, and Hispanic cultures that may be contaminated with lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Using imported cosmetics or certain food products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who use imported cosmetics, such as kohl or surma or certain imported foods or spices that may be contaminated with lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Engaging in certain high-risk hobbies or recreational activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who engage in high-risk activities (eg, stained glass production or pottery making with certain leaded glazes and paints) or have family members who do",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renovating or remodeling older homes without lead hazard controls in place",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who have been disturbing lead paint, creating lead dust, or both or have been spending time in such a home environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Consumption of lead-contaminated drinking water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women whose homes have leaded pipes or source lines with lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Having a history of previous lead exposure or evidence of elevated body burden of lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who may have high body burdens of lead from past exposure, particularly those who have deficiencies in certain key nutrients (calcium or iron)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Living with someone identified with an elevated lead level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who may have exposure in common with a child, close friend, or other relative living in the same environment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Centers for Disease Control and Prevention. Guidelines for the identification and management of lead exposurein pregnant and lactating women. Atlanta 2010. Available at:",
"        <a href=\"file://www.cdc.gov/nceh/lead/publications/leadandpregnancy2010.pdf\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"         file://www.cdc.gov/nceh/lead/publications/leadandpregnancy2010.pdf",
"        </a>",
"        . Retrieved March 7, 2012.",
"       </li>",
"      </ol>",
"      Reproduced with permission from: Committee opinion no. 533: lead screening during pregnancy and lactation. Obstet Gynecol 2012; 120:416. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9373=[""].join("\n");
var outline_f9_9_9373=null;
var title_f9_9_9374="Major chemical weapon exposures";
var content_f9_9_9374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of selected major chemical weapon exposures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Decontamination*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nerve agents: tabun, sarin, soman, VX",
"       </td>",
"       <td>",
"        Anticholinesterase: muscarinic, nicotinic and CNS effects",
"       </td>",
"       <td>",
"        <p>",
"         Vapor: miosis, rhinorrhea, dyspnea",
"        </p>",
"        <p>",
"         Liquid: diaphoresis, vomiting",
"        </p>",
"        Both: coma, paralysis, seizures, apnea",
"       </td>",
"       <td>",
"        <p>",
"         Seconds: vapor",
"        </p>",
"        Minutes-hours: liquid",
"       </td>",
"       <td>",
"        <p>",
"         Vapor: fresh air, remove clothes, wash hair",
"        </p>",
"        Liquid: remove clothes, copious washing skin, hair with soap and water, ocular irrigation",
"       </td>",
"       <td>",
"        <p>",
"         Atropine",
"         <sup>",
"          &Delta;&loz;",
"         </sup>",
"         : 0.05 mg/kg IV, IM (minimum 0.1 mg, maximum 5 mg); double the dose and repeat every 2 to 5 minutes as needed to control bronchial secretions or bronchospasm",
"        </p>",
"        <p>",
"         Pralidoxime (with concurrent atropine)",
"         <sup>",
"          &sect;",
"         </sup>",
"         : 25 mg/kg IV or IM (maximum 1 g IV; 2 g IM), may repeat within 30 to 60 minutes as needed, then again every 12 hours for up to two doses as needed for persistent weakness or high atropine requirement; continuous infusion",
"         <sup>",
"          &loz;",
"         </sup>",
"         may be needed to control severe muscarinic symptoms",
"        </p>",
"        Diazepam: 0.3 mg/kg (maximum 10 mg) IV; Lorazepam: 0.1 mg/kg IV, IM (maximum 4 mg); or Midazolam: 0.2 mg/kg (maximum 10 mg) IM as needed for seizures, or severe exposure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"6\">",
"        Vesicants:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mustard",
"       </td>",
"       <td>",
"        Alkylation",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Skin: erythema, vesicles",
"        </p>",
"        <p>",
"         Eye: inflammation",
"        </p>",
"        Respiratory tract: inflammation",
"       </td>",
"       <td rowspan=\"2\">",
"        Hours (immediate pain with Lewisite)",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Skin: soap and water",
"        </p>",
"        Eyes: water (only effective if done within minutes of exposure)",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Symptomatic and supportive care",
"        </p>",
"        Dimercaprol [BAL] 3 mg/kg IM every four to six hours for systemic effects of Lewisite in severe cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lewisite",
"       </td>",
"       <td>",
"        Arsenical",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"6\">",
"        Pulmonary agents:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Chlorine",
"        </p>",
"        Phosgene",
"       </td>",
"       <td>",
"        Liberates HCl, alkylation",
"       </td>",
"       <td>",
"        <p>",
"         Eyes, nose, throat irritation (especially chlorine)",
"        </p>",
"        Respiratory: bronchospasm, pulmonary edema (especially phosgene)",
"       </td>",
"       <td>",
"        <p>",
"         Minutes: eyes, nose, throat irritation, bronchospasm",
"        </p>",
"        Hours: pulmonary edema",
"       </td>",
"       <td>",
"        <p>",
"         Fresh air",
"        </p>",
"        <p>",
"         Skin: water",
"        </p>",
"       </td>",
"       <td>",
"        Symptomatic and supportive care",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Cyanide",
"       </td>",
"       <td rowspan=\"4\">",
"        Cytochrome oxidase inhibition: cellular anoxia, lactic acidosis",
"       </td>",
"       <td rowspan=\"4\">",
"        Tachypnea, coma, seizures, apnea",
"       </td>",
"       <td rowspan=\"4\">",
"        Seconds",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Fresh air",
"        </p>",
"        Skin: soap and water",
"       </td>",
"       <td>",
"        <strong>",
"         Do not delay antidotal therapy if cyanide poisoning is suspected:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Preferred: sodium thiosulfate (25 percent) 1.65 mL/kg IV",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        Hydroxocobalamin 70 mg/kg IV (maximum 5 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Cyanide antidote kit containing amyl nitrate, sodium nitrite, and sodium thiosulfate may be used if hydroxocobalamin is not available",
"         <sup>",
"          &yen;",
"         </sup>",
"        </p>",
"        Sodium thiosulfate should be used alone if concomitant smoke inhalation or carbon monoxide poisoning exists",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"6\">",
"        Riot control agents:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         CS",
"        </p>",
"        CN (Mace)",
"       </td>",
"       <td rowspan=\"2\">",
"        Neuropeptide substance P release; alkylation",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Eye: tearing, pain, blepharospasm",
"        </p>",
"        Nose and throat irritation",
"       </td>",
"       <td>",
"        Seconds",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Fresh air",
"        </p>",
"        Eyes: lavage",
"       </td>",
"       <td rowspan=\"2\">",
"        Ophthalmic analgesic topically (eg, proparacaine 0.5 percent one drop to each eye), symptomatic care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Capsaicin (pepper spray)",
"       </td>",
"       <td>",
"        Pulmonary failure (rare)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; ABCs: airway, breathing and circulatory support; Hgb: hemoglobin concentration; BAL: British Anti-Lewisite; HCl: hydrochloric acid.",
"     <br/>",
"     * Decontamination, especially for patients with significant nerve agent or vesicant exposure, should be performed by health care providers wearing adequate personal protective equipment. For ED staff, this consists of nonencapsulated, chemically-resistant body suit, boots, and gloves with a full-face air purifier mask/hood.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Emergent supportive care including management of airway, breathing, and circulation should be provided as needed in addition to specific antidotal therapies.",
"     <br/>",
"     &Delta; Intraosseous route is likely equivalent to intravenous.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Inhaled ipratropium bromide (500 mcg inhaled, may repeat once) may complement parenteral atropine administration for the treatment of bronchospasm.",
"     <br/>",
"     &sect; Pralidoxime is initially reconstituted to 50 mg/mL (1 g in 20 mL sterile water) for IV administration, and the total dose infused over 30 minutes, or may be given by continuous infusion (loading dose 25 mg/kg over 30 minutes, then 10 mg/kg per hour). For IM use, dilute 1 g pralidoxime with 3.3 mL sterile water to a concentration of 300 mg/mL (same concentration as US Army's Mark 1 and Duodote&trade; autoinjector). Each Mark 1 ATNAA [Antidote Treatment-Nerve Agent Autoinjector] kit holds 2 autoinjectors, one each of atropine 2 mg (0.7 mL), and pralidoxime 600 mg (2 mL); although not approved for pediatric use, they might be considered as initial treatment in dire (especially prehospital) circumstances, for children with severe, life threatening nerve agent toxicity who lack intravenous access, and for whom more precise, mg/kg IM dosing would be logistically impossible. Suggested dosing guidelines are as follows: one autoinjector for patients who weigh 13 to 25 kg and to any child weighing less than 13 kg who is severely affected, two autoinjectors for patients who weigh 26 to 50 kg, and three autoinjectors for patients weighing more than 50 kg.",
"     <br/>",
"     &yen; For dosing of Cyanide antidote kit see UpToDate topic on cyanide poisoning.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Henretig FM, Cieslak TJ, Eitzen EM. Biological and chemical terrorism. J Pediatr 2002; 141:311. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9374=[""].join("\n");
var outline_f9_9_9374=null;
var title_f9_9_9375="Diffuse alopecia in SS";
var content_f9_9_9375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse alopecia in S&eacute;zary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Alopecia is common in patients with mycosis fungoides and S&eacute;zary syndrome and can present as reduced hair density diffusely over the scalp and body or as patches of alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_9_9375=[""].join("\n");
var outline_f9_9_9375=null;
